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Abstract 
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels that 
influence neurotransmitter release, hence constituting a key component of the 
physiological mechanisms of neuronal signalling. This thesis is concerned with the 
properties of the a4P2 nAChR, the most abundant nAChR in the brain, and the major 
contributor to the central effects of nicotine. The a4P2 nAChR is made up of five subunits, 
which in heterologous systems can assemble into at least two different stoichiometries: the 
high sensitivity (HS) (a4h(P2)3 stoichiometry and the low sensitivity (LS) (a4)3(p2)2 
stoichiometry, which might both exist in native tissues. Despite the attractiveness of the 
a.4P2 nAChR as a target for therapeutic intervention, progress in the development of 
a4P2 nAChR-selective drugs has been slowed, partly because of the lack of stoichiometric-
specific receptor models. 
This study presents a strategy to express homogenous populations of a4P2 nAChRs with 
fixed stoichiometry. By using standard molecular biological techniques, pentameric 
concatenated (a4)2(P2)3 and (a4)3(P2)2 nAChRs were engineered. These receptors were 
expressed in Xenopus laevis oocytes and functional studies showed that their functional 
properties resembled those of their non-linked counterparts. Subsequent site-directed 
mutagenesis in combination with functional analysis allowed the identification of the 
agonist-binding subunits in both concatamers. 
Concatenated receptors proved to be suitable for comparative studies of the effects of 
receptor mutation linked to autosomal dominant nocturnal frontal lobe epilepsy. Studies 
carried out on non-linked receptors, showed that the properties of the (a4)3(p2)2 
stoichiometry were affected more markedly than those of the (a4)2(p2)3 stoichiometry. 
Insertion of the mutation in concatenated receptors revealed that the mutation not only 
affected the functional properties of a.4P2 nAChRs but also altered the subunit composition 
of the receptor. 
These studies show that pentameric concatenated constructs are a powerful tool to study 
the function and structure of receptors that assemble in multimeric types in expression 
systems. 
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CHAPTERl 
INTRODUCTION 
1.1 Synaptic transmission 
Nerve cells differ from other cells in the body in their ability to communicate 
rapidly with one another, sometimes over great distances and with great precision. 
Communication between neurons and communication between neurons and their non-
neuronal targets occur at specialised junctions called synapses. The term synapse (from the 
greek synapsis, junction) was introduced in 1897 by Charles Sherrington (Sherrington, 
1897) to refer to the specialised contact zone, described histologically by Ramon y Cajal 
two centuries ago (Ramon y Cajal, 1888), where one neuron communicates with another. 
The normal direction of signal transmission is from the axon terminal to the target cell; 
thus, the axon terminal is called presynaptic terminal and the target cell is called 
postsynaptic cell. Although synapses come in many forms and shapes, we can distinguish 
between two main types: electrical and chemical synapses. 
The electrical synapse, extremely rare in vertebrate brains, is the simplest form of 
synapse. This type of connection occurs at specialised sites called gap-junctions. At a 
gap-junction, the presynaptic and postsynaptic membranes are separated by only about 3 
nm, and this narrow gap is spanned by special proteins called connexins. Six connexins 
assemble together to form a channel called connexon, which allows ions to pass directly 
from the cytoplasm of one cell to the cytoplasm of the other. Unlike most chemical 
synapses, electrical synt;tpses are bi-directional; ionic currents pass equally well in both 
directions. Transmission at electrical synapses is very fast. Thus, an action potential in the 
presynaptic cell can produce, almost instantaneously, an action potential in the 
postsynaptic neuron. In addition to electrical signals, because the connexon is about 2 nm 
in diameter, many small organic molecules such as second messengers, can pass from one 
cell to the other. This may have important, but to date probably still underappreciated, 
consequences for cellular signalling in the brain (reviewed in Eclles, 1964; Katz, 1966). 
Chemical synapses are what we would view as a proper synapse. In the chemical 
synapse, also called unbridged junction, the pre- and postsynaptic neurons are not 
contiguous. There is a discrete separation, called synaptic cleft, between the presynaptic 
and postsynaptic element. In addition, the pre- and postsynaptic membranes are 
morphologically strikingly different. The presynaptic terminal is characterised by a high 
density of vesicles, called synaptic vesicles, which contain the chemical messenger, called 
neurotransmitter; the postsynaptic membrane l'resents clustering of neurotransmitter 
receptors and other molecules. Presynaptic signals are transmitted via the release of 
2 
neurotransmitters from the presynaptic neuron, which bind to receptors located on the 
postsynaptic membrane. What triggers the release of neurotransmitter from vesicles is an 
elevation of the intracellular Ca2+ ([Ca2+]i). The arrival of action potentials at the 
presynaptic terminal results in the opening of voltage-gated Ca2+ channels, which rapidly 
increases [Ca2+]i from about 30 nM to 10-30 µM in the vicinity of the presynaptic 
membrane. Calcium ions then trigger a biochemical cascade that stimulates the movement 
of the neurotransmitter containing vesicles towards the nerve terminal ending, where they 
fuse with the plasma membrane to release their neurotransmitter content into the synaptic 
cleft by exocytosis. The released transmitter then diffuses into the synaptic cleft and binds 
to specific postsynaptic receptors, which results in a postsynaptic cellular response. The 
type of response generated depends on both the type of neurotransmitter released by the 
presynaptic cell and the type of receptors present on the postsynaptic membrane (reviewed 
in Belles, 1964; Katz, 1966). 
There are many different types of neurotransmitter, and typically a neuron releases 
only one type. Most neurotransmitters fall into one of the following three chemical classes: 
a) amino acids such as glutamate, glycine and y-aminobutyric acid (GABA); b) amines 
such as acetylcholine (ACh), dopamine (DA), noradrenaline (NA) and serotonin (5-HT); 
and c) peptides such as dynorphin, enkephalins, substance P and neuropeptide Y (reviewed 
in Triggle and Triggle, 1976). 
Postsynaptic membrane receptors can be ionotropic and metabotropic receptors. 
Ionotropic receptors generate faster and shorter responses than metabotropic receptors. 
Typically, ionotropic receptors are activated by amino acid and amine neurotransmitters, 
whereas all three types of neurotransmitters can activate metabotropic receptors (reviewed 
in Kandel, 2000). 
Ionotropic receptors are ligand-gated ion channels (LGICs), which, upon activation, 
directly open a channel, which is more or less selective for certain ion species. This results 
in a very fa~t alteration of the permeability of the postsynaptic membrane and causes a 
change in the transmembrane potential of the cell, called postsynaptic potential. If the 
postsynaptic potential is of sufficient high amplitude, an action potential may be elicited 
and this will be transmitted to the end of the axon of the postsynaptic cell thus perpetuating 
the electrical signal to the adjacent cell. The signal can be either excitatory in the case of 
depolarising currents, or inhibitory in the case of hyperpolarising currents. What 
determines whether synaptic signals produce excitation or inhibition is the type of ions that 
can pass through the ion channel of the postsynaptic receptors. For example, ACh-gated 
3 
ion channels at the neuromuscular junction are highly permeable to Na+ and thus, when 
they open, the net effect is a depolarisation of the postsynaptic membrane. If, however, the 
transmitter-gated channels are permeable to er, because the chloride equilibrium potential 
is negative, the net effect of transmitter-dependent activation of the ion channel will be to 
hyperpolarize the postsynaptic cell from the resting membrane potential (reviewed in 
Kandel, 2000). 
Metabotropic receptors are associated to G-proteins and they generate slower and 
longer-lasting signals than their ionotropic counterparts. The type of signals generated by 
this type of postsynaptic receptors involves three steps: 1) binding of the neurotransmitter 
to metabotropic receptors embedded in the postsynaptic membrane; 2) activation of 
G-proteins by the bound-receptors; 3) activation of effector proteins by the activated 
G-proteins. Effector proteins can be G-protein-gated ion channels embedded in the 
postsynaptic membrane, or they can be enzymes that synthesise second messengers that 
diffuse away in the cytosol (e.g., cyclic AMP, inositol triphosphate) or stay within the 
membrane compartment (e.g., diacylglycerol). Second messengers can activate additional 
enzymes in the cytosol or plasma (reviewed in Kandel, 2000). 
Different neurones release different neurotransmitters and they are often grouped 
according to the neurotransmitter that they release. For example, neurones that release the 
neurotransmitter A Ch are called cholinergic neurones. The cholinergic system is one of the 
most important and phylogenetically oldest pathways in the nervous system. Cholinergic 
neurons communicate by releasing ACh and the key molecules that transduce the ACh 
message are the muscarinic and nicotinic acetylcholine receptors (nAChRs). The nAChR 
in the central nervous system (CNS) is a key molecule involved in the propagation of 
signals between nerve cells and their targets at the CNS and peripheral synapses and it 
appears to exert a predominantly modulatory influence on brain mechanisms. The 
cholinergic innervation acting via nAChRs regulates processes such as neurotransmitters 
release, cell excitability and neuronal integration. nAChRs have been identified as crucial 
elements in CNS functions such as consciousness, attention, and memory. Dysfunction of 
nAChRs leads to a perturbation of the cholinergic system causing various diseases during 
development, adulthood and aging (Gotti et al., 1997; Lindstrom, 1997; Changeux and 
Edelstein, 2001; Hogg et al., 2003). 
This study is concerned with the pharmacological and structural properties of a 
particular subtype of nAChRs, the a4~2 receptor. This protein belongs to the Cys-loop 
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superfamily of LGIC and is an important target for therapeutic intervention in a number of 
diseases of the brain such as age-related cognitive impairment and neurodegenerative 
diseases, epilepsy, schizophrenia, mood disorders, chronic pain, attention deficits, and 
nicotine addiction. 
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1.2 Nicotinic acetylcholine receptors 
nAChRs are cation-selective ion channels which generate fast cationic currents 
upon binding to ACh. nAChRs belong to the Cys-loop superfamily of LGIC which also 
includes serotonin type 3A (5HT3A), glycine, y-aminobutyric acid type A (GABAA), 
GABAc and zinc-activated channels (ZAC), and invertebrate glutamate-, histamine-, and 
5HT-gated chloride channels (Karlin, 2002; Jones and Sattelle, 2006). nAChRs were first 
identified and characterised at the vertebrate neuromuscular junction and in the Torpedo 
californica electric organ. The muscle nAChR of Torpedo is the prototype for all the 
nAChRs and indeed for all the members of the Cys-loop family of receptors. 
1.3 Structure of Torpedo nAChRs 
nAChRs are transmembrane proteins composed of five subunits arranged around a 
central water-filled pore (McGehee and Role, 1995; Jones et al., 1999). To date 17 nAChR 
subunits have been cloned. The subunits have been divided into muscle-type (al, ~l, o, y, 
and a) and neuronal-type (a2-a10 and ~2-~4) subunits. The a subunits, both the muscle-
and the neuronal-type, possess two adjacent cysteines essential for ACh binding, whereas 
the non-a subunits do not. The muscle-type nAChR is the best studied, as it can be found 
in large amounts in the Torpedo electric organ, from which it is easily extracted and 
purified. The receptor is composed of two al subunits and ~I, o and B (y in the foetus) 
subunits organised in a clockwise alyal~l() arrangement. In contrast, the 12 neuronal 
subunits can form a number of different nAChR subtypes, which can be either homomeric, 
made of only one type of subunit (e.g., a7 receptors) or heteromeric, made of two or more 
distinct subunits (e;,g., a4~2, a9~10, a6~2~3a4). 
All nAChR subunits are similar in amino acid sequence and have the same 
membrane topology. Each subunit comprises: 1) a large extracellular amino-terminal 
domain (ECD), which contains the agonist binding site, several glycosylation sites, and at 
least one highly conserved cysteine bridge. In addition to its role in competitive ligand 
binding the ECD is essential for the correct ass~mbly of the receptor (Chavez and Hall, 
1992; Verral and Hall, 1992). This region also contains sites that interact with allosteric 
modulators as well as an immunogenic region, against which a large fraction of 
autoantibodies against nAChR is directed in the autoimmune disease myasthenia gravis 
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(Tzartos et al., 1998); 2) three hydrophobic membrane-spanning segments (Ml-M3) 
separated by short loops; 3) a large and variable intracellular domain, which contains 
putative phosphorylation sites for serine/threonine kinases; 4) a fourth transmembrane 
segment M4 with a relatively short extracellular carboxy-terminal end (Galzi and 
Changeux, 1995). Also common to all the a-subunits is the presence in the first 
extracellular domain of a cysteine-loop (Cys-loop) defined by two cysteines (Cys) that in 
the mammalian subunits are separated by 13 amino acids . The Cys-Cys pair is required for 
agonist binding (Fig. l. l ). 
Fig. 1.1. Ribbon diagram of the al subunit. The figure shows the side view of the al subunit. Locations of 
the functionally important A, B, C, Pl - P2 and Cys loops in the N-terminal domain of the subunit are 
indicated. The transmembrane domains (Ml-4) and the intracellular M3-M4 loop are shown in yellow. (From 
Unwin, 2005). 
At low resolution the Torpedo nAChR appears as an integral elongated 
transmembrane protein, ~160 A long, that protrudes by ~60 and ~20 A into the synaptic 
and intracellular compartments, respectively, composed of five similar rod-shaped subunits 
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arranged around the central axis, with a symmetry perpendicular to the membrane. It 
creates a central pore, with a diameter of -25 A at the synaptic entrance, which becomes 
narrower at the transmembrane level, and makes a narrow water-filled path across the 
membrane (Unwin et al., 1988). The ion conducting pathway, which is -40 A long, is 
bounded by two large vestibules, which serve as pre-selectivity filters for ions (Unwin et 
al., 2002; Unwin, 2005). The presence of charged groups at the mouth and on the inner 
wall concentrate the ions the vestibules select for (cations), while screening out the ions 
they discriminate against (anions). The cation conductance is increased by rings of 
negative charges located at the mouth of the pore. These rings have been shown to 
influence channel conductance (Imoto et al., 1988). 
1.4 The acetylcholine binding site 
Early electrophysiological studies on Torpedo or mammalian muscle nAChRs 
indicated that nAChRs contains two ACh binding sites located in the ECD (Galzi et al., 
1990). The ligand-binding domain shapes a long, ~20 A diameter central vestibule and the 
two binding sites are about 40 A from the membrane surface and 45 A from the gate, on 
opposite sides of the pore (Unwin, 2005). The receptor subunits in the ligand-binding 
domain are each organized around two sets of ~-sheets joined through a disulphide bridge 
forming a Cys-loop, as was shown by the structure of the closely related soluble protein, 
the snail acetylcholine binding protein (AChBP) (Brejc et al., 2001). The agonist binding 
site is a hydrophobic pocket located at the interface between adjacent subunits (Karlin, 
2002; Sine, 2002). Several lines of evidence have demonstrated that, in the case of both the 
Torpedo electric organ and muscle nAChR, the binding sites for nicotinic agonists and 
competitive antagonists are located at the al/o and alfr. subunit interfaces (Fig. 1.2). The 
most compelling supporting findings are: (a) affinity labelling experiments performed with 
a series of competitive antagonists of different chemical structure which showed that the 
chemical probes labelled primarily the a I subunit, and to a lesser extent the y and o 
subunits (Oswald and Changeux, 1982; Dennis et al., 1988; Langenbuch-Cachat et al., 
1988; Pedersen and Cohen, 1990; Middleton and Cohen, 1991 ); (b) expression in cell lines 
of the al subunit with either the 'Y or o subunits which yielded an ACh binding pocket with 
native pharmacology, whereas all other pairwise coexpressions or single expre.ssions of 
subunit failed to give ACh binding sites (Blount and Merlie, 1989). The much stronger 
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labelling of al compared with that of they and 8 subunits suggests an asymmetric location 
of the binding site with respect to the interfaces. It has thus been proposed to refer to the al 
subunit as carrying the 'principal component', and the 8 or y subunit as contributing to the 
'complementary component' of the nicotinic binding site (Corringer et al., 1995). 
Photo-affinity labelling, proteolysis, and mutational studies (Kao and Karlin, 1986; 
Dennis et al., 1988; Galzi et al., 1990; Galzi et al., 1991) made it possible the identification 
of the various residues that compose the principal component of the al subunit of the 
Torpedo receptor. The ligand binding site is formed by the contribution of residues highly 
conserved throughout the LGIC family. These residues are located in three separate loops 
of the polypeptide chain of the principal side of the binding site (Corringer et al., 2000), 
designated A, B and C. The complementary side contributes to the binding site with less 
conserved residues located in loops D, E and F (Fig. 1.2). 
Fig. 1.2. Top view of the extracellular domain involved in the ACh binding site in the muscle-type 
nAChR. The ACh binding sites are located at the aiy and ai8 interfaces. The principal component of the 
ACh binding site is located in the a subunit which contributes with loops A, B, and C. The residues involved 
in the binding site are represented by small spheres. Loop A is fonned by residue Tyr93 (Y), loop B Loop by 
the amino acid Trp 149 (W) and loop C by residues Tyr190 (Y), Cys192 (C), Cys 193 (C) and Tyr198 (Y). The 
disulfide bond in the a subunit is indicated as - S- S-. The complementary component of the high-affinity 
ACh binding site is located in the 8 or y subunit which contributes with loops D, E, and F. (From Arias, 
1997). 
Most of the residues which contribute to the binding pocket are located in loop C in 
the a subunit that at its apex contains the Cys-Cys pair (a1Cys192 - a1Cys193 in 
Torpedo). In addition to these, the most important residues required for ligand binding are 
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predominantly hydrophobic aromatic amino acids, including a.1Tyr93 (loop A), a.1Trpl49 
(loop B), a.1Tyr190 and a.1Tyr198 (loop C), which connect ~-strands in the a subunit 
(Sine, 2002) (Fig. 1.2). All these residues were identified as being near the agonist binding 
site by labelling with a small photo-activable ligand that covalently reacts with the receptor 
and acts as a competitive antagonist (Dennis et al., 1988), and the first three are highly 
conserved in the muscle and neuronal nAChR subunits. Studies in which a series of 
unnatural tryptophan derivatives were substituted in place of the natural residues, 
suggested that the side chain of a 1Trp149 is in Van der Waals contact with the quaternary 
ammonium group of ACh in the bound state of the receptor (Zhong et al., 1998). A single 
channel study by Akk (2001) showed that mutation of this residue affected binding but 
mainly caused impairment of gating. Mutations of a.1Tyr93, a.1Tyr190 and a.1Tyr198 
affect in the same way the apparent affinity of ACh, which suggests that these tyrosine 
residues contribute to stabilization of the quaternary ammonium portion of ACh (Sine et 
al., 1994 ). Incorporation of unnatural amino acids at these positions revealed a prominent 
role of the hydroxyl group and of the aromatic ring of a 1 Tyr93 and a 1Tyr198, respectively 
(Nowak et al., 1995). Chemical labelling also showed that the pair of adjacent cysteines 
(Cys192 and Cysl93) is likely to be close to the binding site (Kao and Karlin, 1986). The 
most important residues in neighbouring subunits that influence ACh binding are Trp57 of 
th~() subunit and the homologous Trp55 of they subunit, localized in the loop D (Chiara et 
al., 1998). Moreover, mutation of ()Asp 180 (loop F) to asparagine, and of the homologous 
yAspl 74 was found to decrease the affinity for ACh (Martin et al., 1996). 
The crystal structure of nAChR, and indeed of any of the members of the Cys-loop 
family of receptors, has not yet been resolved. However, in the last decade two 
breakthrough studies have made it possible to glimpse the three-dimensional structure of 
this important signalling protein. The first breakthrough was the resolution of the crystal 
structure of the fresh water snail protein, the ACh binding protein (AChBP) (Brejc et al., 
2001; Smit et ril., 2001). AChBP is a soluble protein found in fresh water snails that is 
produced and stored in glial cells and released in an ACh-dependent manner into the 
synaptic cleft, where it modulates synaptic transmission. Mature AChBP is a 
homopentamer. Each protomer is 210 amino acids long and has 20 - 23 % sequence 
identity with the ECD of nAChR and 15 - 18 % ~ith the ECD of other LGICs (Smit et al., 
2001 ). The crystal structure of the AChBP showed that the protein subunits in the ligand 
binding domain are each organised around two sets of ten ~-sheets forming a ~-sandwich 
and joined through the disulphide bridge forming the Cys-loop (Fig. 1.3, Brejc et al., 
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2001). This disulfide bond is conserved in the superfamily of pentameric LGICs and is 
important for the assembly of the receptor (Blount and Merlie, 1990; Green and 
Wanamaker, 1997). Nearly all residues that are conserved within the nAChR family are 
present in the AChBP, including those that are relevant for ligand binding. Moreover, 
AChBP binds known nAChR agonists and competitive antagonists such as ACh, nicotine, 
d-tubocurarine (dTC) and a-bungarotoxin (a-Btx) (Smit et al., 2001). As mentioned above, 
in the nAChR residues important for binding are clustered in loop regions (A-F). In the 
AChBP structure, these loop regions form a single pocket region at the subunit interface, 
with loops A-C contributed from one subunit and D-F from another. Loop C is particularly 
prominent in the AChBP and it contains several conserved residues involved in ACh 
binding, including two adjacent cysteins (homologous of Torpedo a1Cys192 and 
a1Cys193) and two tyrosines (homologous of Torpedo a1Tyr190 and a1Tyr198). 
Subsequent crystallization of the AChBP in the presence of nicotinic agonists and 
antagonists (Celie et al., 2004; Celie et al., 2005; Ulens et al., 2006) provided atomic 
resolution details on the atomic interactions between ligands and specific residues in the 
ligand binding site. 
Crystal structures of AChBP bound to agonists (Celie et al., 2004; Hansen et al., 
2005) showed that agonists are fully enveloped by the protein. Trp143 (corresponding to 
Torpedo a 1Trp148) makes strong 1t-cation interactions with the agonist (Zhong et al., 
1998); the other four aromatic residues that form the remainder of the binding cavity, 
direct their 1t electrons or hydroxyl groups toward the agonist. Asp85, situated behind the 
central Trp, forms hydrogen bonds with the main chain to optimize the Trp for interaction 
with agonists (Lee and Sine, 2004). Hydrogen bonds also form between polar moieties of 
the agonist and the protein main or side chains from both faces of the binding site, and in 
some cases include a bridging water molecule. Hydrophobic residues from both faces 
further stabilize ag<,:>nists through van der Waals contacts. Finally, loop C caps the entrance 
to the binding cavity, trapping the agonists. 
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Fig. 1.3. Ribbon representation of the of Lymnaea stagnalis AChBP. Side view of AChBP protomer 
from outside the pentameric ring. The side of the protomer, bearing the conserved Cys loop is called the 
principal (plus) side. Disulphide bridges are indicated in green ball-and-stick representation. (From Brejc et 
al., 2001) 
The second breakthrough in the elucidation of the molecular structure of nAChRs 
and Cys-loop receptors in general was the attainment of electron microscopy images of 
full-length Torpedo nAChRs at a resolution of 4 A. These images revealed the overall 
organisation of the pentameric assembly in its closed fom1, the architecture of the ECD and 
the pore region of each subunit (Miyazawa et al., 2003; Unwin, 2005). The ECD of the a 
subunit of the Torpedo nAChR was shown to contain ten P-strands (six inner sheets and 
four outer sheets) and one major a-helix, like AChBP protomers. This portion also contains 
several loop regions (i .e., the loops A, B and C, the Cys loop and the p l- P2 loop), which 
are critical for receptor function. The subunits in the ligand-binding domain interact mainly 
through polar side-chains. Similar sets of interactions occur in the AChBP (Brejc et al., 
2001 ). The P9- P 10 hairpin of the a subunit incorporates loop C, which is implicated in 
A Ch binding. The side-chains of Tyrl 90, Tyr 198 and Cys 192 in loop C and Trp 149 in 
loop B are conserved in nAChR a subunits and co-ordinate to the bound ACh analogue, 
carbamylcholine, in the complex with AChBP (Celie et al., 2004). Thus, this whole region, 
including the loop A and the adjacent strands ps and P6 of they (or 8) subunit, is involved 
in shaping the A Ch-binding pocket of the receptor. 
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Recently Dellisanti et al. (2007) resolved the crystal structure of the ECD of the 
mouse al subunit bound to the toxin a-Btx at high-resolution (1.94 A), providing new 
insights in the structure-function relationships of the nAChR. The new structure confirmed 
what was already known, but it also revealed the presence of a water-filled hydrophilic 
cavity in the core of the subunit, close to the transmembrane domain, which is thought to 
be important for gating in the intact receptor. These hydrophilic residues are not present in 
the AChBP, which could explain why AChBP is not particularly efficient in gating when 
fused to a transmembrane domain (Bouzat et al., 2004). 
1.5 Gating of the nAChR channel 
Ligand binding induces rapid conformational changes in the receptor, which in turn 
are converted into channel opening within microseconds. The receptor in the closed state 
switches to the open state in a reversible process called gating. In the absence of agonist, 
the nAChR channel can open but with very low probability, whereas in the presence of 
ACh the channel opens with a probability approaching unit. Activation by ACh can 
therefore be viewed as an amplification process in which the probability that the channel 
will open is greatly increased (Jackson, 1986). For all Cys-loop receptors, binding of two 
agonist molecules is required for full amplification. When two molecules of agonist bind to 
the receptor, the channel opens, with an equilibrium constant that increases with increasing 
number of bound agonist. Channel opening is driven by higher affinity of the agonist for 
the open than for the closed state. According to this mechanism the transition from the 
closed to the open state occurs in one step. Recently, a new gating mechanism has been 
suggested for the heteromeric glycine al~ receptor, which, like the nAChR, belongs to the 
Cys-loop superfamily of LGICs. According to this model, gating may be divided into two 
steps: a flip pre-open state, with the channel still closed, and the open state. The flipped 
receptor has higher affinity for the agonist, which could result from domain closure around 
the bound agonist (Burzomato et al, 2004). Subsequent studies showed that the flip 
mechanism also fits nicotinic data very well and it describes more accurately the gating 
behaviour of the receptor (Lape et al., 2008). The flip mechanism could also explain the 
nature of partial agonism in the nAChR family. It has been shown that partial agonists have 
lower affinity for the flipped state rather than low affinity for the open state; it was 
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therefore suggested that partial agonism originates from a reduced ability to flip rather than 
a reduced ability to open (Lape et al., 2008). 
The gating mechanism described above infers a conformational change in the 
ligand binding domain of the nAChR induced by agonist binding. The first structural 
evidence for such transitions can1e from cryo-electron microscopy of the Torpedo nAChR 
following rapid application of ACh (Unwin, 1995). These experiments showed that 
binding of ACh initiates two connected events in the ligand binding domain. One is a local 
structural rearrangement of the ACh-binding site, and the other a larger scale 
conformational change, involving rotational movements predominantly in the two a 
subunits. Subsequent analysis revealed agonist-dependent rotation of the inner ~-sheets of 
the binding domain, and tilting of the peripheral ~-sheets toward the central water-filled 
vestibule (Un win et al., 2002). The crystal structure of AChBP showed a similar tilting of a 
peripheral ~-hairpin, known as loop C (Celie et al., 2004; Hansen et al., 2005). 
Comparison of agonist-free and agonist-bound crystal structures and molecular dynamics 
simulations (Gao et al., 2005) of the AChBP also revealed agonist-dependent motion of 
loop C. These observations were further supported by the refined cryo-electron 
microscopic structure of the Torpedo at 4 A resolution (Unwin, 2005) and the crystal 
structures of the nAChR-like bacterial channels ELIC (Hilf and Dutzler, 2008) and GLIC 
(Bocquet et al., 2009). In the agonist-free receptor loop C is in an 'open' or 'uncapped' 
configuration, which corresponds to the closed or resting state of the channel; in the 
agonist-bound receptor loop C is in a 'closed' or 'capped' configuration, which 
corresponds to the open or desensitise state of the receptor. The capped conformation with 
bound agonist suggests that binding flips loop C from uncapped to capped, thus initiating 
the structural changes that lead to channel opening. 
A coupled triad of residues, aTyr190, aAsp200 and aLys145, was identified as 
physically linked to loop C and it is thought to trigger early steps in the activation process. 
Mutation of any of these three residues markedly impairs channel gating, and all three are 
interdependent in contributing to gating (Mukhtasimova et al., 2005). In the uncapped 
configuration of loop C generated by molecular dynamics simulation of AChBP (Gao et 
al., 2005), the conserved Tyr185 (equivalent to a1Tyr190 in Torpedo) is 8 A away from 
the conserved Lys139 (a1Lysl45 in Torpedo) in ~-strand 7, which forms a salt bridge with 
the conserved Asp 194 ( aAsp200 in Torpedo) in ~-strand 10. In agonist-bound crystal 
structures of AChBP (Celie et al., 2004), loop C tilts inwards and Tyr185 moves closer to 
Lys139 (2 - 3 A), displacing Asp194 from the Tyr/Lys pair. The recent structure of the 
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ligand-binding domain of the al muscle subunit confirms that a1Lys145 and a1Asp200 
form a salt bridge which stabilizes P-strand 7 and 10 (Dellisanti et al., 2007). When the 
agonist binds to the receptor, capping ofloop C weakens the aLys145/aAsp200 salt bridge 
as aTyr190 establishes contact with aLys145. These local changes displace P-strands 7 and 
10, which transmit further changes to the junction of the binding and pore domains. 
Three structural elements of the binding-channel domain interface, the P 1-P2, Cys-
and P8-P9 loops from the ligand-binding domain, and the M2-M3 loop from the channel 
domain, transmit structural changes from the ligand-binding domain to the pore. The 
importance of these loops for coupling binding to gating has been demonstrated by 
generating a chimera receptor in which AChBP was substituted for the binding domain of 
the 5HT3A (Bouzat et al., 2004) receptor, as well as by mutational studies (Lyford et al., 
2003; Bouzat et al., 2004; Chakrapani et al., 2004; Sala et al., 2005). 
Mutational-functional studies subsequent to the publication of the structural model 
of the Torpedo receptor at 4 A resolution (Unwin, 2005) have largely confirmed the 
findings of Unwin (2005). Thus, analysis of the receptor structure revealed a molecular 
pathway from the binding site to the top of the channel-forming M2 domain, in which the 
pre-Ml domain is functionally coupled to the M2-M3 linker through the Pl-P2 loop. 
aArg209 and aGlu45 have been identified as key elements of this pathway (Lee and Sine, 
2005). The side chain of aArg209 from the pre-Ml strand forms a salt bridge with aGlu45 
from the Pl-P2 loop, aligning these residues with aPro272 and aSer269 of the M2-M3 loop 
to create an assembly that interconnects the ligand binding domain with the pore domain 
(Lee and Sine, 2005). Both Arg209 and Glu45 are present in every member of the Cys-
loop receptor family (Le Novere and Changeux, 2001 ), suggesting a common transduction 
mechanism between ligand binding and channel gating (Corringer et al., 2000; Absalom et 
al., 2003; Kash et al., 2003; Kash et al., 2004; Xiu et al., 2005). Mutation of any of these 
residues of the Principal pathway markedly alters channel gating, suggesting that they 
couple binding to gating. A strong physical interdependence was found for the pair 
Arg209/Glu45 and also for the triads Glu45Nal46/Pro272 and Val46/Pro272/Ser269 
providing compelling evidence for physical interactions between these residues. In 
addition, for the 5HT 3A receptor it was proposed that structural changes induced by ligand 
binding lead to cis/trans isomerisation of Pro272 ,in the M2-M3, which may bend the M2-
M3 loop and facilitate rotation of M2 into the open channel conformation (Lummis et al., 
2005). Comparison of x-ray structures ofELIC in the inactive state and GLIC in the active 
state suggests that agonist binding causes translation of the p 1-P2 loop against the M2-M3 
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linker, displacing the tops of the M2 and M3 a-helices away form the central axis, thus 
initiating ion conduction (Hilf and Dutzler, 2008; Bocquet et al., 2009). 
More recently, a parallel coupling pathway has been identified, in which the pre-
Ml domain is coupled to the M2-M3 linker through the Cys-loop (Lee eta/., 2009). Strong 
energetic coupling has been revealed among aPhe135 and aPhe137 from the Cys-loop, 
aLeu210 from the pre-Ml domain, and aLeu273 from the M2-M3 linker. The high-
resolution structures of the bacterial homologs ELIC and GLIC confirm the interaction of 
the Cys-loop with the pre-Ml domain and the M2-M3 loop revealed form the cryo-electron 
structure of the Torpedo AChR. In both Torpedo and bacterial structures, the C-terminal 
half of the Cys-loop associates with the pre-Ml domain, the N-terminal half associates 
with the M2-M3 linker and the prevalent inter-residue contacts are hydrophobic. Studies of 
linear free energy relationship of channel gating suggested that the ~ 1-~2 and the Cys-
loops change conformation at the same time (Jha et al., 2007). A coordinated movement of 
the two loops would displace the linker away from the central axis, moving the tops of the 
M2 and M3 a-helices in the same direction, dilating the top of the pore (Bocquet et al., 
2009; Hilf and Dutzler, 2009). 
Gating of the AChR channel requires global structural changes, yet how these 
changes propagate between subunits remains largely unknown. Low-resolution cryo-
electron microscopy images detected agonist-mediated changes in the a-subunits but not in 
the other subunits (Unwin et al., 2002). However, several lines of evidence show that the 
non-a subunits contribute profoundly to channel gating (Bouzat et al., 2002; Mitra et al., 
2004; Mukhtasimova and Sine, 2007); the non-a subunits may move as rigid bodies in 
response to the a subunits or as part of an intersubunit network. aTyr127, sAsn39 and 
oAsn4 l are good candidates for intersubunit linkages. These residues show the 
characteristics expected of structures that couple agonist binding to channel gating: residue 
proximity, residue conservation, impaired channel gating by single mutations and 
nonadditive changes in gating by double mutations. aTyr127 and sAsn39 or oAsn41 were 
shown to associate in the diliganded closed state but they dissociate in the open state 
(Mukhtasimova and Sine, 2007). 
Electron microscopy of the Torpedo AChR at a resolution of 0.9 nm suggested that 
channel gating primarily involves rotation of the M2 helices (Unwin, 1995). Different 
movements were proposed for the M2 helices: computational studies suggested both a 
twisting and tilting of the M2s (Taly et al., 2005; Cheng et al., 2006a; Cheng et al., 2007); 
lysine substitution along M2 suggested a simple dilation rather than twisting of the M2s 
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(Cymes et al., 2005); molecular dynamic simulations of the neuronal a7 nAChR suggested 
both rotation and tilting (Cheng et al., 2006b); finally, recent studies of molecular dynamic 
simulation of the Torpedo AChR suggested peristaltic motions of M2 and may account for 
all the proposed motions (Wang et al., 2008). The M2 helices from the five subunits form a 
narrow constriction, called resting gate, which represents the barrier to the ion flow. 
Motion of the M2 helices during gating leads to a transient removal of this barrier. In the 
resting gate, the narrow constriction has a diameter of about 3 A, which increases to about 
8 A when the gate opens (Wang and Imoto, 1992). Finally, simulation of the a7 receptor 
motion during gating showed that the M4 domain bends significantly outward during relief 
of the gate (Law et al., 2005). 
The mechanisms described so far centre on stable states of the receptor, open and 
close, but equally important is the transition state that connects them. The transition state is 
important because its free energy relative to closed and open states determines the channel 
gating rate constants. The rate constant for channel opening is high, allowing opening of 
the ACh-occupied channel within tens of microseconds, and also allowing repeated 
opening during each occupancy. The rate constant for channel closing is about 20-fold 
slower, yielding an open-state lifetime of around half a millisecond. Recent studies 
indicated that, after binding, nAChRs move through a number of brief intermediate shut 
states, a 'conformational wave', before the channel opens (Grosman et al., 2000; 
Chakrapani et al., 2004; Auerbach, 2005; Zhou et al., 2005; Purohit et al., 2007). 
1.6 The ion channel pore 
The ion channel domain of the Torpedo nAChR is 40 A long and has a diameter of 
20 A (Miyazawa et al., 2003). The ion channel was initially identified by photoaffinity 
labelling using the open-channel blocker chlorpromazine. Chlorpromazine was found to 
label, in an agonist dependent manner, a unique high-affinity site located within the M2 
transmembrane domain, to which all five the subunits of the Torpedo receptor contribute 
(Heidmann and Changeux, 1984; Giraudat et al., 1986). Studies using chimeras between 
Torpedo ray and bovine nAChR o subunits have ~onfirmed the role of the M2 domain in 
formation of the ion conducting pore, revealing an involvement of the M2 domain and the 
M2-M3 linker in determining the rate of ion transport through the channel (Imoto et al., 
1988). Furthermore, affinities of voltage-dependent blockers were found to be susceptible 
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to mutations within the nAChR M2 domain (Leonard et al., 1988) and changes in 
conductance were observed when charged residues in the linkers near the M2 domain were 
mutated (Imoto et al., 1988). Subsequent photoaffinity labelling studies and substituted 
cysteine accessibility (SCAM) experiments identified further amino acids located in the 
M2 domain of the receptor which were shown to be lining the pore (Hucho et al., 1986; 
Pedersen et al., 1992; Karlin and Ak:abas, 1995). The pattern of labelling supports the 
folding of M2 into an a-helix, in agreement with secondary structure predictions (Le 
.Novere et al., 1999) and high-resolution images of the ion channel of the Torpedo nAChR 
(Unwin, 2005), with the water accessible amino acid residues all being positioned on the 
same side of the helix. Electron microscopy images of the open conformation of the 
channel identified five rods bordering the ion channel, attributed to the M2 segment 
(Unwin, 1995). In the closed form of the receptor, these rods bend inwards, towards the 
central axis, making the lumen of the pore narrower near the middle of the membrane. 
However, the exact location of the constriction point has not been identified yet, and 
different experimental approaches have led to different conclusions: residues at positions 
9' and 13' of M2 that form a hydrophobic girdle (Panicker et al., 2002; Miyazawa et al., 
2003); residues at positions 2' through 6' near the intracellular end of M2 (Wilson and 
Karlin, 1998; Karlin, 2002; Paas et al., 2005); or a location closer to the extracellular 
entrance of the channel (Labarca et al., 1995; England et al., 1999). The diameter of the a.-
helical component is consistent with the notion that ions cross the membrane at this level 
in a fully hydrated state, whereas the narrower diameter of the loop component is expected 
to accommodate only partially dehydrated ions. The critical role of the loop component in 
cation discrimination as well as charge selectivity further supports its contribution to the 
selectivity filter of the channel by specific dehydration of ions. Accordingly, the a-helical 
component would select on the basis of stabilization of hydrated ions within the 
membrane, and the, several phenotypes observed at this level could be explained in a first 
attempt on the basis of a structural reorganization of this portion of the channel. 
The M2 helix seems to have minimal contacts with Ml, M3 and M4, which form 
an outer scaffold around the ion pore. Overall, the ion channel appears to be composed of 
two distinct structural domains: an upper 'alpha-helical component', which delimits both 
the wide portion of the pore and the pharmacological site for non-competitive blockers; 
and a lower 'loop component', which contributes to the narrowest portion of the channel 
(Fig. 1.4) (Dani, 1989; Villarroel and Sakmann, 1992; Wang and Imoto, 1992). 
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Fig. 1.4. A model for the structural and functional organization of the ion channel. The contribution of 
two subunits is shown to illustrate the ion channel, which is actually formed by homologous regions from the 
five subunits of the pentamer. The residues with numbers correspond to the rings involved in ion selectivity 
(circles). (From Corringer et al., 2000) 
1.6.1 Charge selectivity filter 
When a channel activates, permeant ions flow passively down their electrochemical 
gradient, changing the membrane potential and allowing communication between extra-
and intracellular environments. nAChRs are cation-selective ion channels. In most 
nAChRs the dominant ion flux is carried by Na+ and K+ but in receptors such as a.7 
nAChRs Ca2+ permeability is more significant (Bertrand et al., 1993). The permeability of 
monovalent cations increases with their radius, whereas there is an inverse correlation 
between radius and permeability for divalent cations (Keramidas et al., 2004). Cations 
enter the pore through the extracellular vestibule formed by the N-terminal domain or 
through lateral openings, located at the subunit interfaces. Several studies have located the 
'charge selectivity filter' of the Cys-loop LGICs at the intracellular border of M2 
(Keramidas (!t al., 2004). 
Sequence analysis of consensus amino acids facing the ionic pore between different 
LGICs showed a remarkable homology, even between cationic and anionic channels. 
Selectivity for cations is determined by conserved rings of residues located on either side 
of the channel mouth (Imoto et al., 1988) and in fenestrated structures in the cytoplasmic 
domain (Kelley et al., 2003), which stabilise cations and concentrate them relative to bulk 
solution. Mutational studies and molecular dynamics simulations revealed the contribution 
of several residues to ionic selectivity: two rings of polar Ser/Thr, in positions 6' and 12' in 
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the M2 domain (the prime numbering starts at the beginning of the M2); three rings of 
hydrophobic Leu/Val in positions 9', 13' and 16'. The Leu residue located in 9' position is 
the only fully conserved residue and is considered a signature for this class of receptors; 
and three rings of charged Asp/Glu residues, in positions -5', -1' and 20', called 
cytoplasmic, intermediate and extracellular ring, respectively. Equivalent residues have 
been found in the prokaryotic homolog GLIC (Bocquet et al., 2009). Mutations in any of 
the residues that form these rings were found to alter all aspects of ionic selectivity of the 
channel. In the muscle type receptor, residues equivalent to a7Ser240 and a7Glu237 were 
found to be involved in the selectivity and permeability of monovalent cation (Imoto et al., 
1988; Cohen et al., 1992; Villaroel and Sakmann, 1992; Wang and Imoto 1992). In 
contrast, mutation of the residue Glu237 in the a7 receptor abolished calcium penneability 
but preserved that to monovalent cations (Bertrand et al., 1993). In the a7 nAChR, 
insertion of a pro line residue between positions 234 and 23 7, along with the introduction of 
a polar or even charged residue in position Leu247 and Val251 and the mutation Glu237A, 
was shown to convert the receptor from cationic to anionic (Galzi et al., 1992; Corringer et 
al., l 999a; Corringer et al., l 999b) and the reciprocal mutations convert the a 1 glycine 
receptor from an anionic to a cationic channel (Keramidas et al., 2002). Large hydrophobic 
residues in the centre of the pore play an important role in channel closing in nAChRs 
(Revah et al., 1991; Wilson and Karlin, 2001; Miyazawa et al., 2003). It was proposed that 
these hydrophobic residues would impede ion permeation by a process called 'hydrophobic 
gating' as long as the channel does not exceed a certain size (Beckstein and Sansom, 
2006). Unlike in the structure of nAChR, in the bacterial nAChR-like channel ELIC these 
residues physically obstruct the pore in the closed conformation of the channel, thus 
preventing diffusion of ions. 
Molecular dynamics simulations studies of the muscle nAChR (Wang et al., 2008) 
and co-crystallizati9n of AChBP with sulphate anions (Hansen et al., 2008) suggested that 
three more rings of functional analogous polar or negatively charged residues within the 
central vestibule of the ligand binding domain, corresponding to aAsn47, aGlu83 and 
aAsp97, are important for ion conductance. 
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1.7 Desensitisation of nAChRs 
In the mammalian nervous system, nAChRs can be broadly classified as either o.7-
containing receptors that desensitise rapidly (in milliseconds) or non-o.7 receptors that 
desensitise slowly (in seconds). When a medium to high (µM to mM) concentration of 
agonist is applied, nAChRs are first activated and then desensitise, entering a bound, non-
conductive state, with subsequent recovery after agonist removal. This process, called 
'classical desensitisation', develops usually in the range of tens of milliseconds, although 
different subtypes of nAChRs have differential susceptibility to desensitisation. 
Furthermore, different agonists have different ability to desensitise nAChRs. 
Low agonist concentrations can induce desensitisation even without apparent 
receptor activation. This process is called 'high-affinity desensitisation' (Paradiso and 
Steinbach, 2003). High-affinity desensitisation is a slow process (taking seconds to 
minutes), and therefore is more likely than classical desensitisation to be generated during 
chronic exposure to agonists. High-affinity desensitisation is also receptor-subtype 
specific, affecting preferentially o.4~2 rather than a.7 or a.3~4 nAChRs. Together with 
desensitisation, long exposure to an agonist (e.g. nicotine) can produce sustained changes 
in receptor sensitivity due to upregulation of the receptors (Buisson and Bertrand, 2002). 
Recent findings suggested that recovery from desensitisation is agonist-dependent 
(Mike et al., 2000; Meyer et al., 2001; Paradiso and Steinbach, 2003). For example, when 
the onset and extent of desensitisation are similar, the recovery of a.4~2 receptors after the 
removal of nicotine requires much more time than recovery after the removal of ACh 
(Paradiso and Steinbach, 2003). Desensitised receptors are characterised by high affinity 
for agonists indicating that they might be potential traps for unbound agonist molecules 
(Giniatullin et al., 1997; Giniatullin et al., 2001). 
Although identification of the molecular structures underlying desensitisation is 
still incomplete, site-directed mutagenesis within receptor subunits revealed that 
replacement of certain elements can transform the desensitisation properties of the receptor 
when expressed in heterologous systems. However, if mutant receptors display altered 
desensitisation, this does not necessarily prove that the mutated sites are the structural 
motifs responsible for this process. In fact, becau~e desensitisation is a function of agonist 
binding and receptor activation, any mutant expressing changes in these parameters could 
show changes in the properties of desensitisation. Furthermore, receptor properties might 
be influenced by the expression system itself (Lewis et al., 1997). 
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A, single-point mutation (Ser284Leu) in the second transmembrane domain (M2) of 
the a4 subunit strongly increased the rate of onset of classical desensitisation without effect 
on agonist affinity (Matsushima et al., 2002). Other M2 mutations in the a4 subunit can 
produce similar effects whereas mutations in M2 of the ~2 subunit slow desensitisation. 
Single-point mutations in M2 of a7 receptors can greatly decrease the desensitisation onset 
and strongly increase agonist affinity (Revah et al., 1991; Placzek et al., 2004). The 
dissociation between changes in agonist affinity and desensitisation onset suggests that 
there are independent sites for receptor activation and desensitisation (Lopez-Hernandez et 
al., 2004). In addition to single amino acids, larger subunit domains have a role in 
desensitisation. In fact, large regions of the extracellular N-terminal domain of the ~2 
subunit (when combined with the a3 subunit) are important to ensure the fast onset of 
classical desensitisation (Bohler et al., 2001), whereas the N-terminal domain of the a4 
subunit, along with the first three transmembrane domains, appears responsible for high-
affinity desensitisation (Kuryatov et al., 2000). 
Desensitisation is a plastic process, rapidly adapting to changes in neuronal activity 
through modulation by local factors. One of these is the endogenous peptide substance P, 
which powerfully facilitates desensitisation by binding to an allosteric site distinct from the 
ACh-recognition sites (Di Angelantonio et al., 2003). Other modulators are intracellular 
messengers (e.g., Ca2+) that primarily target the recovery from, rather than the onset of, 
desensitisation (Khiroug et al., 1998; Quick and Lester, 2002; Khiroug et al., 2003). 
1.8 Role of the M3-M4 intracellular loop 
The amino acid sequence of the large cytoplasmic loop between M3 and M4 shows 
considerable diversity among different nAChR subunits. The functions of the large 
cytoplasmic loop, however, have not been studied as extensively as the functions of the 
extracellular or transmembrane domains. The structure of this loop was not seen in the 4 A 
structure of Torpedo nAChR and was presun1ed to be disordered (Unwin, 2005). 
Residues in the large cytoplasmic loop near the intracellular end of M4 affect 
assembly of subunits and electrophysiological properties of nAChRs (Yu and Hall, 1994; 
Valor et al., 2002; Kuo et al., 2005; Castelan et al., 2007). Because of the sequence 
diversity of the large cytoplasmic loop, this region might be important for subunit specific 
behaviour and interactions with cellular components and physiology. The large 
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cytoplasmic loop interacts with cytoplasmic transport machinery for trafficking nAChRs to 
synapses (Williams et al., 1998; Temburni et al., 2000; Keller et al., 2001; Ren et al., 
2005; Xu et al., 2006) and residues at the cytoplasmic and extracellular ends of M4 
(Roccamo and Barrantes, 2007) of al affect assembly and targeting to the cell surface. At 
the cell membrane, the large cytoplasmic loop interacts with the cytoskeleton (Bencherif 
and Lukas, 1993; Yu and Hall, 1994; Shoop et al., 2000). Phosphorylation of the large 
cytoplasmic loop (Pacheco et al., 2003; Wiesner and Fuhrer, 2006) was shown to affect 
desensitisation (Huganir et al., 1986; Fenster et al., 1999), expression (Wang et al., 2004; 
Cho et al., 2005) and cytoskeleton interactions (Colledge and Froehner, 1997). 
1.9 Neuronal nAChRs 
Neuronal nAChR are widely expressed in both the central (CNS) and peripheral 
(PNS) nervous systems. To date, nine a ( a2-al 0) and three ~ (~2- ~4) nicotinic subunits 
have been identified in the nervous system, cochlea and a number of non-neuronal tissues 
(Hogg et al., 2003; Gotti and Clementi, 2004). Neuronal nAChRs can be divided into two 
main classes: the aBgtx-sensitive receptors, which contain a7, a8, a9 and/or alO subunits 
and can form homomeric or heteromeric receptors; and aBgtx-insensitive receptors, which 
are heteromeric receptors containing the a2-a6 and ~2-~4 subunits, and bind many 
nicotinic agonists with high affinity but not a-Bgtx (Lindstrom, 2000; Gotti and Clementi, 
2004). 
The ACh or agonist binding site lies at the interface between an a and an adjacent 
subunit which may be the same a subunit in homomeric receptors ( a.7, a8), a different a 
subunit in heteromeric aBtx-sensitive receptors (a.7-a.8 or a.9-alO) or a ~ subunit in 
heteromeric a.Btx-i!lsensitive receptors (Gotti et al., 2006). In heteromeric a.Btx-insensitive 
nAChRs, the primary component of the binding site is carried by the a.2, a.3, a.4 or a6 
subunits and the complementary component by the ~2 or the ~4 subunits whereas, in 
homomeric receptors each subunit contribute to both the primary and complementary 
components of the binding site (reviewed in Changeux et al., 1998; Corringer et al., 2000). 
The a.5 and ~3 subunits carry· neither the primary nor the complementary component, but 
form functional channels in heterologous systems when expressed with another ligand 
binding subunit and a complementary ~ subunit. The a.5 and the ~3 subunits do not 
participate directly in the formation of the binding site but may contribute to the receptor 
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targeting and localisation in neuronal plasma membrane domains (Le Novere et al., 2002; 
Gotti et al., 2005). 
1.10 Subunit assembly and receptor diversity 
Studies on the Torpedo nAChR showed that the assembly of the pentameric 
receptor occurs in the endoplasmic reticulum and it requires the coordinate expression of 
all the receptor subunits and their subsequent oligomerisation before transport through the 
Golgi apparatus to the plasma membrane is signalled (Smith et al., 1987; Blount et al., 
1990; Green and Claudio, 1993). Appropriate nAChR assembly requires the correct 
number of subunits to combine in the correct order. Studies of muscle nAChR assembly 
suggested two possible models: 1) the assembly proceeds in the endoplasmic reticulum 
where specific subunits are added sequentially to the receptor complex according to the 
conformation the complex assumes (Paulson et al., 1991; Green and Claudio 1993; 
Wanamaker et al., 2003); 2) a-y and a-o dimers are formed before these paired subunits 
subsequently interact with the p subunit to assemble the mature pentamer (Smith et al., 
1987; Blount and Merlie, 1990; Wang et al., 1996). Specific subunit associations are 
defined primarily by sequences located in the N-terminal domain 0' errall and Hall, 1992; 
Yu and Hall, 1994; Kreienkamp et al., 1995). Recent studies showed that the variable and 
large cytoplasmatic domain between M3 and M4 also contributes to protein-protein 
interactions involved in nAChR assembly, subcellular localisation and stability (Kukhtina 
et al., 2006; Kracun et al., 2008). 
Diverse combinations of neuronal subunits can assemble into diverse types of 
nAChRs each with different functional properties (Moroni et al., 2006). Moreover, subunit 
composition of nAChRs changes during development (Moretti et al., 2004). Studies of 
recombinant .nAChRs have revealed how neuronal nAChR subunits can assemble in order 
to form functional receptors. a7 is the only mammalian subunit which appears to 
preferentially form homomeric, rather than heteromeric, receptors in heterologous 
expression systems (Couturier et al., 1990; Gerzanich et al., 1994). This is consistent with 
evidence that this subunit forms homomeric receptors in native systems (Keyser et al., 
1993; Chen and Patrick, 1997; Drisdel and Green, 2000). There is also evidence that a7 
can co-assemble with P2 to form a fu~ctional heteromeric receptor (Khiroug et al., 2002). 
The nAChR a9 subunit can generate homomeric receptors when expressed in Xenopus 
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oocytes (Elgoyhen et al., 1994), but it forms a functional nAChR very much more 
efficiently when it is co-expressed with the alO subunit (Elgoyhen et al., 2001; Sgard et 
al., 2002). This finding is consistent with evidences that indicate that native a9-containing 
nAChRs are heteromeric complexes with alO (Elgoyen et al., 2001; Katz et al., 2004; 
Vetter et al., 2007). The neuronal a2-a6 and P2-P4 subunits fail to generate functional 
receptors when expressed individually in Xenopus oocytes (Boulter et al., 1987; Duvoisin 
et al., 1989; Luetje and Patrick, 1991), results that are consistent with studies performed in 
cultured cell lines (Whiting et al., 1991; Rogers et al., 1992; Wong et al., 1995; Ragozzino 
et al., 1997). Despite their inability to form homomeric nAChRs, these subunits are able to 
form functional receptors when expressed as pairwise combinations of one a and p subunit, 
such as a2p4, a3p2, a3p4, a4p2 and a4p4 (Duvoisin et al., 1989; Papke et al., 1989). 
Subunits like the a6 subunit assemble with other a and p subunits to form complex 
heteromeric receptors such as the a4p2a6P2P3 receptor or a6p3p4 (Kuryatov et al., 2000) 
or much simpler receptors such as a6p2 or a6p4 (Gerzanich et al., 1997; Fucile et al., 
1998). Several triplet subunit combinations containing a5 have been distinguished from 
heteromeric 'pair' subunit . combinations on the basis of altered electrophysiological 
properties. These include: a3a5P2 (Wang et al., 1996b; Gerzanich et al., 1998), a3a5p4 
(Wang et al., 1996; Fucile et al., 1997; Gerzanich et al., 1998) and a4a5p2 (Ramirez-
Latorre et al., 1996). The P3 subunit was shown to co-assemble with several nAChR 
subunits, but in most of the combinations it appears to have a dominant-negative effect 
which results in a lack of functional expression of the P3-containig receptor. Co-assembly 
of P3 into functional a3P3P4 nAChRs was, however, demonstrated by heterologous 
expression in Xenopus oocytes by using a reporter mutation approach (Groot-Kormelink et 
al., 1998). Heterologous expression studies also demonstrated the preferential co-assembly 
of a6 into triplet subunit combinations, which include a6p3p4 (Kuryatov et al., 2000; 
Tumkosit et al., 20D6) and also a3a6p4 and a3a6p2 (Fucile et al., 1998; Kuryatov et al., 
2000). 
1.11 Stoichiometry of neuronal nAChRs 
As mentioned above, some nAChR subunits (such as a7) are able to form 
(unctional homomeric receptors (Couturier et al., 1990). In contrast, most nAChR subtypes 
form heteromeric receptors, containing at least one type of a subunit and one type of non-a 
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subunit. The different combinations of a and alp subunits give receptors which differ in 
terms of cation permeability, activation and desensitisation kinetics, and ligand 
pharmacology. 
The Torpedo muscle-type ACh receptor has been well characterized and shown to 
be a pentameric protein composed of two ACh-binding al subunits and one of each of 
three structural subunits, pl, y, and 8. The stoichiometry of most other nAChRs, on the 
other hand, remains to be fully elucidated. 
nAChRs purified from chick brain (Whiting and Lindstrom, 1986; Whiting et al. 
1987), rats (Whiting and Lindstrom, 1987), and cattle (Whiting and Lindstrom, 1988) have 
shown to be composed of only two types of subunits: ACh-binding a subunits, and 
structural P subunits. Biochemical and electrophysiological studies showed that both chick 
a4P2 (Anand et al., 1991; Cooper et al., 1991) and human a3P4 subtypes have a 
stoichiometry of 2a and 3P when heterologously expressed in Xenopus oocytes injected 
with cRNAs or cDNAs ratio of 1/1 (alp). Studies conducted in Xenopus oocytes also 
showed that a9 and alO co-assemble with the stoichiometry (a9)z(a10)3 (Plazas et al., 
2005). 
However, more recent data indicate that this is an oversimplification. Several lines 
of evidence show that some neuronal nAChR subunit can assemble into receptors with 
alternate stoichiometries and that this can influence the pharmacological and functional 
properties of the receptor. Several studies showed that in heterologous systems the human 
a4 and P2 subunits can assemble in at least two different stoichiometries (Zwart and 
Vijveberg, 1998; Nelson et al., 2003; Moroni et al., 2006; Zwart et al., 2006) and strong 
evidences suggested that a4P2 nAChRs may exist in at least two different stoichiometries 
in the mammalian brain (Marks et al., 1999; Butt et al., 2002; Gotti et al., 2008). In 
heterologous systems the predominant stoichiometries are (a4)3(p2)z and (a4)2(P2)3 
(Nelson et al., 20Q3; Moroni et al., 2006) but other stoichiometric arrangements cannot be 
excluded (Zwart and Vijveberg, 1998). 
Recent studies of more complex nAChRs using reporter mutations showed that 
receptors containing the a3, P3 and P4 subunits assemble with a stoichiometry of 
(a3)2P3(P4)2 (Boorman et al., 2000). 
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1.12 Distribution of nAChRs in the mammalian brain 
The brain cholinergic system is made up of a series of closely and connected 
subsystems consisting of overlapping groups of cells, whose dendrites contact those of 
many other cells. However, each cell innervates a discrete area and establishes its own 
discrete connections. Each cholinergic neuron receives only a small number of innervating 
fibers, which come from different areas of the brain. Each cholinergic subsystem receives 
therefore a large and complete set of information. 
The major cholinergic subsystems in the brain are located in the: 1) magnocellular 
basal complex, which provides the greatest cortical and hippocampal input; 2) 
peduncolopontine-laterodorsal tegmental complex, the second most important cholinergic 
subsystem in the brain. It projects to the thalamic nuclei and midbrain dopamine neurons; 
3) striatum, densely innervated by cholinergic fibers that originate from the intrinsic 
cholinergic neurons and do not project beyond the borders of the striatum; 4) lower brain 
stem, which innervates the superior colliculus, cerebellar nuclei and cortex; 5) habenula-
interpeduncular system, an important station through which the lymbic system can 
influence the brainstem reticular formation; 6) autonomic nervous system. Parasympathetic 
preganglionic cells, located in the encephalic trunk in the sacral segments S2-S4 of the 
spinal cord, project long neuritis to the parasympathetic ganglia located in or near the 
target organs; sympathetic preganglionic neurons, located in the thoracic and lumbar 
segments (from Tl to L3), which project to paravertebral sympathetic ganglia (reviewed in 
Gotti and Clementi, 2004). 
Neuronal nAChRs are expressed in relatively low density in the human brain. In 
addition, their pattern of distribution is relatively homogenous and is not restricted to the 
well-defined brain cholinergic pathways mentioned above. The elucidation of nAChR 
subunits distributiop is currently based on a combination of technical approaches and the 
availability of knock-out or knock-in mice. The neuroanatomical distribution of various 
nAChR subtypes and subunit mRNAs in rodent and chick brain has been well known for 
some years but it has been less well characterised in human brain. The majority of studies 
performed to date, have mapped the distribution of high affinity nAChR sites utilising 
labelled nicotinic agents in homogenates of discrete brain areas or histological brain 
sections. This method is very sensitive, but its specificity for nAChR subtypes is not very 
high because no subtypes-specific ligands are as yet available: [3H]-nicotine and 
[3H]-epibatidine labels all nAChRs; [3H]-cytisine labels the receptors containing the a3, a4 
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and B2 or B4 subunits; [3H}-a-conotoxin-MII labels a3 and a6 containing receptors; and 
[
1251]-aBtx labels a7 and a9/10 receptors (reviewed in Gotti and Clementi, 2004). 
Evaluation of the distribution of specific nAChR subunit, rather than subtypes, expression 
in the human brain has been achieved by in situ hybridisation, quantitative RT-PCR, and 
the use of subunit specific antibodies in immunohistological and immunoblotting studies, 
which give good results in term of specificity and sensitivity. The distribution of receptors 
has also been described in vivo in the human brain using positron emission tomography 
(PET) analysis, a non-invasive imaging technique. Despite the incomplete nature and the 
limitations of the studies performed to date, it is possible to draw a map of nAChRs 
distribution in the human brain (Fig. 1.5). 
Fig. 1 .5. Distribution of nAChR subtypes in the nervous system. Sagittal brain Section showing nAChR 
subtypes expressed in different areas of the central nervous system (upper panel) and in the visual pathway, 
superior cervical ganglia and cochlea (lower panel). (From Millar and Gotti, 2009). 
nAChRs are present in a variety of brain structures, in particular the thalamic, 
neocortical and striatal regions. High affinity nAChR sites as mapped by the binding of 
[3H]-nicotine in both homogenate and autoradiographic studies display a distinct pattern in 
the human brain. The highest levels of binding are observed in the thalamus and nucleus 
basalis of Meynert (NBM) with relatively lower levels in the hippocampus, cortex and 
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caudate putamen (Adem et al., 1987; Perry et al., 1992; Court et al., 1995). High levels of 
binding are observed in the majority of thalamic nuclei with greatest density observed in 
the lateral dorsal nuclei, medial and lateral geniculate nuclei and anterior thalamic nuclei 
(Adem et al., 1988; Spurden et al., 1997). Cortical nAChRs are concentrated in the 
entorhinal cortex and the subicular complex (Court and Clementi, 1995). However, 
regional differences in [3H]-nicotine binding are observed throughout the cortex, with 
distinct laminar distribution of ligand in individual regions. In the somatosensory cortex, 
highest levels are observed in the uppermost and innermost layers with significantly less 
binding observed in layer IV. In contrast, in the primary motor and temporal cortices, 
ligand binding was observed to be considerably denser in the outer layers than in the inner 
layers with a distinct high density and observed in layer III of the temporal cortex. Greatest 
levels of cortical [3H]-nicotine binding are observed in the subicular complex, in particular, 
the presubiculum and entorhinal cortex. In the hippocampus [3H]-nicotine binding is 
generally low in the CAl-4 and dentate gyros, but is greater in the lacunosum moleculare 
in CA2-3 (Perry et al., 1992). This distribution of high affinity nAChR sites in human 
brain has recently been confirmed by autoradiographic studies comparing [3H]-nicotine 
and [3H]-epibatidine (Marutle et al., 1998; Sihver et al., 1998). Two high affinity binding 
sites in the temporal cortex, thalamus and cerebellum of human brain have been identified 
with [3H]-epibatidine (Houghtling et al., 1995; Marutle et al., 1998). These sites are likely 
to represent binding to a4~2 and a3 nAChRs. However, differences in regional binding 
between [3H]-nicotine and [3H]-epibatidine were observed with a proportionally higher 
level of [3H]-epibatidine binding in the thalamus and cerebellum, possibly reflecting 
selectivity for different nAChR subtypes between nicotine and epibatidine - i.e., greater 
selectivity of [3H]-epibatidine for a3 nAChRs. 
The pattern of nAChR sites in the cortex of human brain with regard to their 
laminar distributiop has also been determined with the use of [3H]-nicotine, [3H]-cytisine 
and [3H]-epibatidine and autoradiographic analysis of whole human brain hemispheres 
(Sihver et al., 1998). The laminar distribution of all three ligands was generally similar to 
the highest levels of binding observed in layers I, III and V, and particularly high levels 
observed in layer III of the primary sensory motor cortex and inferior frontal sulcus. 
However, examination of the regional distribution of the three ligands suggests the 
presence of three different binding sites within the human cortex. The first site is thought 
,to be a common site for [3H]-nicotine, [3H]-cytisine and [3H]-epibatidine, and is likely to 
represent binding to a4 subunits in the brain. The morphological distribution of 
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[3H]-nicotine and [3H]-epibatidine indicate that they bind to an additional site specifically 
noticeable in the primary motor cortex, layer Illb of the occipital cortex and layer V of the 
superior temporal sulcus, as their binding in these regions is significantly greater than that 
of [3H]-cytisine. Although more detailed, these observations are generally consistent with 
the regional laminar distribution of [3H]-nicotine binding sites as described by Perry et al. 
(1992). Although relatively few [125I]-aBtx binding studies have been performed on human 
brain, comparison of [125I]-aBtx and [3H]-nicotine autoradiography reveals a distinct 
pattern of binding for the two ligands. A single high affinity [125I]-aBgtx site is identified 
in human brain, with the highest density of binding observed in the hippocampus 
contrasting to the relatively sparse concentration of [3H]-nicotine binding sites in this 
region (Rubboli et al., 1994; Court et al., 1995; Breese et al., 1997a). [125I]-aBtx and [3H]-
nicotine also show a distinct pattern of distribution in the thalamus. A recent study 
compared the relative distribution of the two ligands in this brain region (Spurden et al., 
1997). Consistent with previous reports [3H]-nicotine binding was high in the majority of 
thalamic nuclei, particularly the lateral dorsal, medial geniculate, lateral geniculate and 
anterior nuclei. In contrast, the relative level of [1251]-aBtx binding is lower in all of these 
nuclei, with the highest level of binding observed in the reticular nucleus, NBM and the 
horizontal limb of the diagonal band of Broca (Breese et al., 1997a). 
On the basis of the results of in situ hybridisation studies, it seems that the most 
important and diffused receptor subtype in the human brain is the a4~2 type, but the 
a4~4/~2 subtype is also present in important regions such as the striatum, hippocampus 
habenula and cortex (Fig. 1.5). The a3~ receptor is the major subtype in the autonomic 
ganglia and adrenal medulla as well as in subset on CNS neurones in the medial habenula, 
dorsal medulla, pineal gland and retina (reviewed in Gotti and Clementi, 2004). Both the 
a4~2 and the a3~4 subtypes may also contain the a5 subunit, whose presence is believed to 
increase the rate Qf channel desensitisation and calcium permeability (Lindstrom, 2000; 
Gentry and Lukas, 2002). In addition to these major central and peripheral nAChR 
subtypes, many other native subtypes with more complex subunit compositions have been 
recently identified in the CNS. In situ hybridisation experiments and immunopurification 
and immunoprecipitation studies have shown the presence of a6 mRNA in the substantia 
nigra and ventral tegmental area (VTA), the locu~ coeruleus and retina, as well as in rodent 
striatum, the superior colliculus and nucleus genicolatus lateralis (Champtiaux et al., 2003; 
. Moretti et al., 2004). The primate brain has also a substantial presence of a2~2, which may 
be an important subtype in particular brain regions (Han et al., 2000). a7-containing 
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receptors are highly expressed in the cortex, hippocampus and subcortical limbic regions 
of the brain, and at low levels in the thalarnic nuclei (reticular, geniculate), in the 
cerebellum, pituitary and pineal glands, and basal ganglia. mRNA for a9 subunits has been 
detected in sensory end organs, such as cochlear hair cells (Vetter et al., 1999), nasal 
epitelium, skeletal muscle of the tongue and in the pitituary gland (Hiel et al., 2000). The 
alO has also been identified in the lymphoid tissue (Kawashima et al., 2007). 
a6-containing nAChRs are expressed at higher concentrations on nerve terminals than in 
the cell body/dendrite compartment, suggesting that the a6 subunit, or another subunit 
regularly associated with a6 (such as P3), plays a targeting role (Gotti et al., 2005). 
1.13 Non-neuronal localisation of nAChRs 
It is now well-estabilished that in addition to neurotransmission ACh is involved in 
cell-to-cell communication in various non-neuronal systems as well as in many aspects of 
cell biology and homeostasis (Grando et al., 2007). Moreover non-neuronal cholinergic 
communication and regulation have been demonstrated not only in mammalian cells but 
also in primitive uni- and multicellular organisms such as bacteria, algae, protozoa, sponge 
and primitive plants and fungi (Wessler et al., 1999; Wessler et al., 2001; Wessler et al., 
2003; Horiuchi et al., 2003). 
mRNAs coding for the a4, a5, a7, P4 and P2 subunits have been found in vertebrate 
adult muscle (Corriveau et al., 1995; Sala et al., 1996; Maelicke et al., 2000). a7 is highly 
expressed in mammalian muscle during development and the perinatal period, and 
decreases later on in adult life (Maelicke et al., 2000). The function of neuronal nAChRs in 
muscle is not known, but it is possible that they may control various metabolic and trophic 
functions, and perhaps gene expression. Nicotinic binding sites are also present on 
lymphoid cells (reviewed in Kawashima and Fujii, 2000); the receptor subtypes likely to be 
expressed are a3p4, u4P2 and a7. It has long been known that also macrophages express 
nAChRs and in particular the a7 subtype. Human epidermal keratinocytes express nAChRs 
that have the biophysical properties of a a3 subtype (Grando et al., 1995), but the presence 
of other subtypes has also been shown. a3, a5, and a7 nAChR subunits are present in 
bronchial epithelial cells (Zia et al., 1997) and a4, a7 and p2 in neuroepithelial bodies (Fu 
et al., 2003 ). The vascular system contains a number of nAChR subunits in endothelial 
cells (a3, a5, a7, alO, p2, P3, and P4) and vascular smooth muscle (a2, a3, a4, a5, u7 and 
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alO) (Macklin et al., 1998; Brugmann et al., 2003), which probably play a role in 
controlling angiogenesis and cell proliferation. nAChRs expressed in astrocytes (Sharma 
and Vijayaraghavan, 2002; Graham et al., 2003) seem to be involved in modulation of 
synaptic activity. 
1.14 Biophysical properties of neuronal nAChRs 
The most basic conformational states of nAChRs are the closed state at rest, the 
open state, and the desensitised state (Dani, 2001). In the closed state the channel is not 
conducting, but the receptor can bind ligands. Upon binding ACh, the receptor undergoes 
an allosteric transition from the closed, resting conformation to the open state. The nAChR 
ion channel is stabilized in the open conformation for several milliseconds. The continued 
presence of agonist leads to ion channel closure and receptor desensitisation, which lasts 
for many milliseconds or more. In this condition, the receptor is refractory to activation 
although it displays higher affinity for agonist binding (Dani, 2001 ). 
As mentioned before, nAChRs form cation-selective ion channels. When a pulse of 
ACh is released at the synapse, the channels in the post-synaptic membrane open, and the 
initial electrochemical driving force is mainly for sodium ions to pass from the 
extracellular space into the interior of the cell. As the membrane depolarises, the driving 
force increases for potassium ions to go in the opposite direction. Although sodium and 
potassium carry most of the nAChR current, calcium can also make a significant 
contribution (Decker and Dani, 1990; Castro and Albuquerque, 1995). Calcium ions entry 
through nAChRs can be biologically important because of the intracellular signalling 
functions of free Ca2+. 
The rate at which the nAChRs proceed through the various conformational states 
and the selectivity with which it conducts cations in the open state, depend on many 
factors, including the subunit composition, and is influenced, in particular, by the exact 
amino acid sequence of the subunits. Therefore, the diversity of nAChR types has the 
potential to produce many different responses to endogenous or exogenous agonists. The 
speed of activation, the intensity of membrane depolarisation, the size of the ionic signal, 
the rate of desensitisation and recovery from desensitisation, the pharmacology, and the 
regulatory control of the A Ch response will all depend from the subunit composition of the 
receptor, as well as other local factors (Dani, 2001 ). 
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1.15.1 Agonists 
Nicotinic agonists interact with the ACh-binding site on the nAChR to produce 
channel activation. They are generally charged ammonium compounds, as electrostatic 
interactions with the receptors favour compounds with a positively charged core (Swanson 
and Albuquerque, 1992). By homology to the Torpedo nAChR, heteromeric nAChR are 
believed to possess two binding sites that act in a positively co-operative manner, thus both 
sites must be occupied by agonists to induce receptor-channel activation. For homomeric 
nAChRs, agonists are believed to occupy all five binding sites present in the pentameric 
molecule, however it remains unclear whether complete occupancy of all binding sites is 
required for receptor activation. 
The major agonist identified and routinely used as probes for neuronal nAChRs are: 
nicotine, cytisine, anatoxin and the highly potent alkaloid epibatidine. Nicotinic agonists 
display a limited subtype-selectivity, however, there is a difference in rank order of 
potency for each compound that depends on the specific combination of a and p subunits 
and on the species studied, as described below. 
The neurotransmitter ACh is the endogenous agonist for nAChRs. ACh binds with 
high affinity at u4P2 receptors but its lack of selectivity for nicotinic versus muscarinic 
receptors limits its utility as a nicotinic ligand. 
The prototype agonist for nAChRs is nicotine, an alkaloid isolated from the plant 
Nicotiana tabacum. This classical agonist is most commonly employed to distinguish the 
ligand-gated nAChRs from the muscarinc G-protein coupled ACh binding receptors. 
Nicotine binds with high affinity to heteromeric neuronal nAChRs and with lower affinity 
to the muscle and homomeric neuronal receptors. The u4P2 receptor appears to show the 
highest sensitivity towards nicotine (Flores et al., 1992). Nicotine is widely used in 
behavioural studi~s. 
Cytisine is a toxic alkaloid, isolated from Cytisina laburnum. Cytisine is an agonist 
at most nAChR but its affinity for neuronal P2- or P4-containing nAChR (Luetje and 
Patrick, 1991; Papke and Heinemann, 1994) is about 100-fold higher than that for neuronal 
homomeric or muscle nAChR (Chavez-Noriega et al., 1997; Slater et al., 2003). The 
functional efficacy of this agonist depends on tlie identity of the p subunit present in the 
receptor; cytisine has full efficacy at P4-containing nAChRs, whilst its efficacy is greatly 
, reduced at P2-containing receptors (Luetje and Patrick, 1991). At the u4P2 nAChR cytisine 
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displays stoichiometry-dependent efficacy, which may be potentially useful in drug design 
(Jyioroni et al., 2006). 
Anatoxin-A is a natural alkaloid produced by the freshwater cyanobacterium 
Anabaena flos-aque. Studies using recombinant a4P2 and a7 nAChRs showed anatoxin-A 
to be considerably more potent than nicotine, with greater action at the a4P2 receptor than 
at the homomeric a7 receptor (Thomas et al., 1993). 
Epibatidine is an azabycycloheptane alkaloid isolated from the skin of the 
Ecuadorian poisonous frog Epipedobates tricolour. Epibatidine is the most potent natural 
agonist at nAChRs yet known (Spande et al., 1992) and it is structurally similar to nicotine 
and ACh. It activates all nAChRs with high potency, but it shows highest potency for the 
a4P2 receptor. 
1.15.2 Competitive antagonists 
Competitive antagonists are compounds that interact with the ACh-binding site on 
the nAChR, stabilising the receptor in the closed conformation and preventing access for 
agonists. In general, competitive antagonists are larger compounds than agonists and they 
are more likely to interact with a larger area of the receptors (Swanson and Albuquerque, 
1992). As for agonist alkaloids, most competitive antagonists originate from a wide variety 
of natural sources. Unfortunately, the number of subtype-selective antagonists is very 
limited and not all are commercially available. 
The classic competitive antagonist is dTC, obtained from the South American shrub 
Chondrodendron tomentosum, and well known as one of the neurotoxic components of the 
South American Indians' arrow poison. It has been identified as having cholinergic 
properties for almost 100 years (Chiappinelli, 1985). dTC binds non specifically to all 
nAChR with simil~r low micromolar sensitivity and it is able to fully antagonise functional 
responses mediated by a wide variety of nAChRs (Chavez-Noriega et al., 1997). However, 
at the muscle nAChR it shows differential affinity for the two agonist binding sites. A high 
affinity site lies at th~ interface formed by the a and s or y subunits and a low affinity site 
is present at the a and 3 subunit interface (Blount and Merlie, 1989; Sine and Claudio, 
1991). 
Dihydro-p-erythroidine (DhPE) is a purely competitive antagonist for neuronal 
.nAChRs isolated from Erythrina americana seeds. DhPE is a potent alkaloid that blocks 
heteromeric and homomeric nAChR subfamilies at sub-micromolar concentrations, 
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although it appears to be a more efficient antagonist at a4P2 and a3P2 nAChRs (Decker et 
al., 1995). 
The snake toxin a-Btx, isolated from the venom of the Taiwanese banded krait, 
Bungarus multicinctus, is the most well-established subtype-selective nicotinic antagonist. 
It has been widely employed in the identification and characterization of nAChR and in 
displacement binding studies to define novel nicotinic compounds. a-Btx binds to skeletal 
muscle and homomeric neuronal nAChR with high-affinity and specificity; however it 
does not block any of the alp heteromeric nAChRs (Chiappinelli, 1985; McGehee and 
Role, 1995). Neuronal-Btx (n-Btx), also extracted from the venom of Bungarus 
multicinctus, is a potent blocker of many of the heteromeric nAChRs. It produces pseudo-
irreversible blockade of a3P2 receptors in the nanomolar range and of a4P2 nAChRs in the 
micromolar range. However, receptor conformations containing the a2 subunit appear to 
be almost insensitive to n-Btx (Luetje et al., 1990). 
The a-conotoxins are small peptide toxins purified from the venom of Conus snails, 
with specificity for nAChR subtypes (Mcintosh et al., 1999). Three well characterise a-
conotoxins are specific for neuronal nAChRs. a-Conotoxins Mii blocks ACh-mediated 
responses in heteromeric receptors, displaying highest affinity (nanomolar range) for the 
a3P2-containing subtype and least affinity for the muscle nAChR (Cartier et al., 1996; 
Harvey et al., 1997; Mcintosh et al., 1999). The a-conotoxin Iml reversibly blocks the 
homomeric a7 receptors with nanomolar affinity, but it is even more potent at the a9 
receptor (Johnson et al., 1995). In comparison, this neurotoxin has no effect on any 
heteromeric nAChR subtypes containing pair wise combinations of a2-a4 with either P2 or 
P4 subunits. a-conotoxins AulB is a selective antagonist of a3P4 nAChRs (Luo et al., 
1998; Grady et al., 2001) but it is less potent than a-Conotoxin Mii. 
Methylcaconitine (MLA) is an alkaloid isolated from the seeds of Delphinium 
brownie and it is oapable of specifically and potently producing blockade of a7 nAChRs in 
brain and membrane preparations at low nanomolar concentrations (Alkondon et al., 
1992). MLA also blocks a3P2 and a4P2 nAChRs, although at concentrations greater than 
100 nM (Eaton et al., 2003). 
Strychnine is a colorless crystalline alkaloid isolated form the seed of the Strychnos 
nux vomica tree. Strychnine is a competitive antagonist of glycine receptors but it has also 
been shown to block homomeric a7 nAChRs at micromolar concentrations (Albuquerque 
et al., 1998; Garcia-Colunga and Miledi, 1999) and homomeric a9 and heteromeric a9/a10 
receptors at nanomolar concentrations (Elgoyhen et al., 2001). 
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1.15.3 Allosteric modulators 
The function of neuronal nAChRs is influenced by a variety of modulatory 
compounds, including physiostigmine, steroids, ethanol and Ca2+ ion channel blockers, that 
do not bind to the classical ACh sites, but to a number of structurally distinct allosteric 
sites, which are in turn insensitive to ACh. 
Noncompetitive allosteric activator sites are located on the a subunit of the 
receptor. Compounds that bind to this site, called allosterically potentiating ligands 
(APLs), enhance channel opening and ion conductance (Pereira et al., 1993). When tested 
alone, generally, they tend to behave in an agonist-manner with low efficacy at low doses 
and as open-channel blockers (OCB) at high doses. When co-applied with ACh or nicotine, 
however, they potentiate agonist-induced activation, indicating that agonists and APLs can 
bind simultaneously to the receptor, interacting at different sites. APLs include the 
cholinesterase inhibitor physiostigmine (Seerden et al., 1998), tacrine, galanthamine 
(Badio et al., 1997; Smulders et al., 2005), the alkaloid codeine (Che et al., 2001) and the 
neurotransmitter serotonin at low doses (Albuquerque et al., 1996). More recently, 
activating properties have been reported for 17~-estradiol on human a4~2 nAChR (Curtis 
et al., 2002) and for cocaine methiodide on a7 receptors (Francis et al., 2001 ). 
In contrast, compounds that bind to the non competitive negative allosteric sites, 
called non-competitive inhibitors (NCis) or OCBs, inhibit ion channel function. These 
include chloropromazine, local anaesthetics, ethanol and barbiturates (Lena and Changeux, 
1993). NCis act on two distinct sites: the high affinity site is thought to be located within 
the ion channel, in the M2 transmembrane domain. Binding to this site is facilitated by 
agonist activation of the receptor and produce a rapid reversible ion channel blockade with 
ion conductance blocked by simple steric hindrance; the second site binds ligand with low 
affinity and it is thought to be located at the interface between the receptor and the lipid 
membrane. 
It is important to notice that many substances show a dual mode of action, being 
competitive/qon-competitive blockers, or activators/blockers, depending on the dose 
employed, on the receptor subtype, or on the introduction of certain mutations in the 
channel pore. For instance, serotonin applied at subnanomolar concentration behaves as an 
APL, whereas at micromolar concentrations it inhibits the activation of the channel in a 
voltage dependent manner and at a7 receptors containing the mutation L248T (Fucile et 
al., 2002a). The GABAA receptor antagonist bicuculline shows a similar behaviour, being 
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a non-competitive antagonist on heteromeric receptors, a competitive antagonist on the 
wild-type a7 receptor, and an agonist on the L248T mutant a7 receptor (Demuro et al., 
2001). 
Muscarinic receptor antagonists such as atropine and scopolamine and the 
acetylcholine esterase inhibitors physostigmine, tacrine and galanthamine, at 
concentrations between 1 and 100 µM, enhance ion currents evoked by low concentrations 
of ACh in oocytes expressing human a4B2 nAChRs. However, at saturating ACh 
concentrations the same range of concentrations of these compounds inhibits the function 
of the receptors (Smulders et al., 2005). Insights on the mode and site of action of this class 
of APLs were recently given by Hansen and Taylor (2007), who showed that APLs such as 
galanthamine and cocaine bind to sites located at interfaces contributed by conserved 
hydrophobic residues. This site resembles the benzodiazepine site of the GABAA receptor 
in the sense that both contain residues that occupy positions homologous to residues 
contributing to the agonist site. 
Steroids have the ability to desensitise nAChRs by action at a site located in the 
extracellular hydrophilic domain that is distinct from the ACh site (Bertrand et al., 1991; 
Inoue and Kuriyama, 1991 ). Progesterone, corticosterone and dexamethasone are potent 
inhibitors of a3-containing receptors expressed in SH-SY5Y cell lines at nanomolar to 
micromolar concentrations, without affecting ACh binding (Ke and Lukas, 1996). 
Moreover, corticosterone is known to desensitise nicotinic receptors and to produce 
tolerance to the effect of nicotine (Grun et al., 1992; Pauly and Collins, 1993; Robinson et 
al., 1996). 
L-type Ca2+ channel antagonists such as nimodipine and nifedipine are capable of 
blocking agonist induced activation of nicotinic receptors (Lopez et al., 1993) and are able 
to inhibit noradrenaline release from chromaffin cells in a non-reversible dependent 
manner (Gandia et al., 1996). The mechanism of action of these compounds is unknown 
but the binding site is proposed to be located within the ion channel. Interestingly, Ca2+ 
ions themselves modulate the function of the receptor. Multiple Ca2+ binding sites exist on 
both muscle and neuronal receptors (Fairclough et al., 1993), which when activated 
produce a voltage sensitive decrease in conductance. A further category of Ca2+ binding 
sites, present only in neuronal nicotinic recept9rs, potentiates agonist activation of ion 
currents in a voltage insensitive manner (Mulle et al., 1992). 
Recently, a new class of selective nicotinic allosteric potentiators was identified 
(Broad et al., 2006; Timmermann et al., 2007). Three novel (2-amino-5-keto)thiazole 
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compounds were reported to act as selective modulators of central but not ganglionic or 
neuromuscular nAChRs. These compounds selectively potentiate human recombinant a7, 
a2p4, a4p2, and a4p4, but not a3- or al- containing nAChRs or other ion channels (Broad 
et al., 2006). The allosteric modulator 1-(5-chloro-2-hydroxy-phenyl)-3-(2-cloro-5-
trifluoromethyl-phenyl)-urea is a selective potentiator of the a7 homomeric receptor and it 
was shown to produce cognitive enhancement in vivo (Timmermann et al., 2007). The 
discovery of these compounds may have a profound impact on the treatment of cognitive 
dysfunctions. 
1.16 Physiological functions of native nAChRs 
Although the molecular structure and biochemistry of neuronal nAChRs have been 
extensively characterised, less is known about their functional significance, especially in 
view of the diverse receptor subunit combinations that appear to exist. The various 
locations of neuronal nAChRs at the pre-, peri-, and extra-synaptic sites, in addition to the 
post-synaptic sites, provide also a variety of means of modulating neuronal function 
(Lindstrom, 1997). nAChRs have an important role in ganglionic transmission and control 
of the peripheral autonomic system (Ascher et al., 1979), but their role in the CNS has not 
yet been fully elucidated. They are known to be implicated in various complex cognitive 
functions, such as attention, learning, memory consolidation, arousal, sensory perception, 
and in the control of locomotor activity, pain, perception and body temperature regulation 
(reviewed in Gotti et al., 1997). Most of the data supporting these functions came from 
gene knockout experiments or from behavioural studies performed with nicotine or 
nicotinic receptor antagonists in humans or animals, and natural models of nicotinic 
denervation, such f\S degenerative brain diseases. 
nAChRs were first localised at presynaptic sites in the PNS and CNS during the 
late 1980's. Studies using nerve terminal preparations (e.g., synaptosomes) in recent years 
have demonstrated that presynaptic nAChRs enhance the release of a wide variety of 
neurotransmitters, including glutamate, noradrenaline, dopamine, GABA and serotonin, 
suggesting that the main function of these , receptors in the brain is to regulate 
neurotransmitter release by presynaptic action (Wonnacott, 1997). Thus, in contrast to the 
muscle nAChR, known to mediate fast synaptic transmission, neuronal nACh receptors 
conduct their functional effects mostly through modulation of synaptic transmission. It has 
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Another characteristic feature of neuronal nAChRs is that they display current 
rectification for transmembrane potentials above -40 mV. First reported for the a4~2 
nAChR, this functional feature was also described at other receptor subtypes (Couturier et 
al., 1990; Haghighi and Cooper, 2000). This receptor property allows current flow when 
the cell is hyperpolarised, but the current is progressively reduced when the 
transmembrane potential is more positive than -40 m V. Mutation of a single charged 
residue (Glu-to-Asp) at the inner mouth of the pore of the a7 receptor abolishes 
rectification (Forster and Bertrand, 1995; Haghighi and Cooper, 2000), which arises from a 
voltage-dependent progressive reduction of the channel mean open time. The nAChRs pass 
current and provide Ca2+ influx at highly negative membrane potentials, which provide 
strong driving forces for inward currents. At very active depolarised postsynaptic 
membranes, nAChRs make a progressively smaller contribution because of the voltage-
dependent rectification. Similarly, nAChRs that are expressed presynaptically contribute 
best to signal transmission when the synaptic boutons are hyperpolarised. 
1.15 Pharmacology of neuronal nAChR 
In order to effectively control different nicotinic brain functions through 
pharmacological action, it is essential to identify drugs that act selectively on different 
receptor subtypes, in order to maximise the desired effects and minimise the unwanted 
effects (e.g. on muscle-type receptors). The pharmacology of nAChR has always been 
selective, but this was confined to the discrimination between ligands having an effect on 
muscle and neuronal types, such as the blocking compounds, hexamethonium (more 
effective on neuronal subtypes) and decamethonium (more effective on muscle nAChR). 
However, with th~ increasing awareness of the functional and pharmacological diversity 
within the neuronal subtypes, it has become essential to develop drugs that selectively 
discriminate neuronal receptor subtypes. Much of the discovery process has been based on 
templates from the wide variety of natural sources present in animals and plants. The most 
established ligands that interact with neuronal nAChRs are described in the next Sections. 
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been therefore proposed that the role of nAChR in the brain is to modulate neuronal 
excitability (McGehee and Role, 1995). However, postsynaptic CNS nAChRs also play 
important roles, the most clearly demonstrated being the control of ganglionic transmission 
and fast ACh-mediated synaptic transmission in the hippocampus and in the sensory cortex 
(Jones et al., 1999). 
The role of the most predominant nAChR in the brain, a.4~2, is not fully 
understood. A possible function for this subtype in associative memory was suggested by 
gene knockout, which demonstrated that mice lacking the ~2 subunit lose high affinity 
CNS binding sites, do not produce electrophysiological responses to nicotine in thalamic 
neurons, and fail to exhibit nicotine-enhanced performance in a passive model of cognitive 
function (Picciotto et al., 1995). a4~2 is clearly the main target of nicotine and therefore is 
likely to be important in the reward function, or feeling of pleasure. It also appears to be 
involved in the feeling of pain. In addition, ~2 knockout mice displayed accelerated signs 
of ageing, which implies that this subunit may have a protective role against ageing (Zoli et 
al., 1999). 
nAChRs have also a role during development and neuronal plasticity (Role and 
Berg, 1996; Broide and Leslie, 1999), probably by contributing to calcium-dependent 
activities. nAChRs are expressed in the early stages of foetal life (Court et al., 1997) and 
their density varies during the course of development. Their involvement in axon guidance 
(Pugh and Berg, 1994) suggests that they could be involved in shaping and maintaining 
neuronal circuitries. 
1.16.1 Neuronal nAChR are predominantly presynaptic receptors 
Given the high homology between muscle and neuronal nAChRs, a role in fast 
synaptic transmission in the CNS was anticipated for neuronal nAChRs. However, there 
are only a few examples of this role in the mammalian CNS (Alkondon et al., 1998; 
Frazier et al., 1998), where nAChRs have a more m\)dulatory influence (McGehee et al., 
1995; Role and Berg., 1996). Physiological studies in the early 1990s led to the hypothesis 
that nAChRs in the brain could modulate neuronal function by regulating neurotransmitter 
release (Wonnacott, 1997). Nicotine is known to elicit the release of a wide range of 
neurotransmitters such as DA, NA, glutamate, serotonin and GABA, commonly by acting 
at presynaptic nAChRs, which is consistent with such a modulatory activity. nAChRs are 
located presynaptically on somatodendritic regions of neurones (Clarke, 1993) where they 
act as autoreceptors or heteroreceptors, regulating transmitter release by influencing the 
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nicotinic excitation of a neuron usually does not predominate, it could influence the 
excitability of a group of neurons owing to the broad cholinergic projections into an area. 
Thus, beyond their specific roles at discrete synapses, nAChRs also modulate neuronal 
circuits in a broader sense. An example of nicotinic modulation of circuit excitability was 
seen in hippocampal neurons, where application of nicotinic agonists on interneurons 
caused both inhibition and disinhibition, thus modulating the rhythmic activity in the 
hippocampus (Ji and Dani, 2000). 
1.16.3 Role of neuronal nAChR in non-neuronal cells 
Neuronal nAChRs are also expressed in non-excitable cells, such as lymphocytes, 
monocytes, macrophages, dendritic cells, adipocytes, keratinocytes, endothelial cells and 
epithelial cells of the intenstine and lung (Whaley et al., 1981; Skok et al., 2001; Sharma 
and Vijayaraghavan, 2002). The role of neuronal-type nAChRs in the periphery is complex 
and different nAChR types are responsible for different functions. Among these, the role of 
nAChRs in inflammation has stimulated great interest in the field of anti-inflammatory 
therapeutics. The nAChR subtype involved in the anti-inflammatory pathway was recently 
identified. Stimulation of the a7 nAChR present on the membrane of tissue macrophages 
controls the production of inflammatory cytokines acting at the post-transcriptional level 
(Wang et al., 2003). 
1.17 Upregulation of nAChRs 
Nicotinic receptors go against the generally accepted paradigm in cell membrane 
receptor studies th~t over-exposure to agonists produces receptor down regulation whereas 
prolonged inactivation by antagonists has the opposite effect (Gentry and Lukas, 2002). 
Studies of the brain of tobacco smokers and animals chronically exposed to nicotine have 
in fact showed that long term exposure to nicotine, at concentrations found in the blood of 
smokers, results in an increase in the number of nAChRs (called up-regulation) (Gentry 
and Lukas, 2002; Perry et al., 1999). This particular effect might be due to the fact that 
nicotine also acts as a time-averaged antagonist, as demonstrated by functional studies of 
pative and transfected nAChRs in which the constant presence of an agonist leads to 
desensitisation (Picciotto, 2003). 
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The molecular mechanism underlying the up-regulation of nAChRs was 
investigated both in vitro and in vivo. Prolonged nicotine exposure induces up-regulation 
of homomeric a7 and heteromeric a3~2, a4~2, a6~2 and a3~4 receptors expressed in 
heterologous systems. Moreover, it was recently shown that the presence of the ~3 subunit 
in a6~2P3 and a6~4~3 subtypes produces greater nicotine-induced up-regulation than that 
observed in the same receptors lacking the p3 subunit (Broadbent et al., 2006). This is 
probably due to a direct effect of the ~3 subunit on subtype assembly. Both a7- and a3-
containing receptors are up-regulated by chronic nicotine treatment, but to a different 
extent and at higher doses than those necessary to up-regulate the a4p2 subtype. In 
addition to nAChR subtype, up-regulation may also depend on the host cell. For instance, 
it was shown that nicotine exposure decreases the functional response of a4p2 and a7 
receptors expressed in Xenopus oocytes (Peng et al., 1997), but a4~2 receptors stably 
expressed in HEK.293 cells are not desensitised by chronic nicotine exposure (Buisson and 
Bertrand, 2001 ). 
In vivo studies showed that chronic nicotine treatment does not increase nAChR 
mRNA levels in mouse brain (Marks et al., 1992), suggesting that up-regulation of the 
receptors is due to post-transcriptional mechanisms. Studies of the brains of animals 
chronically treated with nicotine and those of human smokers have shown that the most 
up-regulated receptor is the a4~2 subtype (Perry et al., 1999; Gentry and Lukas, 2002; 
Tumkosit et al., 2006). However, the data concerning nicotine up-regulation in vivo are 
contradictory. Studies of a6-containing receptors after nicotine exposure reported 
upregulation (Parker et al., 2004), downregulation (Lai et al., 2005; Mugnaini et al., 2006) 
and no change (McCallum et al., 2006). This discrepancy might be due only to the 
different protocols used, which can lead to different brain nicotine levels and/or kinetics, 
thus explaining the different results observed in the different studies. A further level of 
complexity in studying the in vivo effects of nicotine is due to the presence of different 
receptor subtypes that may be differently sensitive to up-regulation. 
Most of our knowledge of the up-regulation of nAChRs is based on studies on the 
a4~2 subtype. Several models have been proposed to explain the up-regulation of this 
receptor subtypes observed after chronic nicotine treatment: 1) an increase in receptor 
transport through the secretory pathway to the plasma membrane (Harkness and Millar, 
2002); 2) a decrease in surface receptor internalisation due to nicotine-induced 
conformational modifications that prevent the removal of receptors from the cell surface 
(Peng et al., 1997); 3) the isomerisation of surface receptors into a more easily activated 
43 
high affinity conformation (Buisson and Bertrand, 2001; Vallejo et al., 2005); 4) an 
increase in subunit assembly and/or a decrease in receptor turnover (Wang et al., 1998; 
Nashmi et al., 2003; Darsow et al., 2005; Kuryatov et al., 2005). Assembly, trafficking and 
cell surface expression of the receptors are key steps in nicotine-induced up-regulation. 
Recent studies by Sallette et al. (2004) identified two segments in the extracellular domain 
of the p2 subunit that are critical for the up-regulation of P2-containing subtypes. The 
authors suggested that nicotine binding to immature oligomers leads to a conformational 
reorganisation of these segments, strengthens the interactions between adjacent subunits, 
and facilitates the maturation process toward high affinity receptors (Sallette et al., 2004; 
Sallette et al., 2005). These results are in good agreement with the findings of Kurjatov et 
al. (2005), who showed that nicotine acts as a pharmacological chaperone, inducing an 
active or desensitised conformation, which assembles more efficiently. Another critical 
factor for receptor assembly and trafficking is subunit availability. Ficklin et al. (2005) 
showed that ubiquilin-1 (an ubiquitin like protein) plays an important role in nicotine-
induced up-regulation by sequestering the subunits on proteasomes and thus decreasing 
their availability. A recent work by Rezvani et al. (2007) showed that nicotine, at 
concentrations achieved by smokers, reduces proteasomal activity, produces accumulation 
of ubiquitinated synaptic proteins, and increases total protein levels. The authors propose, 
therefore, that nicotine acts as an inhibitor of proteasome function blocking endoplasmic 
reticulum-associated degradation of unassembled nAChR subunits, which in tum increases 
the availability of subunits for assembly into mature receptors that are trafficked to the cell 
surface. 
1.18 nAChRs and nicotine addiction 
The VTA has been implicated in the rewarding motivational effects of a wide 
variety of addictive drugs, including nicotine (Corrigall et al., 2000; Laviolette and van der 
Kooy, 2003)._Within the VTA, both dopaminergic and GABAergic neurons are implicated 
in signalling pathways or reward (Laviolette and van der Kooy, 2003). Neurons within the 
VTA have a wide variety of nAChRs (Wooltorton et al., 2003), and nicotine can activate 
both the dopaminergic and GABAergic neurons of the VT A (Yin and French, 2000; 
Mansvelder and McGehee, 2002). In the VTA nAChRs are expressed on the soma of 
dopaminergic neurones (Klink et al., 2001 ), on GABAergic terminals (Mansvelder et al., 
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2002) and also on glutamatergic terminals (Mansvelder and McGehee, 2000; Mansvelder 
et al., 2002). The early acute effects of nicotine predominantly affect GABAergic neurons, 
where GABA release is modulated by a4~2 nAChRs (Klink et al., 2001). The stimulation 
and fast subsequent desensitisation of a4~2 receptors produces prolonged stimulation of 
dopaminergic neurons by removal of the inhibitory GABA input. Nicotine also acts on 
presynaptic nAChRs located on VT A glutamatergic terminals which show a lower rate of 
desensitisation after nicotine exposure, eliciting an excitatory glutamatergic input to the 
dopaminergic neurons (Mansvelder et al., 2002). Several studies have suggested that the 
presynaptic action of nicotine in the CNS, especially glutamate release is mediated mainly 
by presynaptic a7 receptors (McGehee et al., 1995; Girod et al., 2000). Finally, 
dopaminergic neurons express nAChR a4, a3, a5 , a6, ~2 and ~3 subunits (Klink et al., 
2001). The somatodendritic nAChRs on dopaminergic neurons of the VTA can directly 
excite these neurons by receiving cholinergic signals ascending from outside the VTA 
(Oakman et al., 1995). This process eventually results in transient DA responses that are 
terminated by nAChR desensitisation (Blaha et al., 1996; Pidoplichko et al., 1997). 
Fig. 1.6. Modulation of DA release in the VTA by nAChRs. Native nAChRs modulate DA release in 
dopaminergic neurons of the mesolimbic and nigrostriatal pathways both directly and indirectly. nAChR 
agonists exert ·direct modulation of DA release through presynaptic and preterminal nAChRs. Alternatively, 
activation of a.7 nAChRs on glutamatergic tem1inals triggers the release of Glu, which in tum stimulates 
ionotropic Glu receptors on dopaminergic terminals, finally inducing DA release. Adilitionally, 
desensitisation of the a.4P2 nAChR on GABAergic intemeurons can remove the inhibitory GABA input on 
dopaminergic neurons, thereby indirectly eliciting DA release. (From Kalamida et al. , 2007) 
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1.19 nAChRs in ageing and neurodegenerative diseases 
nAChRs numbers in the brain change considerably during development and aging 
in all animal species. Many studies have demonstrated that the concentration of nicotinic 
binding sites, particularly the ones with high affinity for agonists, steadily decreases 
throughout life in nearly all of the studied human brain regions. One exception is the 
thalamus, in which the binding sites remain constant or increase. In the case of subunit 
distribution, there is a general agreement that the ~2 subunit decreases with age in all brain 
structures, especially in the neocortex and hippocampus, a.4 and a.7 decrease in the 
neocortex, and a.3 in the enthorinal cortex. Loss of nAChRs during ageing will tend to 
predispose brain areas to the consequences of further loss as a result of age-related 
neurodegeneration. 
Initial studies on the cholinergic system in Alzheimer's disease (AD) revealed a 
severe loss of both cortical innervation and basal forebrain neurons (Perry et al., 2001 ). 
Successive studies have reported important deficits of nAChRs in temporal and frontal 
cortex, hippocampus and various thalamic nuclei of patients with AD, as measured by 
radiolabelled agonist binding in autopsy tissue and in vivo PET analyses (Paterson and 
Nordberg, 2000). Immunohistochemical studies on temporal cortex indicated reduced 
staining with both a.4 and ~2 directed antibodies (Sparks et al., 1998); this decline was also 
confirmed by western blot analysis (Guan et al., 2000) and additional immunochemical 
studies (Wevers et al., 1999). 
The nicotinic cholinergic system is also involved in Parkinson's disease (PD) 
(Burghaus et al., 2003). The central feature of this disease is the loss of dopaminergic 
neurons in the substantia nigra and degeneration of subcortical noradrenergic, 
serotoninergic and cholinergic nervous pathways. nAChRs are very important in 
promoting the release of DA in the nigro-striatal pathway, and both the a.6~3~2 and the 
a.4~2 subtypes in striatum are responsible for the release of DA from nerve endings (Quik 
and Kulak, 2002; Champtiaux et al., 2003). In experimental rodent and monkey models of 
PD, there is a selective decrease in the number of a.6-, a.4- and ~2-containing receptors as 
detected by means of specific ligand binding or immunoprecipitation experiments 
(Champtiaux et al., 2003; Kulak et al., 2002; Lai et al., 2004). There is a general consensus 
that [3H]-nicotine and [3H]-epibatidine binding is decreased in the striatum of PD patients 
(Court et al., 2000; Guan et al., 2000; Martin-Ruiz et al., 2000). A decrease in nAChRs 
similar to that reported in AD has also been found in the cerebral cortex of PD patients, 
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and is mainly due to a decrease in a4- and a7-containing receptors (Burghaus et al., 2003). 
This reduction of nAChRs in the brain of patients affected by Alzheimer's and Parkinson's 
diseases can be one of the causes of the mild cognitive impairment associated with these 
diseases. Targeting presynaptic nAChRs may therefore be advantageous for PD patients. It 
was recently shown that stimulation of a7 nAChRs protects neuronal cells form 
degeneration and neuronal death induced by AP42 amyloid protein that has a high affinity 
for this subtype (Wang et al., 2000). It has therefore been proposed that the a7 receptor 
may play a key role in pathological accumulation of AP42 in neurons that express this 
subtype. 
1.20 nAChRs in schizophrenia and mood and attention disorders 
Several lines of evidence suggest the possible involvement of nAChRs in 
schizophrenia: ( 1) high prevalence of smoking among schizophrenic patients (90% 
compared to 33% in the general population (Lohr and Flynn, 1992; Perry et al., 2001); (2) 
positive correlation between smoking and negative (but not positive) symptoms (Patkar et 
al., 2002). Recent brain autopsy data indicate that schizophrenic patients have altered 
nAChRs (Court et al., 2000; Martin-Ruiz et al., 2003). The involvement of heteromeric 
receptors is doubtful; on the other hand, the involvement of homomeric a7 receptors is 
much more relevant. Schizophrenic patients have a small, but significant and reproducible 
decrease in [1251]-aBgtx binding sites and a7 immunoreactivity in the hippocampus 
(Freedman et al., 1995; Leonard et al., 1996), the reticular nucleus of the thalamus, and the 
cingulated and frontal cortex (Martin-Ruiz et al., 2003). Genetic linkage analysis also 
provided evidence of the involvement of a7 receptors; the human a7 gene is in fact 
partially duplicatedjn schizophrenic families. 
Although to a lesser extent than schizophrenic patients, there is also evidence that 
nAChR are implicated in mood. Tobacco smoking is higher in depressed individuals than 
in the normal population (Poirier, 2002) and smoking cessation is associated with 
depression in individuals with a history of depression. Nicotine was reported to be 
antidepressive and mood stabiliser in humans (Shytle et al., 2002), and a number of 
antidepressant inhibit neuronal nAChRs. Moreover, nAChRs were involved in both the 
anxiolitic and the axiogenic effects of nicotine in experimental animals (Picciotto et al., 
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2002), although further studies are needed to establish whether nAChRs have a real 
relevance in the control of mood disorders. 
nAChRs are also involved in disorders such as Tourette's syndrome, whose 
symptoms are ameliorated with administration of nicotine, and attention-deficit 
hyperactivity, which is often associated with maternal smoking (Leonard et al., 2001) and 
a potential target for nicotinic ligands-based therapies. 
1.21 nAChRs and nociception 
Neuronal nAChRs have been shown to play an important role in the antinociceptive 
pathway. The antinociceptive activity of nicotine is been known since 1932, but interest in 
nicotinic receptor-mediate analgesia started only after the discovery of the analgesic 
properties of epibatidine and of its high affinity for the nicotinic receptors. The a4~2 
subtype is the main nicotinic receptor involved in the antinociceptive activity, but other 
subtypes such as a4a5~2 could also contribute (Marubio et al., 1999; Decker et al., 2004). 
1.22. Role of nAChRs in epilepsy 
Mutations (mainly recurrent and site specific) in the nAChR a4 and ~2 subunits are 
now established causes of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) 
with incomplete penetrance (Steinlein et al., 1995; De Fusco et al., 2000). The cholinergic 
system is know to have a major effect on sleep modulation (Steriade and Contreras, 1995), 
therefore a defect in nAChRs is not surprising in this particular form of epilepsy. The 
mutations lead to jncreased sensitivity to ACh, a change in Ca2+ permeability, thus 
facilitating the. synchronisation of the spontaneous oscillations in the thalamo-cortical 
circuits and generating seizures (Raggenbass and Bertrand, 2002), and perhaps to a change 
of receptor stoichiometry (Cagdas et al., 2009). Further evidence of the relevance of the 
a4-containing receptors in epilepsy come from the finding that mice lacking a4 subunits 
are more sensitive to the proconvulsant effects of GABA antagonists (McColl et al., 2003) 
and the fact that anti-nAChRs drugs have antiepileptic activity (Loscher et al., 2003). 
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1.23 The a4p2 nAChR 
The a4P2 nAChR is the predominant nAChR subtype in the mammalian brain. The 
a4 and p2 subunits represent the most abundant nAChR subunits in chick and rat brains 
(Whiting et al., 1987; Schoepfer et al, 1988; Wada et al., 1989; Flores et al., 1992), and a4 
mRNA is widely detected throughout the human cerebral cortex (Wevers et al., 1994). 
Rodent brain regions expressing the a4 and p2 subunits show high affinity for (-)-nicotine 
(Clarke et al., 1985; Deutch et al., 1987: Swanson and Albuquerque, 1987; Marks et al., 
1992); moreover, in p2 knock-out mice (-)-nicotine binding to brain slices is fully 
abolished, demonstrating that P2-containing nAChRs constitute the high affinity binding 
site for (-)-nicotine (Picciotto et al., 1995). The a4P2 nACh subtype is located mainly 
presynaptically on GABAergic (Alkondon et al., 1996; Lu et al., 1998; Zhu and 
Chiappinelli; 1999; Klink et al., 2001) and dopaminergic neurons (Grady et al., 1992; 
Klink et al., 2001; Champtiaux et al., 2002; Zoli et al., 2002). nAChRs composed of a4 
and p2 subunits modulate neurotransmitter release (Dani, 2001) and play a direct role in 
nicotine addiction (Picciotto et al., 1998; Marubio et al., 1999). In P2 knock-out mice, 
nicotine fails to elicit striatal DA release, fails to increase discharge frequency of midbrain 
dopaminergic neurons, and fails to elicit self-administration (Picciotto et al., 1998). This 
nAChR subtype is elevated in brain tissues from smokers (Benwell et al., 1988; Breese et 
al., 1997b) and, similarly, in mice chronically exposed to nicotine (Marks et al., 1983 ). 
Alterations in the level and/or activity of a4P2 nAChRs have been implicated in different 
neuropathologies. In the brain of Alzheimer's patients, the nAChR density is markedly 
reduced (Whitehouse et al., 1986; Aubert et al., 1992), as well as the high affinity binding 
sites for (-)-nicotine (Perry et al., 1995). a4P2 nAChRs are also thought to be involved in 
Parkinson's diseases (Rusted et al., 2000) and mutations in both the a4 and the P2 subunits 
have been linked tQ autosomal dominant nocturnal frontal lobe epilepsy (Steinlein, 2004) 
and benign familial neonatal convulsions (Beck et al., 1994). 
The stoichiometry of the a4P2 nAChRs in the brain has not yet been elucidated. 
Several studies showed that this nAChR subtype can exist into at least two different 
stoichiometries (Zwart and Vijveberg, 1998; Nelson et al., 2003; Zwart et al., 2006). a4 
and p2 nAChR subunits expressed heterologously in mammalian cell lines (Buisson and 
Bertrand, 2001; Nelson et al., 2003; Kuryatov et al., 2005) or Xenopus oocytes (Zwart and 
Vijveberg, 1998; Zwart et al., 2006; Moroni et al., 2006) assemble into a mixture of 
receptors with high (HS) or low sensitivity (LS) to activation by ACh. HEK293 cells stably 
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transfected with the a4P2 nAChR have a large majority of receptors with low A Ch affinity 
and slow desensitisation. Metabolic labelling of these cells with [35S]-Methionine showed 
that the receptors have a stoichiometry of ( a4)3(p2)2. Long-term exposure to nicotine, 
transfection with additional P2 subunits or overnight culture at low temperature (29 °C) 
result in an increase in the number of receptors characterised by high sensitivity to A Ch 
and a stoichiometry of (a4)2(P2)3 (Nelson et al., 2003). The alternate functional forms of 
the a4P2 nAChR are not simply a consequence of expressing a4 and P2 subunits in 
heterologous systems. Several lines of evidence suggest that neurones may also express 
both a4P2 nAChR forms and that the relative amounts of the two receptor forms influences 
basal behaviours and sensitivity to acute and chronic exposure to nicotine. Firstly, 
functional studies showed biphasic agonist concentration-response curve for stimulation of 
putative a4P2 nAChR function in mouse thalamic preparations (Marks et al., 1999; Butt et 
al., 2002). Such function is not present in the thalamus of a4-/- or P2-/- knockout mice, 
which also lack high affinity epibatidine sites (Picciotto et al., 1995). More recent studies 
from cortical and thalamic synaptosomes of heterozygous a4 ( a4+1") and P2 (p2+1") mice 
showed that native a4p2-nAChR very likely have alternative stoichiometries, which can be 
influenced by the relative level of expression a4 and p2 mRNAs (Gotti et al., 2008). This 
study showed that partial deletion of a4 induced a large decrease in the response of the 
component with lower ACh sensitivity and decreased the relative proportion of the a4 
subunit in assembled receptors. Similarly, partial deletion of p2 induced a decrease in the 
component with higher A Ch sensitivity and an increase in the relative proportion of the a4 
subunit in assembled receptors. These results strongly suggest that a4p2 nAChR with 
different stoichiometries are expressed in native tissues (Gotti et al., 2008). Secondly, the 
pharmacological properties of the alternate forms of a4P2 nAChR expressed 
heterologously in Xenopus oocytes closely resemble those of thalamic a4p2 nAChRs 
(Marks et al., 199<.l; Butt et al., 2002). Thirdly, a polymorphism in the a4 subunit gene in 
mice (CHRNA4 A529T) increases the ratio of high to low sensitivity a4P2 nAChRs (Kim 
et al., 2003) and accounts for mouse strain-specific differences in measures of a4p2 
nAChR functions such as sensitivity to nicotine-induced seizures, effects of nicotine on Y-
maze activity, respiratory rate, and body temperature (Tritto et al., 2002; Kim et al., 2003 ). 
The a4P2 nAChR represents an important target for drug development and the 
understanding of its structure-function relationship is a necessary requirement for further 
i;tdvancements in the development of a4P2-selective compounds. Progress in the 
development of a4p2 nAChR-selective drugs and understanding of the precise roles of this 
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receptor type in brain functions and diseases, particularly nicotine addiction, has been 
slowed down by the existence of alternate forms of the a4~2 nAChR and by the difficulties 
in expressing them separately. Functional and mutational studies showed that it is possible 
to obtain either the HS (a4)z(~2)3 or the LS (a4)3(~2)z stoichiometry by injecting the 
nucleus of Xenopus oocytes with 1: 10 or 10: 1 a4/~2 subunit cDNA ratios, respectively 
(Moroni et al., 2006). The extreme injection ratio cannot however exclude the presence of 
other stoichiometries, as demonstrated by the biphasic response of the receptors 
heterologously expressed in Xenopus oocytes to stoichiometry-selective compounds, such 
as 5I-A85380 (Zwart et al., 2006). Low order concatamers, such as dimers, have been used 
to express separately the two alternate stoichiometries (Zhou et al., 2003). However, it was 
shown that dimers of nAChR subunits can assemble improperly, forming pentamers with a 
dangling subunit, dipentamers or even more complex cons.tructs (Zhou et al., 2003; Groot-
Kormelink et al., 2004). An alternate approach is to concatenate the five subunits into 
pentamers to produce receptors of fixed stoichiometry and subunit order. This thesis 
describes the use of such approach to express separately functional ( a4)2(~2)3 and 
( a4 )3(~2)2 receptors. 
1.24 Concatenation of subunit for the study of LG I Cs 
Subunit concatenation by synthetic linkers was first applied succesfully to K+ 
channels in order elucidate the architecture and function of the protein (Isacoff et al., 
1990). This approach was later used for the study of many other ion channels, such as 
cyclic nucleotide-gated ion channel (Varnum and Zagotta, 1996), the epithelial Na+ 
channel (Firsov et al., 1998), transport proteins (Emerick and Fambrough, 1993). 
One of the first application of subunit concatenation to ligand-gated ion channels 
was to prove the topology for the P2X receptor (Newbolt et al., 1998). This strategy was 
then applied to the other members of the Cys-loop superfamily of ligand-gated ion 
channels, such as GABAA receptors (Im et al., 1995; Baumann et al., 2001; Baumann et 
al., 2002), glycine receptors (Grudzinska et al., 2005) and nAChRs (Zhou et al., 2003; 
Groot-Kormelink et al., 2004; Groot Kormelink eta!., 2006; Carbone et al., 2009). 
The use of concatenated receptors has proved to be useful for: 1) characterisation of 
r~ceptor architercture (Newbolt et al., 1998) and stoichiometry (Grudzinska et al., 2005); 
2) characterisation of the properties of receptors that contain different subunit isoforms in 
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specific locations (Minier and Sigel, 2004a; Boileau et al., 2005); 3) selective introduction 
of mutations into a specific subunit that occurs different times in a receptor , thus 
facilitating the investigation of positional effects of mutations associated with diseases 
(Gallaher et al., 2004; Chapter 4 of this thesis); 4) expression ofhomogenous population of 
receptors with a fixed stoichiometry and arrangement (Zhou et al., 2003; Tapia et al., 
2007; Carbone et al., 2009; Chapter 3 of this thesis). 
In order to construct concatenated receptors with functional properties comparable 
to those of their non-linked counterpart, concatenation of subunit has to follow some 
important rules: 1) subunit concatenation is possible only if the N-terminus and the C-
terminus of the subunit are both on the same side on the membrane; 2) the nature and the 
length of the synthetic linkers is critical to ensure normal receptor function. A short linker 
will impair receptor function leading to the formation of non functional receptors 
(Baumann et al., 2001 ); a long linker will lead to the formation of dipentameric receptors, 
monopentamers with a dangling subunit o more complex constructs (Groot-Kormelink et 
al., 2004; reviewed in Minier and Sigel, 2004b); 3) the signal peptide should be present 
only in the first subunit and should be removed from all the .others to avoid proteolysis of 
the construct (see Chapter 3 of this thesis); 4) the order of the subunits in the concatenated 
receptor plays an important role in determining the functional and pharmacological 
properties of the receptor. As shown in Chapter 3 a specific subunit order is needed for 
each receptor type to ensure proper function of the receptor. 
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Thesis synopsis 
The findings of this thesis are described in detail in Chapters 3-5. Chapter 3 describes 
concatenation of ( a4)2(~2)3 and ( a4)3(~2)2 nAChRs. Chapter 4 describes the localisation of 
the binding sites in the concatenated receptors and Chapter 5 shows how concatenated 
receptors can be used for mutational studies. These chapters are divided into four Sections, 
namely Introduction, Experimental procedures, Results and Discussion. The experimental 
procedures described in each Chapter are those that were specifically used to examine the 
issues raised by the studies described in that chapter. Routine experimental procedures 
used throughout this study are described in Chapter 2. Finally, Chapter 6 briefly 
summarises the most relevant findings of the work, relating the most recent findings in the 
nAChRs field to the results presented here. 
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Aims of the thesis 
The overall aim of this study was the engineering and functional characterisation of 
( a.4)2(~2)3 and ( a.4)3(~2)2 nAChRs expressed in heterologous expression systems. Specific 
aims were: a) concatenation of a.4 and ~2 subunits in order to produce pentameric 
concatenated receptors with defined subunit composition and order and their functional 
characterisation; b) localisation of the binding sites in concatenated ( a4)2(~2)3 and 
(a4)3(~2)2 nAChRs in order to use them as a tool for mutational studies; c) analysis of the 
effect of a mutation causing ADNFLE on the two stoichiometries. 
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CHAPTER2 
Materials and Methods 
2.1 Reagents 
Standard laboratory chemicals were of Analar grade and were purchase from BDH 
Ltd., UK. Acetylcholine (ACh), dihydro-p-erythroidine (DHPE), (-) nicotine, A85380, 
epibatidine, cytisine and ZnCb were purchased from Sigma-Aldrich (St Louis, MO, USA). 
51-A85380 was purchased from Tocris (UK). TC2559 was a gift from Targacept Inc. 
(Winston-Salem, NC, USA) and sazetidine-A from Eli Lilly (Surrey, UK). 5-Br-cytisine 
(5-Br-Cys) was a gift from Professor Bruce Cassels (University of Chile, Santiago, Chile). 
2.2 Animals 
Adult female Xenopus laevis toads were purchased from Horst Kaehler (Hamburg, 
Germany). Toads were housed in accordance with Home Office regulations. Briefly, toads 
were housed in black tanks filled with dechlorinated water (> 15 L per toad) that was kept 
in a temperature-controlled room (18 °C). The animals were kept under a fixed 12 hour 
light/dark cycle. Toads were fed twice a week with pellets purchased from the supplier. 
The water was refreshed weekly. 
2.3 Molecular Biology 
DNA ligations, maintenance and growth of Escherichia coli bacterial strains and 
the use of restriction enzymes were carried following the procedures described by Maniatis 
et al. ( 1989). Plasmid isolation and DNA gel purification were carried out using 
commercially available kits (Qiagen, UK). 
The u4 and P2 subunit cDNAs were subcloned into the pCI vector (Promega, UK). 
The pCI vector is endowed with a 5' and 3' intronic regions flanking the multiple cloning 
site (MCS). These regions are part of the p-globin gene family and are known to stabilise 
transcripts and to promote the recruitment of the RNA by polysomes. In order to minimise 
differences in the transcription of the two cDNAs, that may be brought about by different 
untranslated regions flanking the coding regions of the subunit cDNAs (Briggs et al., 
2,006), sub-cloning was performed by PCR using primers annealing at the start and end of 
the translated sequence of the cDNAs. Using these primers, Xba I and Not I restriction 
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sites were introduced at the 5' and 3' ends respectively of both subunit cDNAs for 
subsequent cloning into the MCS of the pCI vector. The full-length sequence of the 
subcloned cDNAs was verified by DNA sequencing (Geneservice, Department of 
Biochemistry, Oxford University, Oxford, UK). 
2.4 Single Point Mutations 
Residues of mutant or wild a.4 or ~2 subunits are numbered in term of the full 
length, including the signal peptide sequences. To obtain the position in the mature form, 
subtract 30 from the number for a.4 and 25 for ~2. 
Point mutations were carried out using the QuikChange™ Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Oligonucleotides for PCR reactions 
were purchased from Eurofins MWG Operon (Germany). In order to increase the number 
of positive transformants, the protocol used was slightly modified from the manufacturer's 
instructions, as described below: 
1) Oligonucleotides (35 to 45 long, melting temperature (TM) > 80 °C) were 
synthesised carrying the desired mutation in the middle. 
2) Primers were diluted to a final concentration of 150 ng/µl and used m the 
subsequent PCR. 
3) The PCR mix consisted of the following: 
IX reaction buffer 
100 ng plasmid DNA 
200 ng sense pnmer 
200 ng antisense primer 
· 6 % dimethyl sulphoxide (DMSO) 
0.1 mM deoxyribonucleotides triphosphate (dNTPs) 
2.5 U Pfu DNA polymerase 
nuclease-free water to a final volume of 50 µl 
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4) The parameters for the PCR run were as follows: 
95 °C for 1 minute 1 cycle 
95 °C for 45 seconds } 
55 °C for 1 minute 15 cycles 
68 °C for 6 minutes 
5) 10 units of the enzyme Dpn I were added to the PCR mixture in order to degrade 
the parental methylated DNA, which corresponds to the template (non-mutated 
DNA), and to leave intact only the newly formed DNA (non-methylated and likely 
containing the desired mutation) 
6) X-Gold competent cells were transformed with 30 µl of the digestion product. After 
overnight incubation, 3 colonies were picked and amplified by growing them in 5 
ml ofLuria-Bertani (LB) medium at 37 °C. After overnight growth, the cDNA was 
isolated from the bacteria using commercially available DNA purification kits. The 
purified plasmid was fully sequenced to confirm the presence of the desired 
mutation and verified the sequence of the non-mutated regions. 
2.5 Construction of concatenated receptors 
The strategy used for the construction of concatenated receptors will be described 
in details in Chapter 3. Briefly, each subunit underwent two sequential PCR steps in order 
to prepare it for concatenation. The primers used for the PCR reactions are listed in 
Appendix 1. The first PCR step eliminated the stop codons, inserted the Kozak sequence 
GCCACC immediately before the signal peptide of the first subunit and added half of the 
length of the linker upstream and downstream from the 5' and 3' coding regions of each 
subunit. The second PCR step introduced the second half of the linker and unique 
restriction sites_ upstream and downstream of the linker to allow successive subcloning into 
a modified pcDNA3.1 Hygro (-)plasmid vector (Invitrogen, UK). This plasmid was also 
used to assemble the concatamers. The restriction sites used for the subcloning are listed in 
Chapter 3. Subunits were ligated sequentially into pentameric constructs using standard 
ligation procedures following verification, by full-length cDNA sequencing, that the PCR 
steps had not introduced any mutation in the constructs sequence. Following assembly, 
pentameric concatamers were subcloned into a modified pCI vector (Promega, UK). In 
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addition a Swal site was inserted downstream the SV 40 late region for linearization prior 
to RNA in vitro transcription. 
2.6 Insertion of mutations in concatenated receptors 
To produce mutant concatenated (a4)3(p2)2 and (a4)2(p2)3 receptors each a4 or P2 
subunit was modified separately and subsequently ligated into the pentameric constructs 
using standard ligation procedures. The full-length sequence of mutant subunit cDNAs was 
verified by DNA sequencing. 
2. 7 In vitro transcription of concatenated receptors 
Concatenated constructs ligated into the pCI modified vector were linearised 
overnight with Swa I. The restriction digestion was terminated by adding the following: 
• I/20th volume 0.5 M EDTA; 
• l/101h volume 5M NH4 acetate; 
• 2 volumes of ethanol 
and dissolved in TE buffer pH 8 at a concentration of 1 µg/µl. RNA transcription was 
carried out using the mMessage mMachine kit (Ambion, UK). In order to increase 
efficiency of the transcription, the protocol used was slightly modified from the 
manufacturer's instructions, as described below: 
1) IX NTP/CAPmix 
IX reaction buffer 
1 ug · linear template DNA 
2uL enzyme mix 
nuclease-free water to a final volume of 20 uL 
2) The mix was incubate at 30 °C for 2 hour. 
3) The transcripted RNA was then treated with 2U of TURBO DNase at 37 °C for 15 
min in order to remove the template DNA. 
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RNA was column-purified using the QiaQuick RNA Purification Kit (Qiagen, UK) and 
stored at -80 cc. RNA was quantified both by gel electrophoresis and by 
spectrophotometric reading. 
2.8 Xenopus laevis oocytes preparation 
Oocytes were collected from adult female Xenopus laevis, anaesthetised and 
sacrificed according to Home Office guidelines. A visceral incision was made through the 
skin and body wall. The ovaries were removed and stored in OR2 solution (82 mM NaCl, 
2m M KCI, 2 mM MgCh, 5 mM HEPES adjusted to pH 7.6 with NaOH). Only oocytes at 
the stage V and VI of maturation were isolated. The theca and epithelial layers were 
manually removed by using fine forceps. The remaining follicular cell layer was removed 
by incubating the oocytes for 7 minutes in type IA collagenase (0.5 mg/ml) dissolved in 
OR2 and placed on a rotating platform. Oocytes were maintained at 18 cc in an incubator 
in a modified Barth's medium (88 mM NaCl, 1 mM KCl, 2.4 mM NaHC03, 0.3 mM 
Ca(N03)2, 0.41 mM CaCh, 0.82 mM MgS04, 15 mM HEPES and 5 mg/I neomycin, pH 
7.6 adjusted to pH 7.6 with NaOH). 
2.9 Microinjection of cDNA and cRNA 
Needles for microinjection were prepared from glass capillary tubing (Drummond, 
Broomall, PA, USA), which were pulled in one stage using a horizontal microelectrode 
puller (Campden Instruments, UK - Model 753). Prior to use the tip of a selected needle 
was broken using fine forceps to give a narrow tip length of approximately 3 mm with an 
external ranging from 1.0 to 1.5 µm. The needle was back-filled with light mineral oil and 
loaded onto a Drummond nanoinjector (Drummond, USA). 
For expression of non-linked (a4)2(~2)3 and (a4)3(~2)2 in Xenopus oocytes, wild-
type or mutant human a4 or ~2 subunit cDNAs, ligated into the pCI expression vector, 
were dissolved in nuclease-free water at a concentration of 1 µg/µl (spectrophotometric 
and agarose gel electrophoresis determinations). Mixtures of either wild-type or mutated 
~4 and ~2 cDNA at 1: 10 or 10: 1 ratios (Moroni et al., 2006) were then diluted to reach a 
concentration of 0.16 µg/µl. The nucleus of oocytes was injected with 18.4 nl, thus the 
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amount of total cDNA injected was kept constantly equal to 3 ng. To maximise the 
opportunity of hitting the nucleus, the needle was directed towards the animal pole. The 
needle tip was assumed to reach the nucleus after penetrating the oocytes for one third of 
its diameter. 
For expression of concatenated (a4)2(~2)3 and (a4)3(~2)2 receptors, the appropriate 
cRNA was dissolved in nuclease-free water at different concentrations for the different 
constructs. 50 nl of RNA mix were injected into the cytoplasm of the oocytes. For studies 
of the effects of chaperone protein 14-3-3 on the functional expression of the pentameric 
concatamers, 2 ng of cRNA coding for rat 14-3-3 was co-injected with concatamer-cRNA. 
The cDNA for this protein was kindly provided by Dr. R. Anand (Ohio State University, 
USA). 
Injected oocytes were transferred to a sterile Petri dish containing modified Barth's 
solution and incubated at 18 °C for a maximum of 5 days. The Barth's solution was 
changed daily and oocytes that had degraded were removed to minimise enzymatic damage 
to healthy cells. 
2.10 Electrophysiological Recordings 
Recordings were performed 2-6 days post-injection. Oocytes were selected 
according to their appearance; only oocytes with integral membrane and no signs of 
degradation were chosen for electrophysiological recordings. Oocytes were placed in a 0.1 
ml recording chamber and continuously perfused at a rate of 10 ml/min with modified 
Ringer solution (in mM: NaCl 150, KCl 2.8, HEPES 10, BaCb 1.8 and adjusted to pH 7.2 
with 5 mM NaOH), unless otherwise stated. Switching between different solutions 
occurred through tnanually activated valves. All solutions were freshly made prior to 
recordings. Unless otherwise mentioned, a nominally Ca2+ free solution was chosen in 
order to minimise the contribution to the response of Ca2+ -gated chloride channels which 
are endogenous to the Xenopus oocyte (Barish, 1983) and may be activated by Ca2+ entry 
through the heterologously expressed nAChRs. 
Oocytes were impaled by two electrod~s connected to a Geneclamp 500B amplifier 
(Molecular Devices, CA, USA) for standard voltage clamp recordings. Oocytes were 
yoltage-clamped at -60 mV, except for the determination of the reversal potential of the 
ACh-elicited currents. Electrodes were made from borosilicate capillary glass (GC 150 TF, 
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Harvard Apparatus, MA, USA) using a vertical two stage electrode puller (Narishige PP-
83). The electrodes were back-filled to approximately 5 mm from the top with a solution of 
1 mg/ml agarose dissolved in 3 M KCl and stored at room temperature. Prior to recordings 
electrodes were filled with 3 M KCl and only electrodes with a resistance between 0.5 and 
2 MQ were used for voltage clamping. Typically, traces were filtered at 1 kHz during 
recording and digitized at 10 kHz using the DigiData 1200 interface (Molecular Devices, 
CA, USA). All experiments were carried out at room temperature (approximately 20 °C). 
2.11 Time course of desensitisation 
To study the effect of mutations on receptor desensitisation the decay of currents 
elicited by 30 s applications of ACh ECso or saturating ACh concentrations was examined. 
The amplitude of the current measured between peak and plateau was used as an estimate 
of the fraction of desensitisation occurring during a brief exposure to the agonist. To 
compare the rate of desensitisation of the wild type and mutant responses, the desensitising 
phase was fit to a one or two-component exponential, as appropriate (see Section 2.14), 
obtaining an apparent time desensitisation constant ('t). 
2.12 Study of Zn2+ sensitivity and Ca2+ permeability 
The sensitivity to Zn2+ was assessed by co-applying a range of Zn2+ concentrations 
with non-desensitising concentration of ACh, 1 µM ACh for linked and non-linked 
(a4)2(~2)3 nAChRs and 10 µM ACh for linked and non-linked (a4)3(~2)2 receptors. For 
Zn2+ to attain equilibrium around impaled oocytes, Zn2+ was pre-applied for 30 s to the cell 
prior to co-application of ACh and Zn2+. Concentration-response relationships for Zn2+ 
were obtained using this protocol. Peak responses elicited by ACh + Zn2+ were normalized 
to the peak response of the appropriate ACh alone. 
The Ca2+ permeability of the receptors was determined by constructing current-voltage 
(1-V) relationships and measuring the shift in the teversal potential of ACh EC50 currents in 
the presence of 1.8 mM Ca2+ or 18 mM Ca2+ in the perfusing Ringer solution. The I-V 
relationship characteristics of the ACh-elicited current in wild-type and mutant receptors 
was determined as follows. First, membrane was held at -60 m V and then the passive cell 
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properties were measured by steeping the voltage by 10 mV steps from -60 mV to +20 - 30 
mV. The membrane was then returned to -60 mV and an EC50 concentration of ACh was 
applied, the holding voltage was then stepped by 10 mV from -60 mV to +20 -30 mV, and 
ECso ACh was applied at each step. The passive cell properties were then substracted from 
the ACh-elicited currents. The I-V curve was obtained by plotting the amplitude of the 
ACh-induced currents as a function of the holding voltage. The reversal potential of the 
ACh-induced currents was taken as the voltage prior to that at which the ACh-currents 
became positive. 
2.13 Western Blot Assay 
Western blot assays were carried out on total membrane homogenates prepared 
from oocytes expr~ssing heterologously either concatenated or non-linked a.4~2 nAChRs. 
Oocytes were homogenised six days after microinjection with free a4 and ~2 subunits 
cDNAs or concatamer cRNAs. Four batches of oocytes (50 oocytes per batch) were used. 
Oocytes were homogenised using an ice-cold homogenisation buffer (150 mM NaCl, 2 
mM CaCb, 2% Triton-XlOO, 20 mM TrisHCl, pH 7.4, supplemented with lµM pepstatin, 
1 mg/ml leupeptin, 2 mM PMSF) at a ratio of 10 µl buffer/oocyte. Homogenates were 
centrifuged twice at 1000 x g for 5 min at 4 cc to remove the yolk and the supernatants 
were then re-centrifuged at 10,000 x g for 10 min at 4 cc. Aliquots of the supernatants 
containing 30 µg of protein were separated by SDS-PAGE electrophoresis (Novex, 7% 
Tris-acetate gels; Invitrogen, UK). The proteins were subsequently transferred onto 
nitrocellulose membranes (Optitran BA-S83, Schleider & Schuell, Germany) by electro-
blotting (2 h transfer at room temperature at 25 m V). Membranes were blocked for 2 h at 
' 
room temperature with 5% non-fat dry milk in phosphate buffered saline containing 0.1 % 
Tween 20 (Sigma:Aldrich Co, UK). Membranes were then incubated overnight at 4cc 
with 0.7 µg/ml of primary antibody (AChRa4 (H-133) or AChR~2 (H-92), Santa Cruz 
Biotechnology, USA) and further incubated for 3h at room temperature with 2 µg/ml of 
secondary antibody (Cy-5-goat anti-rabbit IgG conjugate, Invitrogen, UK). Bound 
antibodies were visualised on a Typhoon variable mode imager (GE Healthcare, UK). The 
identity of the bands was determined based on molecular weight of the immunoreactive 
protein (a4 = 70 kDa; ~2 = 50 kDa). 
63 
2.14 Data Analysis 
Fits to full concentration-response curves for individual oocytes were made 
independently and then averaged in order to compare significant differences between 
groups. Concentration-response data for wild type or mutant a.4~2 receptors were fitted 
using one and two components sigmoidal dose-response equations, 
Y = I/ImaXBottom + (I/ImaXTop- I/ImaXBottom)/(1 + lOA((LogECso-X)*nHill)) 
Y = I/ImaXBottom + [(I/ImaXTop - I/ImaxBottom)*Fraction/(1 + IQA((LogECso_1 - X)*nHill1))] 
+ [I/ImaXTop - I/ImaXBottom)*(l-Fraction)/(1 + lQA((LogECso_2 -X)*nHilh))] 
where X is the logarithm of the agonist concentration, Y is the peak amplitude of the 
normalized current response, Imax is the maximal current and nHill is the Hill slope. An F 
test determined whether the one-site or two-site model best fit the data; the simpler one-
component model was preferred unless the extra sum-of-squares F test had a value of p 
less than 0.05. 
The peak responses elicited by ACh plus Zn2+ were normalized to the peak 
response of the appropriate A Ch alone. Where a single component concentration-response 
relationship was evident, data were fitted to the Hill equation shown above. When Zn2+ 
produced both a potentiating and inhibiting effect, the data were fitted to the following 
equation designed to account for the potentiating and inhibitory effects of Zn2+ on a.4~2 
receptors assuming this cation binds to two distinct sites on the receptor: 
I= (1 + ((Imax - 1)/(1 + lOA((logECso- X) * nHillpot))))/(1 + lOA((logICso-X) * nHillinh)) 
where I represe~ts the current responses at a given Zn2+ concentration (X), Imax, represents 
the maximally potentiated peak, ECso and ICso are the concentrations of Zn2+ inducing 
half-maximal potentiation or inhibition, respectively, and nHillpot and nHillinh are the Hill 
coefficients for potentiation and inhibition, respectively. F tests were always performed to 
assess the fitting of the data; the simpler one:"'component model was preferred unless the 
extra sum-of-squares F test had a value of p < 0.05. 
Current decay data were fit to either the mono-exponential function 
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y = (Ao * e-Cth:)) + B 
or the bi-exponential equation 
y =(Ao * e-('d-i:2)t) + B 
where y is the ACh-evoked current, Ao the amplitude at time zero, t time, -r, d or -r2 are the 
apparent time constant and B the level of current reached at the end of the application. 
Data analyses were performed using Graph PAD-Prism software 5 (GraphPad 
Software, CA, USA). Data were pooled from at least three different batches of oocytes. 
Statistical significance was determined using one-way analysis of the variance (ANOV A) 
or Student's t test (two-tailed unpaired tests) as appropriate. Values of p < 0.05 were 
considered statistically significant. 
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CHAPTER3 
Pentameric concatenated ( a4)2(B2)3 and 
( a4)3(B2)2 nicotinic acetylcholine 
receptors: subunit arrangement 
determines functional expression 
3.1 Introduction 
Heterologous co-expression of a4 and p2 nAChR subunits produces high- and low-
affinity receptor populations evidenced by biphasic ACh concentration-response curves. 
High- and low-affinity a4p2 nAChRs result from the assembly of receptors with two 
distinct stoichiometries: (a4)2(P2)3 (high-affinity subtype) and (a4)3(p2)2 (low-affinity 
subtype) (Nelson et al., 2003; Moroni et al., 2006; Zwart et al., 2006), although 
pharmacological studies of a4p2 nAChR expressed heterologously in Xenopus oocytes 
suggest that other stoichiometric arrangements may also occur (Zwart and Vijverberg, 
1998; Lopez-Hernandez et al., 2004). (a4)2(P2)3 and (a4)3(p2)2 receptors differ profoundly 
in sensitivity to activation by agonists, desensitisation kinetics, unitary conductance 
(Nelson et al., 2003; Moroni et al., 2006), Ca2+ permeability (Tapia et al., 2007) and 
sensitivity to both Zn2+ modulation (Moroni et al., 2008) and chronic exposure to nicotine 
(Nelson et al., 2003; Kuryatov et al., 2005; Moroni et al., 2006). Several studies showed 
that both (a4)2(p2)3 and (a4)3(p2)2 are likely to be present in the brain (Marks et al., 1999; 
Butt et al., 2002; Gotti et al., 2008) and it was been suggested that their relative ratio may 
influence basal behaviours influenced by a4p2 receptors as well as sensitivity to the acute 
effects of nicotine (Stitzel et al., 2001; Tritto et al., 2002; Kim et al., 2003). Hence, the 
separate expression of (a4)2(p2)3 and (a4)3(p2)2 in heterologous systems has become an 
increasingly attractive approach for aiding the characterisation of the properties of these 
receptors and for the development of stoichiometry-specific a4p2 nAChR drugs. 
There has been several attempts at expressing ( a4)2(p2)3 and ( a4)3(p2)2 nAChRs 
separately in heterologous systems. These include injection of 1: 10 or 10: 1 ratios of a4 and 
p2 subunit cDNAs into the nucleus of Xenopus oocytes (Moroni et al., 2006), growing 
human embryonic kidney 293T cells stably transfected with a4 and P2 subunits at 29 °C or 
chronically exposed to nicotine (Nelson et al., 2003). Although, as suggested by 
monophasic · ACh concentration-response curves, these approaches yield very 
homogeneous populations of (a4)2(P2)3 or (a4)3(p2)2 receptors, it is not conclusive that 
they abolish concurrent expression of multiple forms of the a4p2 receptor. As suggested by 
the biphasic concentration-response curves produced by agonists such as 51-A85380 at 
a4P2 nAChR produced with the 10:1 cDNA ratios (Zwart et al., 2006) the presence of 
other receptor stoichiometric arrangements cannot be excluded. 
Tandem subunit constructs with two subunits attached together by synthetic AGS 
linkers have also been used to constrain the stoichiometry of a4p2 nAChRs. However, this 
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approach can lead to the formation of dipentamers (Zhou et al., 2003) or linked subunits 
may not be fully incorporated into the pentameric structure of the receptor (Groot-
Kormelink et al., 2004). 
An alternative approach that circumvents the problem of subunit isoforms and 
stoichiometry heterogeneity is the production of concatenated receptors with forced 
stoichiometry. In these receptors, the subunit arrangement is fixed by predetermining the 
order of subunits by fusion at the DNA level. Recently, this strategy was used to produce 
functional expression of (a3)2(P4)3 nAChR (Groot-Kormelink et al., 2006) and 
(a1)2(p2)2y2 GABAA receptors (Baur et al., 2006). As suggested by functional studies, 
pentameric (a3)2(p4)3 and (alh(P2)2y2 GABAA concatamers are similar to their non-
linked counterparts, which shows that concatenation of Cys-loop subunit receptors to 
pentamers does not alter receptor functions. And, as shown by studies of concatenated 
GABAA receptor, this approach offers the unique possibility of studying positional effects 
of point mutations (Baumann et al., 2003; Baur and Sigel, 2005) and positional effects of 
subunit isoforms (Minier and Sigel, 2004a; Boileau et al., 2005). 
Therefore, in order to facilitate the study of the structural mechanisms underlying 
the functional properties of the two alternate stoichiometries of the a4P2 nAChR, 
concatenated (a4)2(P2)3 and (a4)3(P2h receptors were engineered. Several strategies have 
been used to construct pentameric concatamers of Cys-loop receptors. For the 
concatenation of the GABAA receptor subunits, linkers of variable lengths and containing 
three different amino acid residues (glutamine, proline and alanine) were used. 
Importantly, the signal peptide of every subunit, but the first one, was removed (Baur et 
al., 2006). By comparison, in the approach used to construct concatenated a3P4 nAChR 
(Groot-Kormelink et al. 2006), the subunit cDNAs were bridged using fixed-length linkers 
composed of 8 glutamines and the signal peptide was maintained in all five subunits. The 
choice of polyglutarnine linkers was based both on the water-solubility of the sequence and 
the random coil conformation that acquires in water (Altschuler et al., 1997), making it an 
ideal linker for this purpose. 
This chapter describes the construction of three types . of fully concatenated 
(a4)2(P2)3 and (a4)3(p2)2 nAChRs constructed using different strategies and their 
expression and functional characterisation in Xenopus oocytes. The results obtained 
suggest that the subunit order plays an important role in the synthesis of concatenated a4P2 
11AChRs. 
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3.2 Experimental procedures 
3.2.1 Overall strategy 
Three types of a4P2 receptor concatamers were constructed. Because of the 
homology between the a3P4 and the a4P2 nAChRs, the first type of pentameric 
concatamers were engineered using the procedure described by Groot-Kormelink et al. 
(2006) to construct the (a3)2(P4)3 nAChR concatamer. Because both subunits expose both 
C- and N-termini on the extracellular side, the C-terminus of one subunit was covalently 
linked, at the cDNA level, to the N-terminus of the subsequent subunit. The subunit order 
for the first type of pentameric concatamers was p2_p2_a4_p2_a4 for the (a4)2(P2)3 
receptor and P2_a4_a4_p2_a4 for the (a4)3(p2)2 receptor. The signal peptides were 
maintained in all subunits which were linked by 8 glutamines (Q8) linkers. For clarity, 
these constructs are referred to as P2(QB)P2(QB)<l4(QB)P2(Q8)a4 and P2(QB)<l4(QB)<l4(Q8)P2(Q8)a4, 
respectively. 
The second type of constructs maintained the subunit order of the previous. 
However, the signal peptide was removed from all the subunits but the first and the 
subunits were bridged by alanine-glycine-serine linkers (AGS) of variable length to 
compensate for the differences in the length of the C-terminus of the a4 and the P2 
subunits (Zhou et al., 2003). Thus, an (AGS)6 was used to join p2 to the a4 subunit, 
whereas an (AGS)9 linker bridged the a4 to the p2 subunit. These constructs are referred to 
as P2(AGs)P2(AGS)<l4(AGs)P2<AGS)U4 and P2<AGS)<l4(AGS)<l4(AGS)P2(AGs)a4, respectively. 
The third type of constructs used a subunit order of p2_a4_P2_a4_P2 for the 
(a4)2(p2)3 receptor and p2_a4_P2_a4_a4 for the (a4)3(p2)2 receptor. In these constructs, 
the signal peptide was removed from all the subunits but the first and the subunits were 
bridged by AGS linkers of variable length, as in the P2(AGs)P2(AGs)a4(AGS)P2(AGs)a4 and 
p2(AGS)<l4(AGS)<l4(AGS)P2cAGS)<l4 constructs. 
Single a4 and P2 subunits were modified by two sequential steps of PCR in order to 
add the linker and introduce unique restriction sites to allow successive subcloning into a 
modified pcDNA3.1 Hygro(-) plasmid vector. This plasmid was also used to assemble the 
concatamers. The pentamers were subsequently assembled using standard ligation 
reactions following verification, by full-length cDNA sequencing, that the PCR steps had 
not introduced any mutation in the constructs sequence. Following assembly, pentameric 
concatamers were subcloned into a modified pCI vector. 
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3.2.2 Modification of plasmid expression vectors to host pentameric constructs 
The expression vector pcDNA3.l Hygro(-) was chosen for subcloning of single 
subunits and for assembling the concatameric constructs after linkers and restriction sites 
were added. The pCI vector was used as expression vector for nuclear injection in Xenopus 
oocytes and for in vitro transcription for the reasons explained in Section 2.3. The multiple 
cloning site (MCS) of both plasmids was modified by oligonucleotides hybridisation in 
order to introduce restrictions sites for the subcloning of the modified single subunits or the 
concatenated constructs. 
The oligonucleotides used to modify the pcDNA 3.1 vector were: 
Nhe I Ase I Swa I Xba I BstB I Age I 
Oligo Forward: CTAGC GGCGCGCC ATTTAAAT TCTAGA TTCGAA ACCGGT 
Pme I Xho I 
GTTTAAAC C 
Xho I Pme I Age I BstB I Xba I Swa I 
Oligo Reverse: TCGAG GTTTAAAC ACCGGT TTCGAA TCTAGA ATTTAAAT 
Ase I Nhe I 
GGCGCGCCG 
After hybridization the resulting double-strand DNA linker was ligated into the pcDNA3.1 
Hygro(-) between Nhe I and Xho I (bold and underlined). 
The oligonucleotides used to modify the pCI vector were: 
Eco RI Ase I Xba I Age I Xho I Swa I 
OHgo Forward: AATTC GGCGCGCC TCTAGA ACCGGT CTCGAG ATTT AAAT 
EcoR V Not I 
GATATCGC 
Not I Eco RV Swa I Xho I Age I Xba I 
Oligo Reverse:· GGCCGC GATATC ATTTAAAT CTCGAG ACCGGT TCTAGA 
Ase I Eco RI 
GGCGCGCCG 
After hybridization the resulting double-strand Dl'f A linker was ligated into the pCI vector 
between Eco RI and Not I (bold and underlined). 
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The hybridisation of the oligonucleotides was carried out as follows: 
1) Forward and reverse oligonucleotides were synthesised in order to carry 3' 
and 5' overhanging ends. 
2) Oligonucleotides were diluted to a final concentration of 1 µg/µl. 
3) The hybridisation reaction consisted of the following reagents: 
10 mM Tris HCl pH 8 
lOmM MgCh 
20 µg Oligo Forward 
20 µg Oligo Reverse 
1 % DMSO 
nuclease-free water to a final volume of 100 µl 
4) The reaction mix was placed in a water containing bath at 95 °C for 5 
minutes; the bath was then cool slowly to reach room temperature 
(overnight). 
5) The reaction mixture was isopropanol-precipitated and the resulting double 
stranded DNA was resuspended to a final concentration of 1 µg/µl and used 
for standard ligations. 
The pCI modified vector was also further modified to carry a unique restriction site 
(Swa I, downstream of the SV 40 region) for cDNA linearization, which was needed for in 
vitro RNA transcription. The site was introduced using the QuikChange™ Site-Directed 
Mutagenesis Kit as described Section 2.4. 
3.2.3 Subcloning of single subunits into modified pcDNA3.1 Hygro(-) 
Single a4 and ~2 subunits underwent two sequential PCR amplification steps. The 
first PCR step eliminated the stop codons (for all constructs) and signal peptides (for the 
second and third type of constructs) and inserted the Kozac sequence GCCACC 
immediately before the signal peptide of the first subunit. Half of the length of the linker 
(i.e., Q4, (AGS)3 or (AGS)41s) was added with the first PCR step upstream and downstream 
from the 5' and 3' coding regions of each subunit.. The second PCR step introduced unique 
restriction sites upstream and downstream of the linkers to allow successive subcloning 
into modified pcDNA 3.1 Hygro(-) plasmid. 
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All PCR reactions were performed in the following way: 
1) Oligonucletides (35 to 50 bp long), were synthesised in order to pair 20 to 
25 bases of the coding region of either the a4 or the (32 subunit (TM 63-65 
oc). 
2) Primers were diluted to a final concentration of 10 µM and used in the 
subsequent PCR. 
3) The PCR mix consisted of the following: 
lX Thermo Polymerase Buffer II 
50 ng plasmid DNA (either a.4 or (32 subunit or product of the first 
PCR reaction) 
lmM MgS04 
0.1 µM forward primer 
0.1 µM reverse pnmer 
6% DMSO 
0.1 mM dNTPs 
200 U Vent polymerase 
nuclease-free water to a final volume of 50 µl 
4) The parameters for the PCR run were as follows: 
95 °C 
95 °C 
(TM-10) 6C 
72 °C 
for 1 minute 
for 45 seconds } 
for 1 minute 
for 2 minutes and 30 sec ds 
1 cycle 
30 cycles 
Subsequently, the second PCR reaction was loaded on a 1 % agarose gel and 
isolated from plasmidic template by using a Gel Extraction Kit (Qiagen, UK). The PCR 
product was eluted in 50 µl of Tris HCl buffer pH 8. Single subunits were subcloned 
singularly into .the pcDNA 3.1 Hygro(-) modified vector using the unique restriction sites 
added by the second PCR reaction. For all concatamers the subunits were subcloned 
between the following restrictions sites regardless of the subunit being a.4 or (32: 
1st subunit: Ase I I Xba I 
2nd subunit: Xba I I Age I 
3rd subunit: Age I I Xho I 
4th subunit: Xho I I Not I 
5th subunit: Not I /Eco RV 
72 
The absence of unwanted mutations, the correct insertion of the linkers and of the 
restriction sites flanking the coding region of the subunits were verified by full-length 
sequencing. 
Subunits were ligated sequentially into pentameric constructs using standard 
ligation procedures as shown in Fig. 3 .1. 
-----;,.. 
·First PCR 
reaction 
r-1---...... 1 __... 
~ 
Ase I Xbal 
-t 
Second PCR 
reaction 
Ase I Xba Age I Age I Xho I 
~·~-+ ~
• Ase I Xbal Age I Xho I Xhol 
~,.-,_,~*-1"(1 ~z·~•d :JI~ -t 
Ase I Xba Age I Xhol Not I 
Ase I Xba Age I • Xhol Not I X-c:::E:J~-* ,, j•d 
Not I 
Nntl EeoRV 
EeoRV 
Fig. 3.1 Diagram showing the experimental approach used to create concatenated a4fl2 receptors. 
Starting from wild type a4 and ~2 subunits two successive PCR steps were performed to add linkers (grey 
rectangular box) and .:imique restriction sites (X). The modified subunits were sequentially ligated into 
pentameric constructs using standard ligation procedures. 
Following assembly, pentameric concatamers were excised from the pcDNA3. l 
Hygro(-) modified vector and ligated into the pCI modified vector between Ase I and Eco 
RV for nuclear injection inXenopus oocytes and in vitro transcription. 
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3.2.4 cDNA and cRNA injection in Xenopus oocytes. 
Stage V and VI Xenopus oocytes were prepared as previously described in Section 
2. 7 cRNA transcription was carried out as described in Section 2.6. In each oocyte up to 
150 ng of cRNAs were injected for the first and second type of constructs in a volume of 
50 nl. For the third type 5-10 ng of cRNAs were sufficient to obtain a good level of 
functional expression. 
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RESULTS 
3.3.1 The pharmacological profile of P2cQs>P2cQs)a4cQs)P2cQs)a4 and 
P2(Qs)a4(QS)a4(QS)P2(QS)OA is different from that of their non-linked counterpart 
P2cQs)P2(Qs)a4(QS)P2<Qs)a4 and P2(Qs)a4(QS)U4(QB)P2(QS)a4 constructs were examined 
to see if they produced functional expression in Xenopus oocytes. Fig. 3.2 shows that five 
days after microinjection with 150 ng or 100 ng of cRNA coding for 
P2(Qs)P2(QS)U4(QS)P2(QS)a4 and P2(Qs)a4(QS)U4(QB)P2<QS)a4 receptors functional expression 
was markedly and significantly lower than that obtained by injection of non-linked a:!- and 
P2 cRNAs at a 1: 10 ratio or 10: 1 ratio (p < 0.001, Student's t test, n = 8 - 10). Typically, 
maximal concentrations of ACh induced current responses with an average amplitude of 
0.5 ± 0.1 µA or 3.2 ± 1 µA in oocytes expressing (a4)2(p2)3 or (a4)3(P2)2 non-linked 
receptors, respectively. By comparison, only small currents could be recorded five to six 
days after injection of more than 150-fold the usual amount of cRNA (150ng for 
concatamers versus 0.05 - 1 ng for single subunits) (Fig. 3.2 A) . 
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Fig. 3.2. Expression of pentameric P2cQsiP2cQa)a4cQs)P2cQa)a4 and P2cQsia4(Qa)a4cQsJP2cQs)a4 concatamers 
in Xenopus oocytes. A) ACh evoked small inward currents in oocytes microinjected with 150 ng of 
P2<osiP2cosia4cosiP2cos)<l4 (Left panel) and P2cosia4<osia4cosiP2<osia4 (Right panel) cRNAs. Traces evoked in 
non-linked receptors are superimposed for comparison. B) Bar graph comparing the functional expression 
levels of receptors made of concatenated subunits and expressed by means of extreme transfection ratios. 
(*** = p < 0.0001 , Student's t test) 
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Fig. 3.3 shows ACh current responses from oocytes expressing human neuronal 
non-linked a4~2 nAChRs following transfection with a 1: 10 or 10: 1 subunit ( a4/~2) 
injection ratio or with the concatenated constructs. Agonist responses were very similar for 
the two receptors both in time course and agonist sensitivity. Analysis of the concentration-
response curves showed significant differences in EC50 values for linked and non-linked 
receptors (p < 0.05, Student's t test, n = 8 - 10) and a slightly different, albeit non 
significant, value for the Hill slope (data are summarized in Table 3 .1) 
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Fig. 3.3. P2cQsiP2cQsia4cQs)P2cQs)a4 and P2cQsia4cQsia4cQs)P2cQs)a~ receptors have ACh sensitivity similar to 
that of receptors expressed from monomeric constructs. ACh concentration-response curves for 
concatenated. (a4)2W2)3 (Left panel, •) anc;I. (a4)3(~2)2 (Right panel, •). For comparison ACh concentration 
response curves for non-linked receptors are shown as dashed lines. 
The effects of a range of nicotinic agonists and antagonists were evaluated in order 
to characterise the pharmacological properties of the concatenated receptors (Figs. 3.4 A, 
B). Although concentration-response curves for ACh and other ligands were monophasic 
(p < 0.001, F test, n = 8 - 10), suggesting the presence of only one type of receptor 
population, the pharmacological profile of ~2CQ8)~2cQs)a4cQs)P2cQs)a4 and 
P2cQs)a4cQs)a4cQs)P2cQs)a4 receptors was significantly different from that of the 
corresponding non-linked receptor (p < 0.05, Student's t test, n = 8 - 10). The efficacies of 
the full agonists epibatidine, A85380 and TC2559 on the concatenated (a4)3(p2)2 receptor 
were significantly higher than in the non-linked receptor, whereas the partial agonist 
cytisine was less efficacious on the concatenated receptor than in the non-linked (a4)3(P2)2 
receptor (Fig. 3.4 A). Due to the low level of expression, only the full agonists A85380 and 
TC2559 could be tested on the concatenated (a4)2(P2)3 receptor. Efficacy of A85380 was 
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slightly higher on the. concatenated receptor whilst efficacy of TC2559 was drastically 
reduced (Fig. 3.4 B). Affinity values of the compounds tested are summarised in Table 3.1. 
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Fig. 3.4. The pharmacological profile of P2cQsiP2cQsia4cQsiP2cQsia4 and P2cQsia4cQs)a4cQsJP2cQs)a4 
receptors is different from that of non-linked a4p2 receptors. (A) Concentration-response curves of 
nicotinic ligands on the function of concatenated and non-linked (a4)i(~2)3 nAChRs ( • ). (B) Concentration-
response curves of nicotinic ligands on the function of concatenated and non linked (a4)3(~2)2 nAChRs (•). 
Responses were normalised to 1 mM. Agonist or antagonist data were analysed as described in Methods using 
a monophasic sigmoidal equation. Data points represent the mean ± SEM of 8 - I 0 experiments carried out 
using at least two different batches of oocytes. 
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Table 3.1. Functional properties of glutamine-linked ( a4)2(Jl2)3 and ( a4)3(Jl2)2 
receptors. 
(J2QsP2QsU4Qs(J2Qsa4 Non-linked (a4)z(Jl2)3 
I/Imax ± ECsoµM nHill ± I/Imax ± ECsoµM nHill ± 
SEM (95 % CI) SEM SEM (95 % CI) SEM 
3.04 3.8 A Ch 1 (2.5 -9.3) 0.50±0.05 1 (2.1 - 4.7) 0.84±0.11 * 
1.58±0.01 0.022 0.026 1.07±0.15 A85380 * (0.02-0.03) 0.92±0.03 1.38±0.07 (0.01-0.05) * 
TC2559 1.04±0.03 1.04 1.8±0.31 2.52±0.2 1.95 0.82±0.06 * (0.8 - 2.1) * (0.8 - 3) 
P2QsU4Qs«4Qs(J2Qsa4 Non-linked (a4)3(Jl2)z 
I/Imax ± ECsoµM nHill ± I/Imax ± ECsoµM nHill ± 
SEM (95 % CI) SEM SEM (95 % CI) SEM 
A Ch 1 158 0.8±0.03 1 
89 0.97±0.1 
(128 - 178) (76- 120) 
3.65±0.1 
12.13 3.12 A85380 (11.5-12.7) 0.78±0.08 1.42±0.1 0.60±0.07 * (2.3-4.8) * 
0.11±0.01 4.1 0.79±0.07 11.70 Cytisine (2.2-6.4) 0.19±0.02 0.43±0.08 * * (9-28) * 
2.7±0.09 
25 
1.2±0.15 1.25 Epibatidine (17 - 38) 2.1±0.28 0.50±0.07 * * (0.8-3) * 
TC2559 0.21±0.04 1.08 1.03±0.18 0.21±0.04 
1.12 0.87±0.08 * (0.4-4.2) (0.5 - 1.8) 
Dh~E 
0.13 0.85±0.03 
0.25 1.06±0.10 - (0.09-0.17) - (0.12 - 0.47) 
All values are means (95 % CI) or means ± SEM from 5-10 cells. Statistical analysis was 
performed by comparing the agonist EC50, l!Imax and nHill of the concatenated receptors to 
the non-linked receptor using one-way analysis of the variance (ANOV A) to assess 
significance. The * signifies p < 0.05 compared with non-linked ( a.4)2(~2)3 or ( a.4)3(~2)2 as 
appropriate. 
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3.3.2 P2cQs)P2cQs)a4cQs)P2cQsia4 and P2cQs)a4cQs)a4cQs)P2cQs)a4 receptors are degraded 
during synthesis 
The integrity of the concatenated constructs was assessed by Western blotting. 
Western blot analysis showed concatamer proteins of appropriate size 
(P2cos)P2cosia4cosiP2cosia4 290 kD, and P2cQsia4cosia4cosiP2cosia4 . .310 kD) but also small 
amounts of fragments of various sizes that included monomeric and intern1ediate-sized by-
products (Fig. 3.5). 
290 kDa 
310 kDa 
68 kDa 
Fig. 3.5. Western blot analysis of P2cQsJP2cQsJa4cQsJP2cQs)a4 and P2cQs)a4cQsJa4cQs)P2cQs)a4 receptors shows 
the presence of breakdown products. Membrane homogenates prepared from oocytes injected with 
P2cosiP2cQsia4cos>P2cosia4 and P2cQsJa4cosia4cosiP2cQsJa4 cRNAs were resolved and then blotted and 
immunostained as described in Chapter 2. Full length receptors of the expected size 
(P2cosJP2cosia4cosiP2cosJa4 290 k.D, and P2cQsia4cos>a4cosiP2cosia4 . .310 k.D) are produced after injection of 
linked DNA Lnto oocytes. Smaller fragments (indicated by the arrows) are also present, which suggests 
cleavage of the pentameric constructs. 
These findings suggest proteolytic cleavage of P2cQs)P2(Q8la4(Q8JP2(Q8la4 and 
P2(Q8)a4cosia4cosiP2cosia4 proteins. Proteolytic cleavage could have occurred because of the 
presence of signal peptides between the linked subunits. Signal peptides between tethered 
receptor subunits favour degradation of concatenated ligand gated ion channel subunits, 
which subsequently might produce reduced levels of functional expression and/or 
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incorporation of the breakdown products into receptors of complex and unknown subunit 
composition (Nicke et al., 2003; Boileau et al., 2005; Baur et al., 2006; Sigel et al., 2006; 
Ericksen and Boileau, 2007) and possibly novel pharmacological profiles, as found with 
the P2(Q8)P2(Q8)a4(Q8)P2(Q8)a4 or P2(Q8)a4(Q8)a4(Qs)P2(Q8)a4 receptors. 
In an attempt to circumvent the problem of concatamer degradation the signal 
peptide was removed from all the subunits except the first one and the new concatamers 
P2(AGs)P2(AGs)a4(AGs)P2(AGs)a4 and P2(AGS)a4(AGs)a4(AGs)P2(AGs)a4 were constructed. 
3.3.3 Functional expression of P2<AGs>P2cAGs)«4cAGs)P2cAGs)a4 and 
P2cAGs)«4(AGs)«4cAGS)f32cAGS)a4 concatamers is very poor 
Previous studies on pentameric concatamers of GAB~ receptors (Baur et al., 
2006), dimers of alp glycine receptor (Grudzinska et al., 2005) and dimers of a4P2 
nAChR (Zhou et al., 2003) have shown that linkers lengths between 35 and 50 amino acids 
generally produce good functional expression. 
Therefore, in concatamers P2cAos)P2cAos)a4cAos)P2cAos)a4 and 
P2cAos)a4(AGS)a4(AGs)P2(AGS)a4, the overall length of the linker (length of synthetic linker 
plus added restriction enzyme sites and the C-terminus of each subunit) was 43 amino acid 
residues when bridging p2 to a4 or P2 to P2 and 37 amino acid residues when bridging a4 
to P2 or a4 to a4. The linkers were of different lengths to compensate for differences in the 
length of the C-terminus and N-terminal sequence prior to the first conserved secondary 
structure element (a-helix A; Brejc et al., 2001) of the a4 and P2 subunits. In addition, to 
minimise possible amino acid depletion (Sigel et al., 2006), AGS linkers were used, which 
have been previously used to construct a4p2 receptor dimers (Zhou et al., 2003). Three -
six days after microinjection of up to 150 ng of cRNAs coding for 
P2(AGs)P2(AGs)a4(AGs)P2(AGs)a4 and P2(AGs)a4cAos)a4(AGs)P2(AGs)a4 concatarners, functional 
expression amounted to less than 20 nA (not shown). Because of low levels of expression, 
the pharmacological profile of these receptors was not characterised. Although functional 
expression was poor, Western blots showed full-length pentameric concatamers without 
apparent degradation products (Fig. 3.6). 
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290 kDa 310 kDa 
Fig. 3.6. Western blot analysis of P2<AGs>P2<AGS)a4(AGS)P2(AGs)a4 and P2(AGS>a4(AGS)a4(AGS>P2(AGS)a4 
receptors. Western blot analys is of P2(AGs)P2(AGs)a4(AGs>P2(AGsJa4 and P2(AGS)a4cAGSla4(AGSJP2(AGs)a4 proteins 
indicated that the pentameric constructs were not cleaved. Total protein from oocytes injected with 
P2<AGsJP2(AGs)a4cAGs)P2cAGs)a4 and P2(AGS)a4cAGSJa4<AGSJP2<AGS)a4 cRNAs was resolved by reducing SDS-
PAGE on a NuPage 7% Tris acetate gel. lmmunoblot analysis was carried as described in Chapter 2. The 
molecular mass of the concatenated constructs are shown next to the blots. 
3.3.4 P2_a4_p2_a4_P2 and P2_a4_P2_a4_a4 concatamers recapitulate non-linked 
(a4)z(P2)3 or (a4)J(p2)z properties 
Thus far, it has been shown that even though p2_p2_a4_P2_a4 and 
P2_a4_a4_P2_a4 concatamers are synthesised and stable inXenopus oocytes, they express 
very poorly. Previous studies showed that P2-a4 dimers favour the expression of (a4)2(p2)3 
or ( a4)3(p2)2 receptors when co-expressed with free P2 or a4 subunits, respectively (Zhou 
et al. , 2003). Therefore, concatamers with two consecutive P2-a4 interfaces that were 
followed by a a4 or p2 subunit, i.e., P2_a4_P2_a4_P2 or P2_a4_P2_a4_a4 to produce 
(a4)2(p2)3 or (a4)3(p2)2 receptors, respectively, were engineered. In these constructs, only 
the first subunit included the signal sequence at the N-terminus and the overall length of 
the linkers was as described above. 
Robust functional expression of both constructs was achieved in Xenopus oocytes 
(Fig. 3.7). After four days, maximal ACh (1 mM) evoked up to 200 nA of inward currents 
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in Xenopus oocytes microinj ected with 10 ng o.f p2 _ a4 _ p2 _ a4 _P2 cRN A. In the case of the 
p2_a4_p2_a4_a4 construct, 72 h after injection with 5 ng of cRNA, functiona l expression 
was approximately 2 µA. Representative traces evoked by saturating ACh concentrations 
are shown in Fig. 3.7 A. These expression levels were significantly lower than those 
obtained by microinjection of non-linked subunit cDNAs (p2_a4_ P2_a4_ P2 /non linked 
(a4)2(p2)3 = 66 ±. 2% and P2_a4_p2_a4_a4 non- linked (a4)3(p2)2 = 77 ±. 1 %; p < 0.01, 
Student's t test, n = 10) but markedly higher than the levels achieved with th~ 
P2_a4_P2_a4_P2 o.r P2_a4_P2_a4_a4 constructs (p < 0.001, Student's t test, n = 10). 
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Fig. 3.7. Expression levels of p2_a4_p2_a4_p2 and P2_a4_132_a4_ a4 pentameric in Xenopus oocytes. 
A) Inward currents evoked in oocytes injected with IO ng of P2_a4_p2_a4_P2 cRNA (Left) or 5 ng of 
P2_a4_P2_a4_a4 cRNA (Right) by saturating ACh concentration are shown. Traces evoked in wi ld type 
receptors are superimposed for comparison. Arrows indicate the start of the application of ACh. B) Bar graph 
comparing the functional expression levels of HS (Left) and LS (Right) receptors made of concatenated 
subunits and expressed by means of extreme transfection ratios.(*** =p < 0.001 ; ** = p < 0.01; Student's t 
test) 
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It was then tested whether expression of the pentameric concatamers resulted in the 
synthesis of full-length proteins. Western blot analysis revealed proteins of appropriate size 
with no apparent breakdown products, suggesting that the pentameric concatamers do not 
break into fragments or single subunits that could potentially assemble into functional 
receptors (Fig. 3.8). 
290 kDa 310 kDa 
Fig. 3.8. Western blot analysis of p2_a4_p2_a4_P2 and p2_a4_p2_a4_a4 expressed in Xenopus oocytes. 
A) Western blot analysis indicated that pentarneric concatamers P2_a4_P2_a4_p2 and P2_a4_P2_a4_a4 are 
synthesised and stable when expressed heterologously in Xenopus oocytes. Total protein from oocytes 
injected with either P2_a4_P2_a4_P2 and P2_a4_P2_a4_a4 cRNAs was separated by reducing SDS-PAGE 
on a NuPage 7% Tris acetate gel. 
The functional properties of concatenated receptors were very similar to those of 
non-concatenated receptors. At the (a4)2(~2)3 receptor concentration-response curves with 
the agonist ACh indicated that subunit concatenation had little effect on agonist parameters 
with an EC50 of2.37 ± 2 µM (n = 4) and a Hill coefficient of 1.04 ± 0.06 as compared with 
non-concatenated subunits with an EC50 of 2.8 ± 1 µM (n = 7) and a Hill coefficient of 
0.64 ± 0.05 (Fig. 3.9, Left) (p > 0.05, Student's t test, n = 10). Similarly, at the (a4)3(p2)2 
receptor subunit concatenation had little effect on the ACh concentration response curve. 
Analysis of the concentration-response curves showed a small difference, albeit not 
significant, in EC50 values (110 ± 5 versus 90.0 ± 4 µM, for the pentamer and monomer 
constructs, respectively; p > 0.05 , Student's t test, n = 10) but not in the Hill slope (0.92 ± 
0.09 and 0.93 ± 0.08, respectively; p > 0.05, Student's t test, n = 10) (Fig. 3.9, Right). 
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Fig. 3.9. (a4)J(P2)z and (a4)i(P2h nAChRs expressed from the pentameric construct have ACh similar 
to those of receptors expressed from monomeric constructs. Left panel. ACh concentration-response 
curve for concatenated (a4)J(P2)2 (•) compared to non-linked (a4)J(P2)2 receptor (o, dashed line) Right 
panel. ACh dose-response curves for concatenated (a4)i(P2)3 (•) and non-linked (a4)i(P2)3 receptors (o, 
dashed line) The data were best fitted by a one-component sigmoidal equation (p < 0.0001, F test, n = 10) 
The effects of a range of a4P2-preferring compounds were examined to characterise 
the functional pharmacology Qf P2_a4_P2_a4_P2 anµ P2_a4_p2_a4_a4 receptors m 
comparison to their non-linked counterparts. Functional pharmacological prope1iies o.f 
P2_a4_P2_a4_P2 anµ P2_a4_P2_a4_a4 receptors were very similar to those that have 
been previously shown for non-linked (a4)2(p2)3 or (a4)3(p2)2 receptors (Moroni et al., 
2006; Zwart et al., 2006; Zwart et al, 2008) (Fig. 3.10). The value of the EC5o, Vlmax and 
nHill parameters estimated from concentration-response curves are shown in Tables 3 .2 
and 3.3. Like the corresponding non-linked receptors p2_a4_p2_a4_P2 anµ 
P2_a4_p2_a4_a4 receptors were activated by A85380, 5I-A85380, epibatidine and 
TC2559 in a concentration-dependent manner. In contrast, cytisine and 5-Br-Cys evoked 
responses only in oocytes expressing P2_a4_P2_a4_a4 or non-linked (a4)3(p2)2 receptors. 
At these two types of receptors, cytisine and 5-Br-Cys behaved as partial agonists (Fig. 
3.10 B). Sazetidine-A was a full agonist at both P2_a4_P2_a4_P2 and non-linked 
(a4)2(P2)3 receptors (Fig. 3.10 A), whereas at P2_a4_P2_a4_a4 or non-linked (a4)3(p2)2 
receptor it behaved as a poor partial agonist (Fig. 3.10 B). Epibatidine was as potent at 
p2_a4_p2_a4_p2 as at non-linked (a4)2(P2)3 receptors (Fig. 3.10 A). However, A85380, 
5I-A85380 and TC2559 were significantly more potent at P2_a4_p2_a4_P2 than at non-
linked (a4)2(P2)3 receptors (p < 0.001, Student's t test, n = 7 - 10) (Fig. 3.10 A). The 
potency of A85380 and TC2559 was lower at P2_a4_P2_a4_a4 than at non-linked 
(a4)3(p2)2 receptors (p < 0.001, Student's t test n = 7 - 10) (Fig. 3.10 B). It is likely that 
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these differences may be due to mixed expression of both forms of the a4p2 receptor in the 
case of the non-linked receptors. All agonists produced concentration-response curves that 
were best fit to a one-component sigmoidal equation (p < 0.001, F test, n = 5 - 10). 5I-
A85380 produced a monophasic effect on both p2_a4_p2_a4_P2 and non-linked 
(a4)z(p2)3 (Fig. 3.10 A). However, whereas the effects of 5I-A85380 were monophasic at 
p2_a4_p2_a4_a4 receptors, at non-linked (a4)3(p2)z receptors they were clearly biphasic 
(p < 0.001, F test, n = 5 - 10) (Fig. 3.10 B). The EC50 for activation of p2_a4_p2_a4_a4 
receptors by 5I-A85380 was comparable to the low affinity EC50 displayed by this 
compound at non-linked (a4)3(p2)2, whilst the high-affinity EC5o was comparable to that 
displayed at both P2_a4_P2_a4_P4 and non-linked (a4)2(P2)3. The effect of 5I-A85380 on 
non-linked (a4)3(p2)2 is similar to the effects that are observed when 5I-A85380 activates a 
mixed population of high- and low-sensitivity a4P2 receptors expressed in Xenopus or 
mammalian clonal cells (Zwart et al., 2006). This observation suggests that functional 
expression of non-linked (a4)3(P2)2 is contaminated with a small population, about 10%, of 
non-linked (a4)2(P2)3 receptors or other possible stoichiometric combinations (Zwart and 
Vijverberg, 1998; Lopez-Hernandez et al., 2004). Therefore, overall, the findings on the 
effects of A85380, 5I-A85380 and TC2559 on linked and non-linked a4~2 receptors show 
that microinjection of oocytes with extreme ratios of a4 and p2 cDNAs to produce either 
(a4)3(p2)z or (a4)2(P2)3 does not fully prevent the assembly and expression of multiple 
forms of the a4P2 nAChR. 
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Fig. 3.10. Functional sensitivity of concatenated and non-linked (a4)2(p2)3 and (a4)3(p2)i nAChR to 
a4P2-preferring ligands. Concentration-response curves were obtained for the effects of a range of agonists 
on (A) P2_a4_P2_a4_P2 and (B) P2_a4_P2_a4_a4 nAChR (filled symbols) expressed heterologously in 
Xenopus oocytes as described in Methods. Responses were normalised to I mM A Ch. Averaged parameters 
of best fits to agonist or concentration-response data are given in Tables 2 and 3. For comparison ·the 
concentration-response curve constructed for the corresponding non-linked receptors (open symbols, dashed 
line) have been included in A and B. 
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Table 3.2. Functional properties of p2_a4_P2_a4_P2 and non-linked (a4)2(P2)3 
nAChRs. 
p2_a4_p2_a4_P2 Non-linked (a4)2(P2)3 
I/Imax ± ECso µM nHill ± I/Imax± ECso µM nHill ± 
SEM (95% CI) SEM SEM (95% CI) SEM 
2.37 2.8 
A Ch 1 1.04±0.06 1 0.64±0.05 
(2.1 - 2.7) (2.1 - 3.7) 
1.79±0.07 0.047 0.024 
A85380 0.88±0.05 1.38±0.04 1.02±0.11 
* (0.03-0.07) (0.02 - 0.03) 
2.23±0.1 0.014 0.034 
5I-A85380 0.71±0.10 2.08±0.16 0.83±0.1 
* (0.009-0.02) (0.02 - 0.06) 
Cytisine NE - - NE - -
5-Br-Cvs NE - - NE - -
0.16 0.19 
Epibatidine 0.61±0.008 
(0.1 - 0.3) 
0.82±0.10 0.63±0.01 0.86±0.12 
(0.1 - 0.4) 
4.08±0.1 1.9 1.86 
TC2559 1.0±0.14 2.51±0.1 0.89±0.10 
* (1.6 - 2.3) (1.3 - 2.6) 
0.0069 0.0065 
Sazetidine 1.01±0.01 1.01±0.4 0.98±0.09 1.03±0.07 
(5 - 8 nM) (4 - 8 nM) 
All values are means (95 % CI) or means ± SEM from 5-10 cells. Statistical comparisons 
between the concentration-response curve parameters of the concatenated receptors and 
those of the non-linked receptors were carried out using one-way analysis of the variance 
(ANOVA). The * signifies p < 0.05 compared with non-linked (u4)2(~2h receptors. 5-Br-
Cys, 5-Br-cytisine. 
88 
'I 
'' ii 
I I 
Ii 
I' 
'I 
I: 
Table 3.3. Functional properties of (l2_a4_p2_a4_a4 and non-linked (a4)3((l2)2 
nAChRs. 
fl2_a4_p2_a4_a4 Non-linked ( a4)3((l2)2 
l/Imax ± ECsoµM nHill ± Illmax± ECsoµM nHill ± 
SEM (95% CI) SEM SEM (95% Cl) SEM 
A Ch 1 111 0.92±0.09 1 88 0.93±0.08 (82 - 151) (76 - 94) 
A85380 1.53±0.06 2.7 0.80±0.1 1.42±0.06 3.34 0.63±0.06 * (1.7 - 3.9) (2.3 - 4.8) 
0.22±0.04 0.14 
0.99±0.06 * (0.1 - 0.2) 0.4±0.03 
5I-A85380 * 28.20 0.73±0.1 * (17 - 48) 
1.05±0.1 22 1.2±0.4 
* (14 - 35) 
Cytisine 0.27±0.04 55 0.43±0.05 0.24 ±0.04 15.80 0.52±0.1 (11 - 150) (13 - 88) 
5Br-Cys 0.28±0.05 11 1.3±0.12 0.29±0.01 14 0.9±0.1 (10-12) (10 - 19) 
Epibatidine 2.7±0.01 0.30 0.50±0.1 2.4±0.26 2.3 0.62±0.07 (0.2 - 0.6) (0.8 - 7) 
0.15±0.l 0.91 2.73 TC2559 * (0.63-1.3) 1.3±0.3 0.21±0.02 (I.I - 7.1) 0.85±0.30 * 
Sazetidine 0.008 ± 0.0064 0.86±0.11 0.0062 ± 0.0062 0.65±0.1 0.0004 (6-lOnM) 0.0004 (1-8nM) 
One-way analysis of variance (ANOVA) compared the level of significance between the 
values of the parameters of the agonist concentration-response curves of concatenated 
receptors and those of the non-linked receptors. The * signifies p < 0.05 compared with 
non-linked (a4)3(p2)2 receptor. 5-Br-Cys, 5-Br-cytisine. 
Because competitive antagonists bind to a larger domain than their agonist 
counterparts, they provide a mor~ accurate molecular tool to diagnose the integrity of the 
a!P agonist binding interface. Therefore, the a4P2 competitive antagonist DhPE was tested 
on both P2_a4_P2_a4_P2 and P2_a4_P2_a4_a4 receptors (Fig. 3.11). Inward currents 
elicited by ECso of ACh at either P2_a4_p2_a4_P2 and P2_a4_P2_a4_a4 were inhibited 
by DhPE in a concentration-dependent and monophasic manner (p < 0.0001, F test, n = 6). 
The ICso for DhPE at P2_a4_P2_a4_P2 was 12 (9 - 15) nM and at P2_a4_p2_a4_a4 was 
0.3 (0.25 - 0.35) µM. These values are very similar to those of the corresponding non-
linked receptors ((a4)2(p2)3, 17 (14-19) nM; (a4)3(P2)2, 0.2 (0.0.9-0.49) µM) (p > 0.05, 
Student's t test, n = 7 - 10). 
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Fig. 3.11 Concentration-response curves of the a4P2-preferring antagonist DhPE on the function of 
concatenated a4p2 receptors. Concentration-response curves of Dh~E on EC50 ACh responses of 
concatenated (continued line) and non-concatenated (dashed line) (a4)2(~2)3 (Left, •)and (a4)J(~2)2 (Right, 
•) nAChRs. 
3.3.5 Sensitivity of p2_a4_p2_a4_p2 and p2_a4_p2_a4_a4 concatenated receptors to 
Zn2+ activation and Ca2+ permeability 
Further studies examined the sensitivity of the P2_a4_p2_a4_P2 and 
P2_a4_P2_a4_a4 receptors to Zn2+ modulation as well as their Ca2+ permeability. Non-
linked (a4)2(p2)3 and (a4)3(p2)2 receptors differ significantly in their sensitivity to 
modulation by Zn2+ (Moroni et al., 2008) and Ca2+ permeability (Tapia et al., 2007). These 
differences reflect stoichiometry-specific structural signatures. Concentration dependent 
modulation by Zn2+ of currents evoked by ACh revealed that the sensitivity of the a4P2 
concatamers was comparable to that of the corresponding non-linked a4P2 receptors (Fig. 
3.12) (Moroni et al., 2008). Zn2+ inhibited the ACh responses of both p2_a4_p2_a4_P2 
and (a4)2(P2)3 monophasically and with similar ICso values (32 (16 - 67) µM and 
19 (10 - 36) µM, respectively; Fig. 3.12, Left panel) . The ACh responses of both 
P2_a4_P2_a4_a4 and (a4)3(P2)2 receptors were modulated biphasically by Zn2+ (p < 0.01, 
F test, n = 5). Zn2+ concentrations ranging from 1 to 100 µM potentiated A Ch responses at 
P2_a4_p2_a4_a4 or (a4)3(p2)2 100 µM. Zn2+ increased ACh elicited current to 1.82 ± 0.3 
and 1.51 ± 0.5 for P2_a4_p2_a4_a4 or (a4)3(p2)2 respectively (Fig. 3.12, Right panel). 
The ECso for potentiation was 32 (18 - 44) µM for P2_a4J32_a4_a4 receptors and 19 (17 
- 24) µM for non-linked (a4)3(p2)2 receptors. None of these values were significantly 
different (p > 0.05, Student's t test, n = 5). Higher concentrations of Zn2+ decreased the 
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degree of potentiation until at concentrations greater than 800 µM Zn2+ the amplitudes of 
the ACh responses elicited in the presence of Zn2+ were smaller than those mediated by 
applications of ACh alone. Zn2+ inhibited ~2_a4_~2_a4_a4 and non-linked (a4)3(B2)z 
nAChR with a similar ICso values of 810 (800 - 819) µM and 803 (799 - 812) µM 
respectively (p > 0.05, Student's t test, n = 5). 
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Fig. 3.12. Zn2+ sensitivity of concatenated (a4)3(p2)i and (a4)i(p2)3 nAChRs expressed heterologously in 
Xellopus oocytes. Averaged concentration-response for the effects of Zn2+ at concatenated (a4)J(P2)2 (Left, 
•) and (a4)i(P2)3 (Right, •) nACbRs. Tbe effects of Zn2+ on currents activated by EC20 or EC10 ACh 
concentrations on concatenated and non-linked (a4)J(P2)2 and (a4)i(P2)3 nAChRs, respectively, were 
determined as detailed in the Method section. 
Ca2+ permeability was examined by measuring the reversal potential of IAch in the 
presence of 1.8 mM or 18 mM extracellular Ca2+ (Tapia et al., 2007). ~2_a4_~2_a4_a4 
receptors were most permeable to Ca2+ than P2_a4_p2_a4_P2 receptors (Fig. 3.13), which 
would be expected if these receptors replicated the structure and functional properties of 
non-linked (a4)3(p2)2 and (a4)2(P2)3 receptors, respectively. A 10-fold increase in Ca2+ 
concentration shifted the reversal potential of IAch in the positive direction by 4 :f: 0.1 m V 
in P2_a4_p2_a4_P2 receptors (Fig. 3.13, Le.ft; n = 5-7) and 21 ± 5 mV in P2_a4_~2_a4_a4 
receptors (Fig. 3.13, Right; n = 7-9). 
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Fig. 3.13. Cai+ permeability of concatenated (a4)J(p2)2 and (a4)i(P2h nAChRs expressed heterologously 
in Xenopus oocytes. Current-voltage relationship of ~2 _ a4 _~2 _ a4_~2 (Left, •) and ~2 _ a4j32 _ a4_ a4 (Right, 
•) nAChR in the presence of 1.8 mM (non-filled symbols) or 18 mM extracellular (filled symbols) Ca2+. 
~2_a4_~2_a4_a4 were more permeable to Cai+ as judged by the positive shift of the reversal potential when 
the external Ca2+ was increased by tenfold. 
3.3.6 Chaperone 14-3-3 increases functional expression of p2_a4_P2_a4_a4 and 
p2 _ a4 _p2 _ a4 _p2 constructs 
Chaperone protein 14-3-3 interacts with the native (Jeanclos et al., 2001) and 
recombinant a4 subunit (Jeanclos et al., 2001 ; Exley et al., 2006) following activation of 
protein kinase A (PK.A). The interaction is dependent on phosphorylation of a serine 
residue within a PK.A consensus sequence (RSL.S.V; PK.A target underlined) in the large 
cytoplasmic domain of the subunit, which is also a binding motif recognised by 14-3-3 
(Jeanclos et al., 2001; O'Kelly et al., 2002; Exley et al., 2006). The interaction 
significantly increases the steady state levels of a4 subunit alone and a4P2 nAChRs by 
masking of a dibasic retention signal within the large cytoplasmic domain of a4 subunit 
(O'Kelly et al. , 2002). To investigate the effects of 14-3-3 on functional expression of 
a4P2 nAChR concatamers, 14-3-3 was co-expressed with P2_a4_p2_a4_P2 or 
p2_a4_P2_a4_a4. 14-3-3 was found to significantly increase the functional expression of 
both a4P2 con ca tamers (Figs. 3 .14 A, B). These results indicate that subunit concatenation 
does not impair the ability of the a4 subunit to interact with chaperone 14-3-3 protein. 
Interestingly, it was observed that 14-3-3 was more effective at increasing the functional 
expression of the p2 _ a4 _p2 _ a4 _ a4 receptor than that of the p2 _ a4 _p2 _ a4 _P2 receptors. 
Thus, in the case of the p2 _ a4 _p2 _ a4 _P2 receptor, functional expression was increased by 
1.7-fold (p < 0.05, Student's t test, n = 6) whereas functional expression of 
p2_a4_p2_a4_a4 increased by 4-fold (p < 0.0001 , Student's t test, n = 6). 
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Fig. 3.14. Chaperone 14-3-3 increases functional expression of concatenated (a4)J(P2)2 and (a4)2(P2h 
nAChRs. Bargraph of normalized ACh responses at concatenated P2_a4_p2_a4_p2 (Left) or 
p2_a4_p2_a4_a4 (Right) nACh receptors expressed on their own or co-expressed with chaperone protein 14-
3-3. Data are given as means :l; SEM from five to seven oocytes per column.(*= p < 0.05; *** = p < 0.001) 
93 
DISCUSSION 
Characterisation of the a4p2 expressed in heterologous systems is difficult because 
of the variety of receptor subtypes that can be formed (Zwart and Vijverberg, 1998; Nelson 
et al. 2003; Zhou et al., 2003; Lopez-Hernandez et al., 2004; Moroni et al., 2006). An 
alternative approach that circumvents this problem is the expression of LGICs with fixed 
stoichiometry obtained by concatenating subunits in a predefined order and composition. 
Three different approaches to constrain the expression of the alternate 
stoichiometries of the a4P2 receptor were tested. It has been shown here that the 
pentameric constructs P2_a4_p2_a4_P2 and P2_a4_p2_a4_a4 express functionally well in 
Xenopus oocytes and that these receptors recapitulate the sensitivity to activation by ACh, 
Ca2+ permeability and ability to interact with chaperone protein 14-3-3 of the 
corresponding non-linked (a4)2(P2)3 or (a4)3(p2)2 receptors, respectively. Using these 
concatenated receptors, the pharmacological properties of the alternate stoichiometries of 
the a4P2 nAChR were examined, and from the findings it was concluded that the 
pentameric concatamers P2_a4_P2_a4_P2 and P2_a4_p2_a4_a4 are valid models of the 
corresponding non-linked (a4)2(P2)3 and (a4)3(p2)2 receptors, respectively. The sensitivity 
of P2_a4_p2_a4_P2 and P2_a4_p2_a4_a4 receptors to activation by ACh, sazetidine-A, 
cytisine, 5-Br-cytisine, and inhibition by DhPE were comparable to those of the 
corresponding non-linked a4P2 nAChRs. Exceptions were the agonist effects of TC2559, 
A85380 and 5I-A85380, which activated the concatenated receptors and their non-linked 
counterparts with significantly different potency and/or efficacy. In addition, 5I-A85380 
produced a biphasic concentration response curve at non-linked ( a4)3(P2)2 receptors 
comprising a high and a low affinity components whose respective ECso values were 
similar to those of the concatenated P2_a4_p2_a4_P2 and P2_a4_P2_a4_a4 receptors, 
respectively. . 
A straightforward explanation for these results is that one or more linkers may 
affect the pharmacological properties of the receptors. However, because the 
pharmacological profile of port-linked ( a4)3(p2)2 receptors resembles that of a mixed 
population of high- and low-sensitivity a4P2 receptor stoichiometries (Zwart et al., 2006), 
a more likely explanation is that non-linked a4 and p2 subunits produce multiple receptor 
stoichiometries, even when the relative abundance of the subunits is manipulated to favour 
the assembly of only one type of a4P2 receptor, as in the experimental conditions of this 
study. From the biphasic concentration-response curve produced by 5I-A85380 at a4P2 
receptors expressed following microinjection of oocytes with single a4 and p2 cDNAs at a 
ratio of 10: 1, it is clear that approximately 10% of the receptors produced are of the 
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(a4)2(P2)3 or other possible stoichiometric arrangements. The low levels of receptor 
contamination shown in this study are revealed by compounds with exceptional high 
stoichiometry-selectivity, such as 51-A85380 or pentameric concatenated receptors. These 
may still confound functional assays and obscure stoichiometry-specific receptor 
properties (e.g., Zwart et al., 2006). These results indicate that caution should be applied 
when interpreting functional data produced by non-linked a4P2 receptors expressed 
heterologously in surrogate cells. The concentration-response curves obtained with ACh 
and a4P2-preferring agonists indicate that most established a4P2 nAChR ligands 
distinguish, with varying degrees, the alternate stoichiometries of the a4P2 nAChR. In 
addition, the receptors clearly differ in their sensitivity to modulation by Zn2+ and Ca2+ 
permeability. These findings suggest stoichiometry-specific structural signatures as 
determinants of the functional behaviour of the (a4)2(p2)3 and (a4)3(p2)2 nAChR. What 
may be the structural basis for the stoichiometry-dependent properties of the a4P2 nAChR? 
By analogy to the muscle alyarnp1 nAChR (Unwin, 2005), it is thought that the a4P2 
nAChR harbours two functional agonist binding sites, which must be located at the 
a4( + )/P2(-) interfaces (one per interface). This implies that the subunit order around the 
channel is a4P2a4P2( a4/P2). This subunit arrangement is supported by the present reported 
studies on concatenated (a4)2(P2)3 and (a4)3(p2)2 nAChRs. 
On both stoichiometries, the agonist sites are both located at the a4( + )/P2(-) 
interfaces and suggest identical properties. However, one a4(+)/P2(-) interface on both 
stoichiometries is flanked by non-ACh binding P2(+)/a4(-) interfaces, whereas the other is 
flanked by a P2(+)/a4(-) interface and depending on the stoichiometry, by a non-agonist 
binding a4(+)/a4(-) or P2(-)/P2(+) interface. The latter interfaces are stoichiometry-
specific and therefore likely candidates for conferring stoichiometry-specific properties to 
(a4)2(P2)3 and (a4)3(p2)2 nAChR. This view is supported by a recent study on the effect of 
Zn2+ on the alternate forms of the a4P2 receptor, which shows that the signature a4/a4 
interface of the (a4)3(P2h receptor harbours a Zn2+ potentiating site that is absent in the 
(a4)2(P2)3 stoichiometry (Moroni et al., 2008). Additional support for these findings comes 
from recent studies that have shown that accessory subunits influence the function of 
neuronal nAChRs (Kuryatov et al., 2008) and that conserved hydrophobic amino acid 
residues contribute to an allosteric site on heteromeric nAChRs (Hansen and Taylor, 2007). 
Functional expression of both concatamers is increased by co-expression with the 
chaperone protein 14-3-3, indicating that concatenation does not obliterate the 14-3-3 
binding site within the large intracellular loop of a4. The effects of 14-3-3 on the 
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functional expression of P2_a4_P2_a4_a4 and P2_a4_p2_a4_P2 receptors were strikingly 
similar to the effects that have been previously observed when the subunits expressed were 
non-assembled a.4 and P2 (Exley et al., 2006). Exley and collaborators (2006) have shown 
that 14-3-3 favoured expression of low sensitivity (i.e., (a4)3(p2)2) receptors and increased 
the steady-state levels of the a.4 subunit. This effect possibly resulted into greater 
incorporation of a4 subunits into receptor complexes. This possibility could not account 
for the differential effects of 14-3-3 on the a4P2 pentameric concatamers, because the 
subunit composition of these receptors is fixed. A possible explanation is that the higher a.4 
content of the P2_a4_p2_a4_a4 concatamer enhances the stabilising and up-regulating 
effects of 14-3-3 in comparison to its actions on P2_a4_P2_a4_P2 receptors. This implies 
that subunit composition may confer stoichiometry-specific 'receptor maturation' patterns. 
This view is supported by previous studies that have shown that a4P2 nAChR matures 
inefficiently in comparison to a4P4 receptors (Sallette et al., 2004), possibly because p2 
weakens the process of receptor maturation through inefficient subunit interactions and/or 
assembly (Sallette et al., 2004; Sallette et al., 2005). Thus, (a4)2(P2)3 receptors may mature 
less efficiently than ( a4)3(P2)2 receptors, which would lower the functional expression of 
(a4)2(P2)3 relative to that of (a4)3(p2)2 receptors. In this and previous (Moroni et al., 2006; 
Zwart et al., 2006; Moroni et al., 2008) studies it has been found that the heterologous 
functional expression of (a4)3(P2h receptors in Xenopus oocytes is about 30-fold higher 
than that of ( a4 h(P2 )3 receptors. 
Interestingly, neither p2_p2_a4_p2_a4 nor P2_a4_a4_p2_a4 expressed well m 
Xenopus oocytes, even though both constructs were synthesised and stable. This implies 
that the constructs were trafficked inefficiently to the cell surface and/or that the constructs 
did not assemble into properly functional a4P2 receptors. What may influence the 
functionality of these concatamers? In comparison to P2_a4_P2_a4_P2 or 
p2 _ a4 _P2 _ a4 _ a4 concatamers, the P2-a4 interfaces in the p2 _p2 _ a4 _P2 _ a4 and 
p2 _ a4 _ a4 _P2 _ a4 receptors are c preceded by a p2 or are separated by an a.4 subunit 
respectively. Thus, a possible explanation for the low functional expression of 
P2""""P2_a4_p2_a4 and P2_a4_a4_p2_a4 is that their subunit arrangement does not 
facilitate the subunit interactions that drive the assembly and maturation of a4P2 pentamers 
(Sallette et al., 2005). Little is known about the elementary steps leading to assembly of 
pentameric a4P2 complexes, which occurs within the endoplasmic reticulum. By analogy 
to the assembly of the muscle nAChR (Green and Claudio, 1993), it is likely that the 
subunits incotporate into pentamers through sequential steps driven by specific subunit-
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subunit or subunit-chaperone interactions. Thus, when those subunit interactions are 
impaired, which might occur if the subunits are not oriented properly or do not acquire 
appropriate three-dimensional structures, oligomerisation and/or maturation may be 
inefficient, producing ultimately low expression levels or receptors with altered function. 
Interestingly, although p4_p4_a3_p4_a3 pentameric concatamers produce functional 
receptors in Xenopus oocytes, the levels of expression were very poor in comparison to the 
functional expression of non-linked a3P4 receptors (Groot-Kormelink et al., 2006). This 
suggests that positioning p _a interfaces prior to a p or a subunit may be a strategy that 
could be applied across the nAChR family to produce concatamers with good functional 
expression. A subunit domain that may play a critical role in functional expression is the 
C-terminus. Insertion of fluorescent proteins in the C-terminus of p2 nAChR subunit 
(Nashmi et al., 2003), e or y nAChR subunits (Gensler et al., 2001) or y2 GABAA receptor 
subunit (Kittler et al., 2000) results in partial or complete abolition of function. Although 
there is evidence that green fluorescent-tagged C-terminus may affect the function of 
nAChR (Fucile et al., 2002b ), recent studies suggest that the effects of the C-terminus on 
the functional expression of Cys-loop LGIC are likely to reflect its contribution to the 
process of receptor maturation (Butler et al., 2009). Thus, C-terminus single-point mutants 
of the 5-HT3A receptor reduce specific radioligand binding and membrane expression, both 
of which can be partially restored by growing cells expressing the mutant receptors at 
temperatures lower than 3 7 °C (Butler et al., 2009). In the case of pentameric concatenated 
LGIC, poor functional expression could well reflect the fact that the C-terminus of all but 
one subunit (the fifth) of the concatenated subunits is linked to the N-terminus of the 
subsequent subunit (Baur et al., 2006; Groot-Kom1elink et al., 2006). 
In summary, it has been demonstrated here that pentameric concatamers 
P2_a4_P2_a4_p2 and P2_a4_p2_a4_a4 have pharmacological signatures comparable to 
those of non-linked (a4)2(P2)3 and (a4)3(p2)2 nAChRs respectively. Thus, this study 
provides a diagnostic tool for· the alternate forms of the a4P2 nAChR. In addition, 
(a4)z(p2)3 and (a4)3(p2)2 concatamers in combination with mutational and functional 
experimental approaches can be used to aid the characterisation of other possible 
stoichiometric arrangements of the a4P2 nAChR. Concatamers with a subunit order of 
p2 _p2 _ a4 _P2 _a~ or p2 _ a4 _ a4 _p2 _ a4 do not express well in Xenopus oocytes nor do they 
reproduce the pharmacological properties of non-linked receptors. This may be because the 
subunit arrangement of these constructs hinders interactions between subunits or bet~een 
subunits and chaperone proteins that are required for receptor assembly and maturation. It 
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is presently not possible to distinguish between these possibilities because the processes 
that drive the genesis of functional a4~2 nAChRs are essentially unknown. However, 
future studies that address this issue may benefit from the availability of pentameric 
concatenated ( a4 )z(~2)3 and ( a4 )3(~2)z nAChRs whose assembly and maturation, as judged 
by their functional properties and sensitivity to the chaperone protein 14-3-3, may be 
comparable to that of the corresponding non-linked a4~2 nAChR. 
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CHAPTER4 
Identification of agonist binding 
subunits in linked ( a4)2(f,i2)3 and 
( a4)3(f,i2)2 receptors 
4.1 Introduction 
The advantages of pentameric subunit concatamers as receptor models relative to 
receptors assembled from free subunits are twofold. Firstly, the stoichiometry and subunit 
order in concatenated pentamers are fixed. This eliminates the problems encountered in the 
interpretation of functional data from receptors assembled from free subunits (e.g., Zwart 
and Vijverberg, 1998; Nelson et al., 2003; Moroni et al., 2006). As mentioned in Chapter 
3, the subunit composition of non-linked receptors expressed heterologously in surrogate 
systems is influenced by the relative availability of exogenous cDNAs or cRNAs 
introduced into surrogate cells, and often multiple forms of the receptor are co-expressed. 
Additionally, non-linked subunits may form homomeric (Beato et al., 2002) or heteromeric 
(Chamet et al., 1992) receptor complexes that do not exist in vivo. Secondly, concatenated 
receptors allow studies that cannot be carried out using non-linked receptors, particularly 
non-linked receptors with one or two subunits present in multiple copies such as a4P2 
nAChRs. For example, a mutation can be introduced into just one subunit to investigate 
positional effects of single point mutations or positional effects of subunit isoforms. The 
latter studies can be carried out using lower order concatamers such as dimers and trimers 
(Baumann et al., 2001; Baumann et al., 2002; Minier and Sigel, 2004a; Gallagher et al., 
2004; Boileau et al., 2005; Bollan et al., 2008; Kaur et al., 2009); however, the 
complication of unknown stoichiometries still remains as dimers and trimers can give rise 
to several types of receptor ensembles (Bauman et al., 2001). 
Although in fully concatenated pentameric receptors, the complication of uncertain 
stoichiometry and subunit order does not exist, the functional consequences of the 
incorporation of single point mutations in a given subunit cannot be fully appreciated 
unless the functional role and the spatial orientation (i.e., orientation of the positive and 
negative faces) uf the subunit are known. Therefore, in this Chapter, in order to identify the 
function 'and the spatial orientation of a.4 and p2 subunits in p2_a4_p2_a4_p2 and 
p2_a4_p2_a4_a4 receptors, alanine mutants of conserved aromatic residues predicted to 
bind agonists in a4p2 nAChRs were incorporated sequentially into the subunits of 
P2_a4_p2_a4_p2 and p2_a4_P2_a4_a4 and the functional consequences of these mutants 
were investigated electrophysiologically. 
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4.2 Experimental procedures 
4.2.1 cDNA constructs and mutagenesis 
Mutations have been constructed using the QuikChange™ Site-Directed 
Mutagenesis Kit, as previously described in section 2.4. PCRs have been carried out using 
the following primers: 
a4Y126A: primer forward 
primer reverse 
a4W182A: primer forward 
primer reverse 
a4Y223A: primer forward 
primer reverse 
a4Y230A: primer forward 
primer reverse 
~2W82A: primer forward 
primer reverse 
GGACATCGTCCTCGCCAACAATGCTGACGG 
CCGTCAGCATTGTTGGCGAGGACGATGTCC 
CCATGAAATTCGGCTCCGCGACCTACGACAAGGCC 
GGCCTTGTCGTAGGTCGCGGAGCCGAATTTCATGG 
CCTACAACACCAGGAAGGCCGAGTGCTGCGCCG 
CGGCGCAGCACTCGGCCTTCCTGGTGTTGTAGG 
CGAGTGCTGCGCCGAGATCGCCCCGGACATCACC 
GGTGATGTCCGGGGCGATCTCGGCGCAGCACTCG 
CCACCAATGTCGCGCTGACCCAGGAGTGG 
CCACTCCTGGGTCAGCGCGACATTGGTGG 
The full-length sequence of mutant subunit cDNAs was verified by DNA 
sequencing. 
To produce mutant concatenated (a4)3(~2)z and (a4)z(~2)3 receptors each a4 or ~2 
subunit was modified separately and subsequently ligated into the pentameric constructs 
using standard ligation procedures. The full-length sequence of mutant subunit cDNAs was 
verified by DNA sequencing. 
4.2.2 Injection of cDNAs constructs into Xenopus oocytes 
The effect of the mutation has been firstly analysed in non-linked (a4)3(~2)2 and 
(a4)2W2)3 receptors. To express the two a.4~2 nAChR stoichiometries, a4 and ~2 subunit 
cDNAs were combined in a ratio of 1:10 to produce a (a4)2(~2)3 st?ichiometry, whilst a 
subunit ratio of 10: 1 was used to produce a ( a4)3(~2)2 stoichiometry (Moroni et al., 2006). 
The amount of total cDNA injected per oocyte was kept constantly equal to 3 ng. For 
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expression of concatenated receptors 10 ng of cDNA per oocyte was injected (see Section 
2.9). 
4.2.3 Electrophysiological protocols 
Concentration-response curves for ACh and epibatidine were obtained by 
normalizing agonist-induced responses to the control response induced by 1 mM ACh 
alone. A minimum interval of 4 minutes was allowed between acetylcholine applications 
as this was found to be sufficient to ensure reproducible recordings. Concentration-
response data for wild type or mutant a4B2 receptors were fitted using one component 
sigmoidal dose-response equations (see Section 2.14 ). 
The sensitivity to Zn2+ was assessed by co-applying a range of Zn2+ concentrations 
with 10 µM ACh, the ACh EC10 at linked and non-linked (a4)3(B2)2 receptors. For Zn2+ to 
attain equilibrium around impaled oocytes, Zn2+ was pre-applied for 30 s to the cell prior to 
co-application of ACh and Zn2+. Peak responses elicited by ACh + Zn2+ were normalized 
to the peak response of the appropriate ACh alone. Data were fitted to the a two-
component equation designed to account for the potentiating and inhibitory effects of Zn2+ 
on a4B2 receptors assuming this cation binds to two distinct sites on the receptor (see 
Section 2.14). 
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RESULTS 
i 
1: 
i 
4.3.1 Effect of mutations implicated in agonist binding on non-linked ( o:4)2(P2)3 and 
(o:4)3(p2)2 nAChRs 
The study of the functional consequences of substituting residues predicted to bind 
agonists by alanine was initiated to identify the agonist and non-agonist binding subunits in 
concatenated P2_a4_p2_a4_P2 and P2_a4_p2_a4_a4 nAChRs. As mentioned in 
Chapter 1, site-directed mutagenesis and biochemical studies (reviewed in Arias, 2000), 
combined with the structures of the heteromeric Torpedo nAChR (Unwin, 2005; Dellisanti 
et al., 2007), the homomeric prokaryotic proton-gated ion-channels ELIC (Hilf and 
Dutzler, 2008) and GLIC (Bocquet et al., 2009) and AChBP (Brejc et al., 2001; Celie et 
al., 2004 ), have identified several aromatic residues that are mostly conserved among the 
Cys-loop receptors and that are implicated in agonist binding. In Torpedo and muscle 
nAChR these are a1Tyr93, a1Trp149, a1Tyr190 and a1Tyr198 (the positive face of the 
binding site), and residues Trp55 and Trp57 located in the complementary ely or & subunits 
(the negative face of the binding site). In the a4P2 nAChR the homologous residues are 
a4Tyr126, a4Trp182, a4Typ223, a4Tyr230, and P2Trp82. (To obtain the position in the 
mature subunit form, subtract 30 from the number for a4 and 25 for P2). Theoretically, if 
these residues were substituted by alanine, their contribution to agonist binding would be 
abolished, which would impact on agonist binding characteristics such as potency and 
efficacy. It follows then that sequential incorporation of any alanine mutations of any of 
these residues into the concatenated P2_a4_P2_a4_P2 and P2_a4_P2_a4_a4 nAChRs 
receptors should lead to the identification of the subunits implicated in agonist binding. 
Little is known about the effects of a4Tyr126A (a4Y126A), a4Trp182A (a4w182A), 
a4Tyr223A (a4Y223A), a4Tyr230A (a4Y230A), and P2Trp82A (P2wszA) on agonist binding in 
a4P2 nAChRs. Therefore, prior to assaying mutant concatenated receptors, the functional 
effects of a4vizM, a4w182A, a4Y223A, a4Y230A and p2wszA were investigated on non-linked 
(a4)z(p2)3 and (a4)3(P2)2 nAChRs. Fig. 4.1 shows that incorporation of mutant subunits 
a4Y126\ a4Y223A, a4Y230A or p2ws2A into non-linked (a4)2(P2)3 or (a4)3(P2h receptors 
caused significant decreases in the level of current evoked by saturating concentration of 
ACh relative to the values observed in the respective wild-type receptors (p < 0.05, 
Student's t test; n = 10 - 15). In contrast, although a4w182A decreased the maximal level of 
current in (a4)z(p2)3 receptors, its effects on ACh maximal current in.(a4)3(P2h were not 
significant. Western blot analysis showed that the reduced level of functional expression 
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observed in caused not only by impaired gating but also by reduced level of protein 
expression (data not shown). 
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Fig. 4.1. ACh Imax currents in wild-type (w.t) or mutant non-linked (a4h(f32)3 and (a4)J(f32)2 nAChRs. 
Effect of alanine mutations of the conserved aromatic residues thought to contribute to the agonist binding 
site of nAChRs on the functional expression of non-linked (a4)2(p2)3 (Left panel) and (a4)J(P2)2 (Right 
panel) nAChRs. The data represent the mean ± SEM of 5-10 determinations from individual oocytes from a 
same batch. (*** = p < 0.001, Student's t test). 
The sensitivity of non-linked (a4)2(P2)3 and (a4)3(p2)2 nAChRs to activation by 
A Ch was significantly decreased by mutants of a4 Y 126\ a4 Y230A and p2 ws2A (Fig. 4.2, 
Table 4.1) (p < 0.05; Student's t test; n = 10 - 15). a4 Y223 A completely abolished sensitivity 
to activation by ACh in both receptor types. Interestingly, a comparison between the extent 
of the effects of the alanine substitutions in both receptor types showed that non-linked 
(a4)2(p2)3 receptors were more sensitive to changes in the aromatic residues implicated in 
agonist binding (Table 4.1). This further confirms that (a4)2(P2)3 and (a4)3(p2)2 nAChRs 
have significantly different functional properties. 
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Fig. 4.2. Effects of alanine mutants of conserved aromatic residues on the senshivity of non-linked to 
activation by ACh. ACh concentration-response curves obtained from oocytes expressing non-linked wild 
type or mutant (a4)2(p2)3 (Left panel) and (a4)J(P2)2 nAChRs (Right panel). Data were normalised to ACh 
Imax for each individual point. The data represent the mean ± SEM from at least 5 oocytes. The concentration-
response curve parameters obtained from curve-fitting are sununarised in Table 4.1 
106 
The results described above support the view that aromatic residues a4Y126, 
a4W182, a4Y223, a4Y230 and P2W82 are implicated in agonist binding in non-linked 
(a4)2(p2)3 and (a4)3(p2)2 nAChRs. To further test the involvement of these aromatic 
residues in agonist binding, their effects on the sensitivity of the receptors to activation by 
epibatidine, a highly selective agonist of a4P2 nAChR (Moroni et al., 2006) were 
investigated. Fig. 4.3 shows the effects of a4 Y126A, a4 w182\ a4 Y223A, a4 v230A and p2 ws2A on 
the potency and efficacy of epibatidine at non-linked (a4)2(P2)3 and (a4)3(p2)2 nAChRs 
(data summarised in Table 4.1 ). The potency of epibatidine at mutants ( a4Y 126A)3(p2)2, 
( a4 wi 82A)3(p2)2, ( a4 Y223 A)3(p2)2 and ( a4 Y230A)3(p2)2 receptors was significantly reduced (p 
< 0.05; Student's t test; n = 10 - 12), whereas the potency of epibatidine at (a4)3(p2w82A)2 
was not different from that observed at wild type (a4)3(p2)2 receptors. At non-linked 
( a4 Y126A)2(p2)3 and ( a4)2(P2 ws2A)3 epibatidine did not activate currents, even at 
concentrations as high as 3 mM. At non-linked (a4)3(p2)2 nAChRs, a4Y 126A, a4Y230A and 
p2 ws2A increased the efficacy of epibatidine in comparison to that observed in their wild-
type counterparts. In contrast, the efficacy of epibatidine at (a4w 182A)2(B2)3 was not 
different from that observed at the wild type receptor and decreased by about 2-fold at (a4 
wis2A)3(p2)2. As for ACh, the incorporation of a4Y223A into non-linked (a4)2(P2)3 or 
(a4)3(p2)2 receptors abolished sensitivity to activation by epibatidine. The most 
pronounced effect on epibatidine efficacy was observed on the a4 Y230A mutant. Insertion of 
this mutation in the a4P2 nAChR increased the efficacy of epibatidine by about 4-fold in 
the ( a4 Y230A)2(p2)3 receptor and about 9-fold in the ( a4 Y230A)3(p2)2 receptor. This effect is 
likely to be due to changes in receptor gating. The residue Y230 is located in loop C which 
caps the binding and plays an important role in the activation of the receptor (Sine and 
Engel, 2006). 
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Fig. 4.3. Effects of alanine mutants of conserved aromatic residues on the sensitivity of non-linked a4p2 
nAChRs to activation by epibatidine. Epibatidine concentration-response curves obtained from oocytes 
expressing non-linked wild type or mutant (a4)2(~2)3 (Left) and (a4)J(~2)2 (Right) nAChRs. Data were 
normalised to A Ch Imax for each individual point. The data represent the mean± SEM from at least 5 oocytes. 
The concentration-response curve parameters obtained from curve-fitting are summarised in Table 4.1 
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Table 4.1. Functional effects of alanine mutants of conserved aromatic residues in 
non-linked ( a4)2(P2)3 and ( a4)3(p2)2 receptors. 
Non-linked (a4 2<ll2)3 Non-linked (a4)3<82)z 
1/Imax ± ECso µM nHill ± 1/Imax ± ECso µM nHill ± 
SEM (95% Cl) SEM SEM (95% Cl) SEM 
Acetylcholine 
a4p2 w.t. 1 3.2 0.7±0.04 1 
85 
0.7±0.03 (1.4 - 5) (40 - 130) 
159 
1.6±0.02 a4Yl26A N.E. N.D. N.D. 1 (72 - 240) * * 
408 
1.7±0.03 367 1.2±0.07 a4Wl82A 1 (365-450) 1 (280-450) 
* * * * 
a4Y223A N.E. N.D N.D. N.E. N.D. N.D. 
513 
1.7±0.1 406 1.3±0.07 a4y230A 1 (480-550) 1 (170-640) * * * * 
290 240 
1±0.01 p2W82A 1 (70 - 513) 0.86±0.08 1 (150-330) 
* * * 
Epibatidine 
w.t. a4P2 0.6±0.02 
0.2 
0.72±0.1 2.2±0.2 
1.27 
0.54±0.1 (0.01-0.03) (0.4 - 4) 
a4Y126A N.E. N.D. N.D. 4.7±0.09 8 0.9±0.1 * (6 - 23) 
64 1.2±0.4 50 a4W182A 0.57±0.01 (10 - 100) 1±0.1 1±0.1 * (25 - 125) * 
a4Y223A N.E. N.D N.D. N.E. N.D. N.D. 
5.2 ±0.5 
4.3 
8.1±0.3 
11 
a4Y230A (2.4 - 7.5) 1±0.2 (4 - 70) 0.7±0.1 * * * * ,. 
p2W82A N.E. N.D. N.D. 3.9±0.18 
0.7 
0.7±0.1 (0.3 - 1.2) 
All values are means (95 % CI) or means ± SEM from 10 to 15 cells. Statistical 
comparisons between the concentration-response curve parameters of the wild type and 
mutant receptors were carried out using Student's t tests. The * signifies p < 0.05 
compared w.t. receptors. Abbreviations: wild type, w.t; no agonist effect. N.E.; not 
determined, N.D. ' 
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The findings of the study described above confirmed that aromatic residues 
a4Y126, a4W182, a4Y223, a4Y230 and P2W82 are implicated in agonist binding in non-
linked (a4)2(P2)3 or (a4)3(p2)2 nAChRs. Therefore, alanine mutants from any of these 
residues could be used to identify the agonist binding subunits in concatenated 
P2_a4_p2_a4_P2 and P2_a4_P2_a4_a4 nAChRs. Theoretically, the potency and maximal 
currents of agonists at P2_a4_p2_a4_P2 and P2_a4_p2_a4_a4 nAChRs should be altered 
only when alanine mutants of the aromatic agonist binding residues were incorporated into 
an agonist binding subunit. 
4.3.2 Agonist binding p2 subunits in p2_a4_p2_a4_P2 receptors 
To identify the agonist binding subunits in P2_a4_p2_a4_P2 receptors, mutant 
P2W82A was sequentially incorporated into each of the P2 subunits of the concatenated 
receptor. Mutants of the a4 subunit were not used to identify agonist binding subunits in 
P2_a4j32_a4_P2 receptors because, by analogy to Torpedo nAChRs, both a4 subunits are 
presumed to bind agonists in ( a4)2(P2)3 receptors. Fig. 4.4 shows average ACh 
concentration-response curves obtained at wild-type and mutant P2_a4_p2_a4_P2 
receptors. The A Ch concentration-response curve at P2 ws2A _ a4 _p2 _ a4 _P2 receptors 
(mutant p2 in the 1st position of the concatamer) was similar to that obtained at wild type in 
P2_a4_p2_a4_P2 receptors. Thus, at wild type P2_a4_p2_a4_p2 receptors the estimated 
ACh EC50 was 5.22 (2.5 - 10) µM (n = 6) and at P2w82A _a4_p2_a4_p2 receptors the value 
of ACh ECso was 4.6 (2.5 - 8.4) µM (n = 10). In contrast, at P2_a4_p2w82A _a4_p2 
(mutation incorporated in 2nd position of concatamer) and P2_a4_P2_a4_P2w82A (mutation 
present on the 5th position of concatamer) receptors, the respective ACh ECso values were 
significantly decreased to 102 (29 - 353) µMand 124 (37 -421) µM (p < 0.05; Student's t 
test; n = 5). Although the ACh EC50 value obtained at P2_a4_p2w82A _a4_P2 receptors was 
lower than that determined for P2_a4_P2_a4_p2w82A receptors, statistically they were 
found to be similar. Together, the findings of this part of the study indicate that the 3rd and 
5th p2 subunits in P2_a4_p2_a4_P2 receptors are implicated in agonist binding. In 
comparison, the 1st subunit does not bind agonists because the agonist sensitivity to ACh 
was not altered by the incorporation of mutant P2 ws2A into this position. 
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Since the agonist binding sites are located at the interface between the positive face 
of a4 and the negative face of p2, and there are only two a4 subunits in P2_a4_p2_a4_P2 
concatamers, it is concluded that the agonist binding sites are at located at the interface 
between the 211d a4 and 3rd p2 subunits and between the 4th a4 and 5th p2 subunits and that 
the 1st p2 subunit is the accessory subunit in p2 _ a4 _P2 _ a4 _p2. It follows therefore that the 
spatial orientation of the subunits in P2_a4_p2_a4_P2 is as illustrated in the following 
scheme: 
I- B2 + H - a4 + H- B2 + H- n4 + H- B2 +I 
A comparison of the value of the ACh EC50 estimated for the corresponding non-
1 inked (a4)2(P2w82A)3 receptors (ECso 290 (70 - 513) µM and the concatenated 
p2_a4_p2wszA _a4_p2 (EC50 1.02 (29 - 353) µMand p2_a4_p2_a4_p2wszA (124 (37 -421) 
µM) receptors showed that ACh is more potent, almost twice, at the concatenated 
receptors. This is likely to be due to the fact that in the non-linked receptors all the p2 
subunits are mutated whereas in P2_a4_P2wszA _a4_p2 and p2_a4_p2_a4_p2wszA only one 
p2 subunit is mutated. Presumably, when the mutation is incorporated simultaneously into 
the 3rd and 5th p2 subunit the ACh ECso should be similar to that observed at the 
corresponding non-linked receptors. The sensitivity to activation by agonists could not be 
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determined in such receptors because the functional expression of the triple-mutated 
receptors was too low. 
4.3.3 Localisation of the agonist binding a4 subunits in p2 _ a4 _p2 _ a4 _ a4 nAChRs 
The a4 subunit was used to identify the position of the agonist binding sites in 
P2_a4_p2_a4_a4 receptors. Mutant a4Y230A was chosen to identify the a4 subunits that 
bind agonists in P2_a4_p2_a4_a4 nAChRs. In the corresponding non-linked (a4)3(p2)2 
receptor, a4 Y230A decreased sensitivity to activation by ACh or epibatidine, and increased 
the efficacy of epibatidine by 4-fold (Table 4.1). Thus, theoretically, the sensitivity of 
P2 _ a4 _P2 _ a4 _ a4 receptors to activation by agonists should decrease when agonist binding 
a4 subunits carry the Y230A mutation. To increase the reliability of the functional assays, 
the studies that will be described next were carried using epibatidine instead of ACh 
because the former has higher potency and efficacy than ACh at both non-linked (a4)3(B2)2 
(Table 4.1) and P2_a4_p2_a4_a4 (Carbone et al., 2009) receptors. 
Incorporation of a4Y230A into the a4 subunit that occupies the 4th position of the 
concatenated P2 _ a4 _p2 _ a4 _ a4 did not alter the sensitivity of the receptor to activation by 
epibatidine m comparison to that of wild type P2_a4_P2_a4_a4 receptors 
(p2_a4_p2_a4Y230A _a4 epibatidine ECso = 0.29 (0.091 - 0.42) µM (n = 5); 
P2_a4_p2_a4_a4 epibatidine ECso = 0.47 (0.31 - 0.69) µM) (Fig. 4.5). In contrast, when 
the mutation was incorporated into the 211d or 5th position the sensitivity to activation by 
epibatidine was significantly reduced to respectively 2.92 (1.9 - 4.6) µMand 3.2 (1.5 - 7) 
µM (p < 0.05, Student's t test, n = 8 - 9) (Fig. 4.5). 
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Fig. 4.5. Functional effects of a4Y230A on the sensitivity to activation of p2_a4 ·p2_a4_a4 concatamers 
by epibatidine. Mutant a4YZJOA was incorporated sequentially into the 2"d, 4th and 5tli position of concatamer. 
p2_a4_p2_a4_a4 in order to identify the agonist binding a4 subw1its of the receptor complex. Data were 
normalised to epibatidine Imax for each individual point. The data represent the mean ± SEM from at least 5 
oocytes. 
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Taken together, these results indicate that the a4 subunits that occupy the 2nd and 
5th positions in concatamer P2_a4_p2_a4_a4 bind agonists. In contrast, the a4 subunit that 
is in the 4th position in P2_a4_p2_a4_a4 does not bind agonists and is therefore the 
accessory subunit. These findings, together with the restrictions imposed by the rule that 
the agonist binding site is formed at the interface between the positive face of a and the 
negative face of p, indicate that the spatial orientation of the subunits in this concatamer is 
as indicated in the following scheme: 
~I- a4 +H- 82 +H- a4 +H- a4 +I 
and that the agonist binding sites are at the interface between the 2nd a4 and 3rd P2 subunits 
and between the 5th a4 and 1st p2 subunit. 
So far the findings suggest that the 4th a4 subunit in the concatamer 
p2_a4_p2_a4_a4 nAChRs does not participate in agonist binding. In order to explore this 
further, mutant a4E224A was incorporated into the 4th position of the P2_a4_p2_a4_a4 
nAChRs. In a previous study it was shown that non-linked (a4)3(P2)2 receptors are 
selectively potentiated by Zn2+ (Moroni et al., 2008). The potentiating Zn2+ site resides on 
the a4(-)/a4(+) interface of the (a4)3(p2)z nAChR and key residue contributors are a4H195 
on the (-) side of the agonist binding a4 subunit and a4E224A on loop C of the accessory a4 
subunit of the receptor. Fig. 4.6 shows that incorporating mutant a4E224A into the 4th 
. position of concatamer p2 _ a4 _p2 _ a4 _ a4 decreased significantly the potentiating effects of 
Zn2+ on the responses elicited by ACh at this receptor type in comparison to wild type 
receptors (p < 0.05, Student's t tests; n = 10). Thus, the maximal potentiation achieved by 
Zn2+ at wild type p2_a4_p2_a4_a4 was 1.97 ± 0.1 (normalised response, see Section 2.12; 
n = 7), whereas at mutant receptor p2 _ a4 _p2 _ a4 EZZ4A _ a4, maximal Zn2+ potentiation 
decreased to 1.40 ± 0.12 (n = 12). In contrast when the a4E224A was carried by the 5th a4 
subunit, sensitivity to Zn2+ potentiation was not different from that of wild type 
p2_a4_p2_a4_a4 receptors (2.12 ± 0.72; n = 8). 
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Fig. 4.6. Zn2+ sensitivity of wild type and mutant p2_a4_p2_a4_a4 receptors. a4E224A was incorporated 
into the 4th or 5th position of concatamer P2_a4_p2_a4 a4 to detem1ine the effects of the mutation on the 
sensitivity of p2_a4_p2_a4_a4 to potentiation by zi?+. The curves represent averaged concentration-
response for the effects of Zn2+ at wild type and mutant concatamers. The effects of Zn2+ on currents 
activated by EC 10 ACh (10 µM) on concatenated receptors were determined as detailed in Chapter 3. 
Abolition of Zn2+ potentiation by a4E224A in the 4111 position of P2_a4_p2_a4_a4 
receptors could reflect a perturbation of the general properties of the receptor rather than a 
specific effect on the Zn2+ potentiating site. To analyse this possibility ACh dose-response 
curves of the mutant P2_a4_p2_a4_a4 receptors were determined. As shown in Fig. 4.7, 
the ACh sensitivity of P2_a4_P2_a4E224A _a4 receptors (ACh EC50 = 104 (85 - 128) µM) 
was similar to that of wild type P2_a4_p2_a4_a4 receptors (ACh EC5o = 109 (77 - 154) 
µM). When a4E224A was incorporated into the 5th position of P2_a4_P2_a4_a4 receptors 
the sensitivity to activation by ACh was slightly decreased (125 (98 - 167) µM; n =5) but 
this effect was not statistically different from that of wild receptors (p < 0.05; Student's t 
test). 
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Fig. 4.7. Effects of a4E224A on the ACh sensitivity of wild type and mutant p2_a4J2_a4_a4 
receptors. ACh concentration-response data were obtained from wild type and B2_a4_B2_a4E 4A_a4 and 
B2_a4_B2_a4_a4E224A receptors. Data were nomrnlised to ACh Imax for each individual point. The data 
represent the mean ± SEM from at least 5 oocytes. 
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DISCUSSION 
This study has identified the agonist binding subunits in pentameric concatamers 
P2_a4_p2_a4_p2 and p2_a4_p2_a4_a4. It also established the position of the binding sites 
within the concatamers and the spatial orientation of the subunits. These findings should 
increase the insight of studies that seek to understand the positional effects of subunits or 
mutations in a4P2 nAChRs. In both concatamers, the subunits orientate clockwise; 
however, the position of the binding sites is concatamer-specific. In the case of the 
P2_a4_P2_a4_a4 one of the binding sites is assembled at the free alp interface of the 
concatamer, whereas in P2_a4_p2_a4_P2 both binding sites are located at subunit 
interfaces within the concatamer. These differences, together with the subunit order 
requirement for functional expression of concatenated (a4)2(P2)3 and (a4)3(p2)2 receptors 
(Chapter 3 and Carbone et al., 2009), suggest that both concatamers regulate subunit 
assembly differently. 
Although the a4P2 nAChR has not been crystallised, the availability of high 
resolution images of Torpedo nAChRs and the crystal structures of the snail (Brejc et al., 
2001; Celie et al., 2004 ), muscle a 1 subunit bound to a-Btx (Dellisanti et al., 2007) and 
proton-gated prokaryotic ELIC (Hilf and Dutzler, 2008) and GLIC (Bocquet et al., 2009) 
channels, suggests that the agonist binding region of this receptor contains the five 
aromatic residues that are both highly conserved and implicated in agonist binding in Cys-
loop LGICs. In a4P2 nAChRs these residues are a4Y126, a4W182, a4Y223, a4Y230, and 
P2W82, and this study showed that substitution of these residues by alanine severely 
handicapped the interaction of agonists with both non-linked a4P2 nAChRs. 
In agreement with a role in agonist-receptor interaction, alanine mutants of 
a4Y126, a4Wl82, a4Y223, a4Y230, and P2W82 decreased agonist potency, and as judged 
by ACh Imax values they also decreased functional expression. The latter could be a 
consequence of changes in gating and reduced efficiency in the assembly or trafficking of 
the receptor ensembles, as suggested by studies in Torpedo or muscle nAChR (e.g., 
Tomaselli et al., 1991; Sine et al., 2002). In muscle and Torpedo nAChRs, where these 
residues have been studied in depth, the most significant changes observed in receptor 
function by mutants of the conserved aromatic residues of the agonist binding sites, are 
changes in gating. For example, in muscle nAChRs a1W149 (homologous to a4W182) 
interacts with agonists through cation-1t interactions, which are the most stabilising forces 
among the agonist-binding cavity interactions described so far, and _thus substitutions by 
alanine or other residues that impair the function of this residue cause a decrease in 
macroscopic and unitary ACh ECso values (Zhong et al., 1998; Akk, 2001). Similarly, 
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mutations to residues homologous to a4Y126, a4Y223, a4Y230 and P2W82 were shown 
to increase macroscopic ACh EC5o values and impair gating (Sine et al., 1994; Chen et al., 
1995; Auerbach et al., 1996; Akk and Auerbach, 1999; Akk and Steinbach, 2000; Akk, 
2001; Bafna et al., 2009). 
Although A Ch potency was decreased by all of the alanine substitutions assayed in 
this study, there were clear differences in the extent of the reduction caused by the alanine 
mutants. For example, unlike a4 wi szA, a4 Yz3oA or p2 wsz\ a4 yzz3A completely abolished 
sensitivity to ACh in both non-linked (a4)2(P2)3 and (a4)3(p2)z receptors. These 
differences have also been observed in Torpedo and muscle nAChR (reviewed in Arias, 
1997) and reflect the role of each residue in agonist-receptor interaction. Thus, aY190, 
which is homologous to a4Y223, is a key element in a peripheral loop at the principal face 
of the agonist binding region, known as loop C, and is close to the pair of adjacent cysteine 
residues that characterise a subunits. Although a Y 190 does not interact directly with the 
agonist, its position in loop C, which caps the entrance to the binding cavity (reviewed in 
Sine and Engel, 2006) may underlie the profound effects of its alanine mutant on receptor 
function. The other aromatic residues interact directly with agonists but because within the 
agonist binding cavity the agonist interacts simultaneously with the other aromatic 
residues, the absence of one type of these agonist-aromatic residue interactions may not 
lead to complete disruption of receptor function. 
As with other members of the Cys-loop LGIC, a4P2 nAChRs have two agonist 
binding sites that are located in the extracellular domain of the protein at the a4( + )/P2(-) 
interfaces of the receptors. Of relevance to a4P2 function, the magnitude of decrease in 
agonist potency brought about by P2W82A or a4Y230A was similar regardless of the 
position of the agonist binding subunit carrying the mutated residues. This suggests that 
each binding site contributes equally to receptor activation. This is in contrast to the 
muscle nAC.hK whose agonist binding sites display different properties for agonists and 
competitive antagonists (Arias, 2000), as expected from binding sites assembled at 
different subunit interfaces, al/o and al/s(y) (Gotti et al., 2006). However, differences in 
agonist properties have also been reported for alp2y GABAA receptors and in this case 
both agonist binding sites are assembled from al and p2 subunits (Baumann et al., 2003). 
It could be of interest to test alanine mutants of the other aromatic residues such as 
a4W182, which provides the strongest stabilising force acting on agonists according to 
studies of muscle nAChR (Zhong et al., 1998; Brejc et al., 2001; Celie et al., 2004). The 
116 
remammg residues interact with agonists by hydrogen bonding and van der Waals 
interactions, which are, comparatively, of lesser energetic importance. 
The identification of the 4th subunit of concatamer P2_a4_P2_a4_a4 as the 
accessory subunit of the ensemble was confirmed by assaying the effect of Zn2+ on the 
currents elicited by ACh at P2_a4_P2_a4E224A _a4 receptors. a4E224 was suggested by 
Moroni et al., (2008) to contribute to a potentiating Zn2+ binding site that is a functional 
signature of non-linked (a4)3(p2)2 (Moroni et al., 2008) and concatenated 
P2_a4_p2_a4_a4 (Carbone et al., 2009). The site was proposed to be contributed by 
residues located at the a4/a4 interface of (a4)3(P2)2 (Moroni et al., 2008). This interface 
comprises the ( +) side of the accessory a4 subunit and the (-) side of an agonist binding a4 
subunit. The findings of this study fully support this proposal. 
The decrease of sensitivity to Zn2+ potentiation by a4E224A in the 4th a4 subunit 
could reflect a perturbation of the general properties of the receptor rather than a specific 
effect on the Zn2+ potentiating site. After dismantling of the Zn2+ potentiating site located 
in the a4/a4 interface in P2_a4_P2_a4_a4 receptors, the sensitivity of the receptors to 
activation by A Ch was not affected. Thus, the findings of this study support the suggestion 
made by Kuryatov et al. (2008) that the accessory subunit does not participate in agonist 
binding. This study and that of Moroni et al. (2008) also demonstrate that the accessory 
subunit confers pharmacological properties, i.e., sensitivity to potentiation by Zn2+ to a4P2 
nAChRs. This is not a unique characteristic of a4P2 nAChRs. Indeed, the accessory 
subunit in most Cys-loop receptors plays a key role in the pharmacological signatures of 
these signalling proteins. Thus, Hansen and Taylor (2007) showed that aromatic residues 
. found in non-ACh-binding interfaces of humanised AChBP contribute to an allosteric 
binding site sensitive to galanthamine. Also, the y subunit, the non-agonist binding subunit 
in apy GABAA receptors, confers sensitivity to potentiation by benzodiazepines (reviewed 
in Sigel, 2ooi). 
In summary, the findings described in this study clearly identify the functional roles 
of the subunits of P2_a4_p2_a4_P2 and P2_a4_p2_a4_a4 and confirm the presence of two 
binding sites in a4P2 nAChRs and the importance of conserved aromatic residues for 
agonist-receptor interactions. 
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CHAPTERS 
ADNFLE-linked mutations alter the 
stoichiometry of a4~2 nAChRs 
5.1 Introduction 
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a rare familial 
focal epilepsy. It was first described in 1995 and it was the first human epilepsy to be 
linked to a specific gene defect (Scheffer et al., 1995). ADNFLE is characterised by 
clusters of frequent brief nocturnal motor seizures arising mainly during stage II of non-
REM sleep, which seem to originate in the frontal lobe (Scheffer et al., 1995). Affected 
individuals are typically of normal intelligence, although psychosis or schizophrenia, 
behavioural disorders, distinct memory deficits and mental retardation have been reported 
in some individuals with familial ADNFLE (Khatami et al., 1998; Magnusson et al., 2003; 
Bertrand et al., 2005; Derry et al., 2008). 
Patients affected by ADNFLE often respond well to antiepileptic drugs, especially 
carbamazepine (CBZ) (Scheffer et al., 1995), which is the drug of choice for nocturnal 
attacks. One third of the cases, however, commonly patients with a high frequency of 
seizures, are drug resistant (Oldani et al., 1998; Provini et al., 2000). Recent studies 
showed that nicotine and tobacco use induce a reduction or complete control of nocturnal 
seizures (Willoughby et al., 2003; Brodtkorb and Picard, 2006). 
ADNFLE is a monogenic epilepsy linked to a specific nAChR subtype, the a4P2 
nAChR. So far, four a4 (Steinlein et al., 1995; Steinlein et al., 1997; Hirose et al., 1999; 
Leniger et al., 2003) and five p2 (De Fusco et al., 2000; Phillips et al., 2001; Bertrand et 
al., 2005; Hoda et al., 2008) mutations have been linked to ADNFLE. The first six 
mutations identified are located within or at the C-terminal end of the TM2 domain of the 
.. a4 ( a4 S248F; a4 776insL; a4 s2s2L; a4 T265I) or the P2 (P2 V287L; P2 V287M) nAChR subunit. The M2 
domain forms the ion-conducting pathway of the receptor and it is therefore crucial for 
both ion selectivity and allosteric transitions implicated in receptor function (Miyazawa et 
al., 2003). Mµtations in this region alter the transition of the receptor from the closed to the 
open state, thus increasing the probability for the receptor of a transition to the active state 
(Bertrand et al., 1998). 
Little is known about the mechanisms that may induce seizures in ADFNLE 
patients. However, studies on ADNFLE mutated a4P2 nAChRs expressed heterologously 
in surrogate cells have shown that all of these 'mutations affect sensitivity to activation by 
agonists, desensitisation and Ca2+ permeability (Weiland et al., 1996; S.teinlein et al., 1997; 
Bertrand et al., 1998; De Fusco et al., 2000; Matshushima et al., 2002; Bertrand et al., 
2005), all of which could induce seizures. One hypothesis suggests that the increased A Ch 
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sensitivity displayed by ADNFLE mutant a4P2 receptors could lead to seizures (Bertrand 
· et al., 2002). An alternative hypothesis postulates that the reduced Ca2+ permeability of 
ADNFLE mutant a4p2 receptors decreases the influx of Ca2+ into GABAergic presynaptic 
terminals. This would decrease the release of the inhibitory neurotransmitter GABA, which 
would shift the brain excitation-inhibition equilibrium towards excitation (Rodrigues-
Pinguet et al., 2005). More recently, the discovery that a4P2 nAChRs assemble into'two 
different stoichiometries that are likely to exist in neurones (Marks et al., 1999; Butt et al., 
2002; Gotti et al., 2008) and that differ radically in the properties affected by the ADFNLE 
mutations (e.g., sensitivity to agonists, Ca2+ permeability and desensitisation) has 
suggested another putative mechanism through which ADNFLE-linked mutations can 
cause the disease. Because ADNFLE a4P2 receptors display properties similar to those of 
high sensitivity (a4)2(P2)3 nAChRs (i.e., lower Ca2+ permeability and higher sensitivity to 
activation by agonists) (Steinlein et al., 1997; Bertrand et al., 2002; Rodrigues-Pinguet et 
al., 2005), it may be possible that the mutations promote the formation high sensitivity 
a4P2 nAChRs. However, a recent study that examined the stoichiometry of ADNFLE 
mutant a4P2 nAChRs using FRET analysis reported that ADNFLE mutations increased the 
expression of intracellular (a4)3(p2)z receptors and that nicotine exposure restored the 
proportion of the (a4)z(P2)3 stoichiometry to wild type levels. 
To address the issue of whether ADNFLE mutations modify the receptor properties 
or the subunit composition of a4P2 nAChRs, the functional effects of a ADNFLE 
mutation, a4776insL, were investigated in both (a4)z(P2)3 (HS) and (a4)3(p2)2 (LS) receptors. 
The a4776insL mutation was identified in 1997 in the M2 domain of the CHRNA4 gene in a 
Norwegian family affected by ADNFLE (Steinlein et al., 1997). Three extra nucleotides 
are inserted at nucleotide position 776 into the coding region for the C-terminal end of the 
M2 domain leading to the insertion of a leucine residue in the channel pore region. The 
a4 776insL mutl;ltion is the most sensitive mutation to CBZ, which exerts its action on the 
mutant receptor by acting as an open channel blocker (Picard et al., 1999). 
The findings of the studies described in this Chapter on non-linked a4P2 receptors 
are consistent with a mutation-induced change in receptor stoichiometry. This was 
therefore further examined by investigating the effects of a4776insL on the properties of the 
concatenated receptors previously described in 'Chapter 3. The results obtained support the 
proposal that ADFNLE mutations alter the stoichiometry of the a4p2 n~ceptors. 
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5.2 Experimental procedures 
5~2.1 cDNA constructs and mutagenesis 
Mutations have been constructed using the QuikChange™ Site-Directed 
Mutagenesis Kit, as previously described in section 2.4. PCRs have been carried out using 
the following primers: 
primer forward: 
CGCTCACCGTCTTCCTGCTGCTGCTCATCACCGAGATCATCCCGTCC 
primer reverse: 
GGACGGGATGATCTCGGTGATGAGCAGCAGCAGGAAGACGGTGAGCG 
The full-length sequence of mutant subunit cDNAs was verified by DNA 
sequencing. 
To produce mutant concatenated (a4)3(p2)z and (a4)2(p2)3 receptors each a4 or p2 
subunit was modified separately and subsequently ligated into the pentameric constructs 
using standard ligation procedures. The full-length sequence of mutant subunit cDNAs was 
verified by DNA sequencing. 
5.2.2 Injection of cDNAs constructs into Xenopus oocytes 
The effect of the mutation has been firstly analysed in non-linked ( a4)3(p2)z and 
(a4)z(p2)3 receptors. To express the two a4P2 nAChR stoichiometries, a4 and P2 subunit 
cDNAs were combined in a ratio of 1:10 to produce a (a4)2(p2)3 stoichiometry, whilst a 
subunit ratio of io: 1 was used to produce a ( a4)3(p2)2 stoichiometry (Moroni et al., 2006). 
The amount· of total cDNA injected per oocyte was kept constantly equal to 3 ng. For 
expression of concatenated receptors 10 ng of cDNA per oocyte was injected (see Section 
2.9). 
5.2.3 Electrophysiological protocols 
ACh concentration-response curves were obtained by normalizing agonist-induced 
responses to the control response induced by 1 mM ACh alone. A minimum interval of 4 
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minutes was allowed between acetylcholine applications as this was found to be sufficient 
to ensure reproducible recordings. Concentration-response data for wild type or mutant 
a4~2 receptors were fitted using one component sigmoidal dose-response equations (see 
Section 2.14). 
Ca2+ permeability of the concatamers were determined by constructing current-
voltage plots relationships and measuring the reversal potential of ACh ECso currents in 
the presence of 1.8 mM Ca2+ or 18 mM Ca2+ in the perfusing Ringer solution and 
measuring the shift in the reversal potential (see Section 2.12). 
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RESULTS 
5.3.1 Effect of a leucine insertion in the M2 domain of the a4 subunit on the 
expression of a4P2 nAChRs 
In order to characterise the effect of the a4 776insL mutation in the two alternate 
stoichiometries of the a4P2 nAChR, the mutant a4776insL subunit was co-injected in 
Xenopus oocytes with the corresponding wild type p2 subunit in a 1: 10 or 10: 1 a4/P2 
cDNAs ratio, which have been shown to produce high sensitivity (a4)2(P2)3 and low 
sensitivity (a4)3(p2)2 receptors, respectively (Moroni et al., 2006). The mutant receptors 
expressed with this strategy will be referred to as non-linked (a4776i1151) 2(p2)3 and 
( a4 776insL)3(p2)2. 
As shown in Fig. 5 .1, three days after injection both stoichiometries displayed 
robust inward currents in response to ACh. Currents evoked by saturating concentration of 
ACh in the non-linked (a4776insL)2(P2)3 receptor were significantly bigger than the wild 
type (mutant/wild type = 340 ± 10 %, p < 0.05, Student's t test, n = 8); the level of 
expression of the non-linked ( a4 776insL)3(p2)2 receptor was slightly lower than the wild type 
but not significantly different (mutant/wild type= 60 ± 3%, n = 7). 
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Fig. 5.1. Expression levels of mutant (a4776insLh(Jl2h and (a4776insL)J(Jl2)2 receptors in Xeuopus oocytes. 
Bar graph comparing the functional expression levels of mutant and wild type (a4)2(P2)3 (Left) and (a4)i(P2)3 
(Right) receptors. The amplitude of the current responses elicited by maximal concentrations of ACh were 
980 ± 200 nA for the mutant. (a4)2(P2)3 and 300 ± 50 nA for wild type (a4)i(p2)3 .(Left panel). At the 
. (a4)3(P2)2.(Right panel). receptor the maximal A Ch-elicited curTent was 1190 ± 100 for mutant receptors 
versus 2550 ± 165 for wild type receptors. (* p < 0.05, Student's t test) 
Because mutations in signalling proteins might affect not only functional responses 
but also receptor assembly and hence the half-life of the subunits, the steady state levels of 
the subunits in mutant receptors were determined by Western blotting. Immunoblotting 
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with anti-nAChR a4 or anti-nAChR P2 antibody, showed that a4776insL induced an increase 
in the steady state levels of both the a4 (Fig. 5.2 A) and the P2 subunits in the non-linked 
(a4776insL)2(p2)3 (Fig. 5.2 B). Surprisingly, the mutation had a different effect on the on the 
non-linked (a4776insL)3(p2)2 receptor. No apparent changes could be observed for the P2 
subunit (Fig. 5.2 B), whereas the expression of the a4 subunit was decreased compared to 
wild type receptors (Fig. 5.2 A). These results are in good agreement with the level of 
functional expression observed. 
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Fig. 5.2. Western blot analysis of total expression levels of a4 and ~2 nAChR subunits in wild type and 
mutant receptors. Membrane homogenates prepared from oocytes injected with 1: I 0 or I 0: I u4/P2 cDNAs 
ratio were resolved and then blotted and umnunostained as described in Chapter 2. A) Immunostaining of 
wi ld type and mutant (u4)z(P2)3 and (u4)3(P2)2 with an anti-u4 I Ab showed a specific i1m11unoreactive band 
at 68 KDa. B) lmmunostaining of wild type and mutant (u4)2(P2)3 and (u4h(P2h with an anti-P2 I Ab 
showed a specific immunoreactive band at 52 KDa. 
5.3.2 a4776insL mutation increases sensitivity to A Ch of the ( a4)J(P2h stoichiometry 
Previous studies showed that mutation 776insL causes a 10-fold increase in 
sensitivity to agonists in human (Steinlein et al., 1997; Bertrand et al., 1998) and mouse 
a4P2 receptors (Lipovsek et al., 2008), although no changes were detected in rat a4P2 
receptors (Fig! et al., 1998). The concentration-response relationship of the mutant 
receptors for ACh was then analysed. As shown in Fig. 5.3, the mutation had different 
effects on the ACh concentration-response curve of the two stoichiometries. The non-
linked (a4776insL)3(p2)2 receptor showed a significant higher sensitivity for the natural 
agonist than the wild type receptor (Fig. 5.3, Right pane!). For both receptors the data were 
fitted to a one-component Hill equation with an EC50 of 15 ± 3.37 µM for the mutant 
receptor and 88 ± 12.2 µM for the wild type receptor (p < 0.001, Stud~nt's t test, n = 8) and 
a Hill coefficient of 0.44 ± 002 for the mutant receptor and 0.79 ± 0.03 for the wild type 
receptor (p < 0.05, Student's t test, n = 8). Neither the sensitivity for ACh nor the nHill 
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value of the (a4)2(~2)3 stoichiometry were affected by the mutation (Fig. 5.3, Left panel). 
The mutant receptor showed an EC50 of 8.1 ± 2.2 µM and a nHill value of 0.59 ± 005, 
which are not significantly different from the EC50 of 3 .2 ± 0. 7 µM and the Hill coefficient 
of 0.71±005 of the wild type receptor. 
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Fig. 5.3. The mutation affect the ACh sensitivity of the two stoichiometries to a different extent. ACh 
concentration-response curves for mutant (a4776insL)z(p2)3. (Left panel, • ) and (a4776 insL)J(p2)2 (Right panel, 
•). For comparison ACh concentration response curves for non-Jinked receptors are shown as dashed lines. 
5.3.3 Desensitisation of o:47761"sL mutant a4p2 nAChRs 
The a4 776 insL mutation has been reported to affect the response decay of a4~2 
nAChRs (Bertrand et al., 1998; Lipovsek et al., 2008). The rate of decay of the current was 
measured by applying 10 µM and 600 µM ACh to the wild type and the mutant receptors. 
Fig. 5 .4 shows that the a4 776insL mutation caused changes in the rate of decay of the current 
elicited by saturating concentration of ACh on both (a4)2W2)3 and (a4)3(~2)2 receptors. 
Wild type non-linked (a4)2W2)3 nAChR did not show significant desensitisation 
over 30 sec. In contrast, current th.rough the non-linked (a4776insL)2W2)3 receptor decayed 
rapidly by - 80% and then continue to decay slowly in the presence of ACh. The time 
constants of current decay estimated by curve fitting to the equations described in Section 
2.14 are listed in Table 5.1. Currents evoked in both wild type and mutant non-linked 
(a4)3(~2)2 receptors showed notable desensitisation during application of ACh, with a 
decay to a plateau level of - 30% in the wild type receptor and - 50% in the mutant 
receptor. Current decay during agonist application was best fitted with a one-component 
exponential in both receptors. Non-linked (a4776insL)3(~2)2 receptor displayed a faster 
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desensitisation rate than wild type. The time constants of the desensitisation are listed in 
Table 5.1. 
600 µMACh 
mutant 
lOOnA L 
10 sec 
'wild type 
600 µMACh 
'wild type 
300nA L 
10 sec 
Fig. 5.4. ACh evoked inward currents in wild type and mutant non-linked a4~2 nAChR. Representative 
traces illustrating the increase in desensitisation induced by the n4776insL mutation in non-linked (n4)2(P2)3 
(Left panel) and (n4h(P2h (Right pane[) receptors. Traces evoked in wild type receptors are superimposed 
' ' 
for comparison. 
Table 5.1. Time constants of current decay of wild type and a4776insL a4P2 nAChRs. 
(a4)2(P2h ( a4 776insL)2(p2)3 
(a4h(P2h 
( (14 776insL)J(P2)2 
wild type wild type 
-r (sec)lO µM ACh 
Fast component 3.6 ± 1.7 
Slow component 32.6 ± 4.2 26.2 ± 3.7 17.5 ± 2.5 13.6 ±4.5 
-r (sec) 600 µM ACh 
Fast component 1.2 ± 0.6 
Slow component 18.9 ± 2.4 10.4 ± 1.9 10.6 ± 2.3 7.4 ± 1.6 
Time constants of current decay measured at 10 and 600 µM A Ch. Current decay was 
fitted to a one- or two-component exponential as appropriate. 't values are means ± SEM 
from 5-10 cells. 
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5.3.4 a4776insL mutation decreases the Ca2+ permeability of the (a4)3(p2)2 nAChR 
Steinlein et al. (1997) showed that the leucine insertion decreases the Ca2+ 
permeability of a4B2 nAChRs. Ca2+ permeability was assessed by measuring the reversal 
potential of IAch in the presence of 1.8 mM or 18 mM extracellular Ca2+, as described in 
Chapter 2 (Tapia et al., 2007). The Ca2+ permeability of the two forms of the mutant 
receptor was differently affected. The permeability of the divalent cation was significantly 
reduced in the non-linked (a4776insL)3W2)2 receptor, which displayed a 1.7-fold reduction in 
the shift induced by the 10-fold increase in Ca2+ concentration (from 30 ± 5 mV in the wild 
type receptor to 20 ± 4 mV in the mutant receptor; Fig. 5.5, Right) (p < 0.05; Student' s t 
test, n = 5 - 8). In the non-linked (a4776insL)2(B2)3 receptor Ca2+ permeability was not 
affected and the measured shift was 4 ± 0.1 m V in the wild type receptor and 6 ± 0.2 m V 
in the mutant receptor (p < 0.05; Student's t test, n = 6 - 9) (Fig. 5.5, Left). 
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Fig. 5.5 Ca2+ permeability of non-linked (a.4776insL)J(~2)2 and (a.4776insLh(lr2h nAChRs expressed 
heterologously in Xenopus oocytes. Current-voltage relationship of ( a.4 77 insLh(~2)3 (Left, •) and 
(a4776insL)3(p2)2 (Right, •) nAChR in the presence of 1.8 mM (non-filled symbols) or 18 m.M extracellular 
(filled symbols) Ca2+. The leucine insertion decreased Ca2+ pem1eability in the (a4)J(P2)2 receptor as judged 
by the smaller shift of the reversal potential induced in the mutant receptor when the external Ca2+ was 
increased by tenfold. 
5.3.5 Agonists efficacy at a4776insL mutant receptors 
Previous studies showed that a4 776insL affects agonist efficacy (Bertrand et al., 
1998). To investigate the effects of this mutation on agonist efficacy at both types of a4B2 
nAChRs, wild type and mutant receptors were challenged by maximal concentrations of 
stoichiometry-selective agonists. The agonists chosen were cytisine, which is a poor partial 
agonist at the (a4)3(B2)2 receptor (Moroni et al., 2006), and sazetidine-A, which is a full 
agonist at the (a4)2(B2)3 stoichiometry and a very poor agonist at the (a4)3(B2)2 receptor 
(Zwart et al., 2008). In the non-linked (a4776insL)2W2)3 receptor the mutation did not 
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produce significant changes in the efficacy of either agonists ( cytisine: 5 ± 2 % in wild 
type receptors, 5 ± 1 % in mutant receptors; sazetidine A: 93 ± 5 % in wild type receptors, 
90 ± 7 % in mutant receptors; Fig. 5.6, Right). In contrast, a4776insL caused a significant 
increase in the efficacy of both agonists at the non-linked (a4776insL)3W2)2 receptor. The 
efficacy of cytisine increased by 1.6- fold (18 ± 2 % at wild type receptors; 30 ± 5 % at 
mutant receptor; p < 0.01; Student's t test, n = 5 - 8) and the efficacy of sazetidine-A was 
increased by 7.5-fold (6 ± 0.5 % in wild type receptors; 45 ± 0.7 % in mutant receptors;p < 
0.001 ; Student's t test, n = 5 - 8) (Fig. 5.6, Left). 
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Fig. 5.6. Effect of the a4776insL mutation on agonists efficacies of a4~2 receptors. Bar graph comparing the 
efficacy of cytisine and sazetidine A on wild type and mutant (a4)i(P2)3 (Left) and (a4)2(P2)3 (Right) 
receptors. No changes were observed in the (a4)i(p2)3 receptors .{Left panel). Both agonist were more 
efficacious at th~ (a4)3(P2)7 receptor.(Rightpanel). (** = p < 0.01 ; *** = p < 0001; Student' s t test) 
5.3.6 Use of the L9'T reporter mutation to determine the stoichiometry of mutant 
receptors 
So far the findings of the studies described above indicate that a4776 insL affects the 
function of (a4)3W2)2 more markedly than that of its high sensitivity counterpart. As 
shown by the Western blot a4776insL affects the steady state levels of the subunits and its 
effect depends on the ratio of subunit cDNAs used to express either (a4)2(~2)3 or 
(a4)3(~2)2 . Because changes in the relative availability of a4 or ~2 subunits impact the 
subunit composition of the receptors (Zwart and Vijverberg, 1998; Nelson et al., 2003 ; 
Exley et al. , 2006) and because of recent reports that ADNFLE mutations may alter 
receptor stoichiometry (Son et al. , 2009), the subunit composition of both types of mutant 
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a4p2 receptors was investigated by using the reporter mutation L9'T mutation. Mutating 
the 9' hydrophobic amino acid in the pore-lining second transmembrane domain of a 
nicotinic type subunit to a hydrophilic residue makes the resulting receptor more sensitive 
to agonists (Revah et al., 1991), probably by destabilising the closed state. The extent to 
which the agonist EC50 is reduced is approximately proportional to the number of mutant 
subunit in the pentamer (Labarca et al., 1995; Chang and Wheiss, 1999). This approach has 
been previously used to determine the stoichiometry of the a3p4, a3P4bP3 (Boorman et 
al., 2000) and a4P2 combinations (Moroni et al., 2006). 
The a4 776insL subunit was co-expressed with the p219'T subunit in a 1: 10 and 10: 1 
a4/P2 cDNAs ratio and ACh sensitivity of the double mutant receptors was analysed. 
When the p219'T subunit was co-injected with the a4 776insL subunit in a 1: 10 ratio A Ch 
sensitivity was shifted by 400-fold, reducing the EC50 from 4.6 ± 0.6 µM to 0.01 ± 0.004 
µM; when the mutant subunits were co-injected in a 10:1 ratio ACh sensitivity was shifted 
by 7-fold, increasing the apparent affinity of the receptor from 4.3 ± 0.8 µM to 0.59 ± 0.1 
µM. If the mutant receptors present a stoichiometry of ( a4)3(p2)2 as suggested by Son et al. 
(2009), the 2-V of the potency ratio (ECso a4P2 w.t./ECso a4P2 LT) should be similar to the 
previously reported data for the LS a4P2 nAChR (Moroni et al., 2006); if the receptors 
present a stoichiometry of ( a4)2(P2)3 the 3-V of the potency ratio should be similar to the 
previously reported data for the HS a4P2 receptor (Moroni et al., 2006). The expected and 
experimental values obtained for the a4776ins1 p21T are listed in Table 5.2. These data are 
significantly different from those obtained for the wild type receptors by Moroni et al. 
(2006) and are more compatible with receptors with a higher P2 content. However, the 
presence of five mutations in the channel pore might affect the properties of the receptor 
and the L9'T mutation might not be and appropriate approach for determining the 
stoichiometry of a4P2 receptors. 
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Fig. 5.7. Effect of inserting a L9 'T mutation in the p2 subunit in(a4776insL)J(f2h and (a4776insL)i(P2h 
nAChRs. A Ch concentration-response curve for a4 77GinsLp2 (dashed line) and a4 77 insLp2LT (continuous line) 
are shown. The L9'T mutation caused a left-shift in the ACh dose-response curve in both the non-linked 
( a4 7?GinsL)i(p2)3 (Left panel) and the ( a4 77GinsL)i(p2)3 (Right panel) receptors. A Ch concentration-response 
data were fitted with the sigmoidal equation under the constraint of equal slopes (nHill = 1) in order to 
estimate the horizontal distance between the curves as a potency ratio (estimated parameters are shown in 
Table 5.2). The data were best fitted to a single sigmoidal equation (p < 0.001 , F test, n = 8 - 10). 
Tabke 5.2. Effects of TM2 L9'T mutation on the functional effects of ACh on wild 
type and mutant ( a4)z(P2h and ( a4)3(p2)z receptors 
(a4)2(P2h (a4)3(p2)2 
Potency 3-..j 2...; Potency 3-..) 2...; 
ratio ratio 
a4p2 w.t./a4p2LT 18 I 4.2 2.7 465160 7.7 
a4776insL/a4776insLp2LT 36 3.3 6 8 2 2.8 
EC50 are the means of EC50 estimates obtained by fitting separately each concentration-
response curve with a one-component sigmoidal equation, which gave the best fit for all 
data sets. Potency ratios were calculated from fits in which curves were constrained to 
slope equal to 1. Values represent data from three to six experiments (n). 
5.3.7 Expression of the a4776insL mutation in concatenated (a4)z(P2h and (a4h(P2)z 
receptors 
A more reliable approach to analyse the effect of the mutation on the stoichiometry 
of the receptor is the use of concatamers. The mutation has been inserted in all the a4 
subunits of the pentameric constructs, thus producing (a4776insL)3(~2)2 concatenated 
131 
receptors containing three mutations and ( a4 776insL)2(P2)3 concatenated receptors containing 
two mutations. 
The presence of three mutations in the (a4776insL)3(p2)2 receptor induced a marked 
decrease in the level of current from 2200 ± 170 nA in the wild type concatenated receptor 
to 45 ± 5 nA in the triple mutant concatamer (p < 0.05; Student's t test, n = 6) (Fig. 5.8, 
Right). This suggests that the presence of three mutations deeply affects the expression of 
functional receptors. In contrast, the mutation did not significantly affect the level of 
current of the concatenated (a4)2(p2)3 receptor (130 ± 40 nA in the wild type receptor; 170 
± 25 nA in the (a4776insL)2(P2)3 concatamer; n = 8) (Fig. 5.8, Left), suggesting that a 
receptor containing two mutations is efficiently assembled and trafficked to the membrane. 
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Fig. 5.8. Expression level of concatenated (a4776insLh(p2)3 and (a47761"5L)J(P2h receptors in Xe11opus 
oocytes. Bar graph comparing the functional expression levels of mutant and wild type (a4MP2)3 (Left) and 
(a4)z(P2)3 (Right) concatenated receptors. The amplitude of the current responses elicited by maximal 
concentrations of ACh were 170 ± 25 nA for the mutant concatenated. (a4)2(P2)3 and 130 ± 40 nA for wild 
type (a4)2(P2)3.(Lefi panel) . At th« (a4)3(P2)z (Right panel). receptor the maximal ACh-elicited current was 45 
± 5 for mutant receptors versus 2200 ± 170 for wild type receptors. (*** = p < 0.001; Student's t test) 
ACh concentration-response curves for mutant and wild type concatenated 
receptors were then determined. For both receptors data were fitted to a one-component 
Hill equation with an of EC5o of 8.3 ± 1.5 µM for the (a4776insL)2(p2)3 concatamer and 2.37 
± 2 µM for the wild type (a4)2(P2)3 concatamer (p < 0.01, Student's. t test, n = 7) and a 
nHill of 0.62 ± 0.1 for the mutant concatenated receptor and 1.04 ± 0.06 for the wild type 
receptor (p < 0.0001, Student's t test, n = 7) (Fig. 5.9, Left). These data are not 
significantly different from that of the non-linked (a4776insL)2(p2)3 receptor (8.1 ± 2.2 µM 
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and 0.59 ± 005) (see Section 4.3). At the (a4)2W2)3 receptor ACh concentration-response 
curves indicated that the insertion of three mutations had little effect on agonist parameters 
with an EC5o of 145 ± 8 µM and a Hill coefficient of 0.9 ± 0.2 (n = 6) for the mutant 
concatamer as compared with the wild type concatamer with an EC50 of 110 ± 5 µM and a 
Hill coefficient of 0.92 ± 0.09 (n = 9) (Fig. 5.9, Right). These values were significantly 
different from those observed for the non-linked mutant (p < 0.01, Student's t test, n = 6 -
7) (see Section 5.3) suggesting that the mutation affects the stoichiometry of the receptor. 
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Fig. 5.9. ACh concentration-response curves for concatenated a47761"sL~2 receptors. The Left panel 
shows A Ch concentration-response curve for mutant. ( a4 776insL)2(p2)3 concatenated receptors ( • ) and wild 
type, (a4)z(p2)3 concatamers (dashed line, •).Curves obtained from non-linked (a4776insL)z(p2)3 receptor 
shown for comparison (dashed line, o) The Right panel shows ACh dose-response curves for concatenated 
(a4776insL)3(p2)i (•) and wild type, (a4)3(P2h concatamers (dashed line, T) . Curves obtained from non-linked 
(a4776insL)3(p2)2 receptor shown for comparison (dashed line, o). The data were best fitted by a one-
component sigmoidal equation (p < 0.000 I, F test, n = 4 - 7). 
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DISCUSSION 
The functional effect of a4776insL on heterologously expressed a4P2 nAChRs has 
been extensively characterised by several groups. However, most of these studies were 
carried out in systems expre_ssing a mixture of a4P2 receptors with different 
stoichiometries (Steinlein et al., 1997; Bertrand et al., 1998; Figl et al., 1998; Rodrigues-
Pinguet et al., 2003; Rodrigues-Pinguet et al., 2005). Because a4 and P2 assemble in 
alternate forms in heterologous systems (Zwart and Vijverberg, 1998; Nelson et al., 2003; 
Kuryatov et al., 2005; Moroni et al., 2006), which might exist in native tissues (Gotti et al. 
2008), the study described in this chapter were primarily undertaken to investigate possible 
stoichiometry-selective effects of a4776insL. 
One of the most important findings of this study is that a4776insL affects the function 
of the two alternate forms of the a4P2 receptor differentially. The mutation impacted the 
agonist sensitivity, desensitisation and Ca2+ permeability of ( a4 )3(p2)z nAChRs, whereas it 
only modified, markedly, the desensitisation of (a4)2(P2)3 receptors. The differential 
effects of the a4 776insL mutation on the alternate forms of the a4P2 nAChR can therefore 
explain why some authors found that a4776insL causes changes in agonist sensitivity and 
current decay (Steinlein et al., 1997; Bertrand et al., 1998; Lipovsek et al., 2008), whereas 
others reported no changes in these properties (Figl et al., 1998). As it has been extensively 
reported in the last 10 years, transfection of expression systems with equal amounts of a4 
and P2 cDNAs or cRNAs results in the expression of a variety of different subunit 
combinations, each with different pharmacological properties (Zwart and Vijverberg, 1998, 
Buisson and Bertrand, 2001; Houlihan et al., 2001; Nelson et al., 2003; Lopez-Hernandez 
et al., 2004; Kuryatov et al., 2005; Moroni et al., 2006). Thus, it is most likely that 
. previous studies characterised the effect of a4 776insL on a mixed population of a4P2 
nAChRs. 
Desensitisation was the most affected parameter in both the (a4)z(p2)3 and the 
( a4)3(p2)z receptors. Both mutant receptors showed a significant increase in the peak-
plateau current, suggesting that the gating equilibrium must be displaced in favour of the 
desensitised state. The a4776insL mutation also induced an increase in the apparent time 
constant of desensitisation in both stoichiometries. Moreover, the mutant (a4)z(P2)3 
receptor displayed a fast component of desensitisation followed by a slower component, 
. . 
whereas the mutant (a4)3(p2)z receptor only displayed a slow desensitisation component. 
The effect of the mutation on the desensitisation properties of the receptor might be one of 
the main determinants for the dysfunction that causes the epileptic seizures. If the mutant · 
receptors desensitise more rapidly and to a greater extent, as the neurotransmitter 
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accumulates in the synaptic cleft, excessive desensitisation of receptors occurs. The 
decreased function of mutant nAChRs may influence other inhibitory pathways such as 
those mediated by GABAA receptor (Lena et al., 1993) and could therefore lead to 
abnormal high frequency spike discharges. High frequency discharges of thalamo-cortical 
volleys, particular to the frontal lobes, are observed during sleep and could explain the 
linkage between the sleep and the epileptic syndrome. 
The a4776insL mutation changed the ACh sensitivity and Ca2+ permeability of 
(a4)3(p2)2 but not those of (a4)2(p2)3• This implies that if these receptor properties are 
responsible for seizures in a4776insL_linked ADNFLE, then the receptor that mediates this 
disease is the (a4)3(P2h receptor. How could these changes lead to seizures? Changes in 
agonist potency because of mutations in the channel pore are thought to result from 
changes in channel gating increasing the probability of transition to the active state 
(Bertrand et al., 1998; Filatov and White, 1995). The gain of function of the receptor based 
on the increased ACh sensitivity could not entirely explain the nature of epileptic seizures. 
If central cholinergic nerve terminals release nearly saturating A Ch concentrations (as 
other types of synapses apparently do (reviewed in Clements, 1996), then increasing the 
ACh sensitivity of a4P2 nAChRs may only slightly increase the amplitude of nicotinic 
synaptic potentials. However, in the case of volume transmission (Wonnacott, 1997), 
which might be the predominant form of transmission by cholinergic neurones in the brain, 
increased ACh sensitivity could impact significantly the amplitude of nicotinic receptors 
signals. The presence of low Ca2+ permeable receptors only could contribute to ADNFLE 
seizures with two mechanisms: 1) the reduced function of the mutant receptors could 
reduce the a4P2-mediated inhibitory transmitter release in the cortex (McNamara, 1999); 
2) the reduced Ca2+ permeability could shift the balance between <;i4P2-mediated excitatory 
and inhibitory neurotransmitter release during bouts of high-frequency cortical synaptic 
activity, in favour of excitatory transmitter release (Rodrigues-Pinguet et al., 2003). 
a4 776insL increased the functional expression of ( a4 )2(P2 )3 receptors but decreased 
that of (a4)3(p2)2. Western blot analysis showed that when the receptors expressed were of 
the (a4)2(P2)3 type the steady state level of a.4 and P2 was increased relative to those seen 
with the corresponding wild type receptors. This immunoblotting profile is in agreement 
with the increase in functional expression observed for a4776insL mutant (a4)2(P2)3 
receptors. Why would a mutation in the a4 subunit change the steady state level of the p2 
subunit? The step-by-step details of how a4P2 nAChRs are assembled is not known. 
However, recent studies on the effects of chronic exposure to nicotine indicated that the 
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subunits assemble together into various types of intermediaries as they are synthesised 
(Kuryatov et al., 2005; Sallette et al., 2005). Thus, if a4 and P2 subunits are mostly present 
as assembled subunits, then changes in the half-life of one subunit may influence the 
steady state levels of the other one. An increase in the stability of assembled subunits 
would lead to an increase in receptor maturation and trafficking, all of which would 
subsequently lead to higher expression levels. Surprisingly, in comparison to mutant 
(a4)2(p2)3 receptors, when the receptors expressed were of the (a4)3(p2)2 type 
immunoblotting assays revealed a decrease in the steady state levels of a4 subunit with no 
apparent changes in p2 levels and this finding correlates well with the lower functional 
expression observed for mutant ( a4)3(P2)2 receptors. How could the relative availability of 
subunits affect the pattern of changes in subunit steady state levels caused by a4776insL7 The 
different patterns of subunit steady state levels suggest that the assembly of both forms of 
the a4P2 is handle differently. In the case of the genesis of ( a4)3(p2)z intermediaries with 
more than one a4 subunit may predominate and the stability of these may be detrimentally 
affected by the presence of the a4776insL mutation. An obvious consequence of changes in 
the turnover of receptor intermediaries is changes in the subunit composition of the 
receptors assembled. A well know example of how changes in turnover time of subunits 
and receptor intermediaries affect the type of mature receptors expressed is that of the 
effects of chronic exposure to nicotine. Chronic exposure to nicotine up-regulates the 
number of high sensitivity a4P2 nAChRs trafficked to the cell surface and this occurs 
because nicotine stabilises intern1ediaries that favour the expression of this receptor type 
(Corringer et al., 2006). 
The findings that a4 776insL may alter the subunit composition of a4P2 receptors 
agrees with recent studies by Son et al. (2009). In this study it was shown that some 
ADNFLE-linked mutations, included the one analysed in the present study, increase the 
expression (a4)3(P2)2 receptors and decrease the expression ofthe(a4)2(P2)3 stoichiometry. 
The authors· came to this conclusion after having analysed FRET efficiency of mutant 
receptors in N2A cells. However, FRET analysis only measures intracellular receptor 
levels without giving any information on surface receptors. It could therefore be possible 
that the mutant receptors are assembled but they are not trafficked properly to the 
membrane, thus accm_nulating in the intracellular space. Also, as stated by the same 
authors, due to the low level of expression of a4p2 receptors in N2A cells no functional 
analysis was done, therefore they have no information about the properties of the receptors 
expressed on the membrane. 
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To test the stoichiometry-change hypothesis the L9'T mutation was used as a 
reporter mutation to monitor changes in subunit composition of the surface mutant 
receptors. Insertion of the L9'T mutation in the P2 subunit of the mutant receptors shifted 
the A Ch dose-response curve as expected but the extent of the shift was not the expected 
one for a receptor containing three a4 subunits. The shift in the EC5o values was in fact 
more compatible with a higher p2 content in both mutant receptors. However, as already 
mentioned before, the presence of another mutation in the channel pore domain, might 
alter the effect of the L9'T mutation on the receptor. Therefore, these findings need to be 
taken cautiously. 
An unambiguous way of studying the effects of mutations on receptor 
stoichiometry' is the use of concatenated receptors. Analysis of the functional properties of 
(a4)3(p2)2 concatamers containing three mutations showed that the expression of this 
receptor is problematic, probably because the mutation destabilised the receptor which is 
therefore not trafficked to the cell surface. In contrast, good levels of expression were 
achieved after injection of concatenated ( a4)z(p2)3 receptors containing two mutations, 
suggesting that the receptors are stable and that they are trafficked efficiently to the 
membrane. Analysis of the ACh concentration-response curve of the mutant concatenated 
receptors clarified the effect of the a4 776insL mutation on the stoichiometry of the a4P2 
receptor. The EC5o of the (a4)3(p2)z mutant concatamers was not significantly different 
from the wild type value, suggesting that a receptor with a stoichiometry of ( a4)3(p2)z 
containing three mutations does not display a high sensitivity behaviour, as observed in the 
non-linked receptor. The high sensitivity-like properties observed in the mutant non-linked 
··receptor could arise from a change in receptor stoichiometry. This suggestion is supported 
by the results obtained with the mutant (a4)z(p2)3 concatamer, whose properties were 
found to be similar to those of the non-linked mutant receptor. A receptor with a 
stoichiometry of ( a4)2(P2)3 containing two mutations displays mutant-like properties, 
suggesting that the stoichiometry is not altered by the presence of the mutation. However, 
the non-linked receptors expressed with the extreme injection ratio strategy display some 
differences in their functional properties (desensitisation and agonist efficacy) suggesting 
the presence of other stoichiometries. It will be therefore incorrect to say that the mutation 
shifts the stoichiometry of the receptor from (a4)3(p2)2 to (a4)2(P2)3 in a discrete way. It is 
more likely that the presence of a mutated a4 subunit biases the subunit composition of the 
receptor toward a higher p2 content. 
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This study has shown that ADFNLE mutations affect the alternate forms of the 
a4~2 receptors differentially. This is important for unravelling the mechanisms underlying 
the pathophysiology of the disease and also for designing more effective therapeutic 
strategies. Moreover, given the focal nature of ADNFLE, it might help to understand the 
subunit composition of the a4~2 receptor not only in the region involved in the epileptic 
seizures but also in other brain regions. ADNFLE seizures involve thalamo-cortical circuits 
during sleep. In light of the results presented in this Chapter, it could be suggested that the 
thalamus has a higher content of ( a4)3(~2)2 receptors and it is therefore the most affected 
area in patients who present ADNFLE-linked mutations. A higher ( a4)2(~2)3 receptor 
content in the other regions might explain why most of the ADNFLE patients do not show 
any other brain disorder. 
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FINAL DISCUSSION 
The aim of this study was to engmeer functional pentameric concatenated 
(a4)2(p2)3 and (a4)3(p2)2 nAChRs to investigate the functional differences between the two 
alternate stoichiometries of the a4p2 nAChR. The a4P2 is the most abundant nAChR 
present in the human brain and its role in physiological and pathological processes is well 
documented. As shown by several studies, a4 and P2 subunits expressed heterologously 
assemble into two alternate stoichiometries of the a4P2 nAChR that differ markedly in 
their functional and pharmacological profile. There is increasing evidence that both forms 
of the a4P2 receptor exist in neurones and that the ratio between them may impact brain 
functions, or pathologies, influenced by a4P2 receptors (Kim et al., 2003). Thus, the design 
of stoichiometry-specific drugs should make it easier to unravel the mechanisms by which 
this receptor type influence brain functions and would lead to safer and more efficacious 
drugs. The availability of functional concatenated (a4)2(p2)3 and (a4)3(p2)2 nAChRs 
should make these tasks easier. 
Investigation of the functional and pharmacological properties of concatenated 
receptors confirmed that the strategies used so far to study the functional properties of a 
given form of the a4P2 receptor have not solved completely the problem of the expression 
of multiple receptor forms. As shown in Chapter 3, the presence of a small receptor 
contamination is clearly visible when comparing the response of linked and non-linked 
receptors to highly selective compounds, such as TC2559 and 5I-A85380. In contrast, as 
shown in this study, pentameric concatenated receptors proved to be the ideal tool for the 
expression ofhomogenous populations of receptors. 
Another important implication of this study is that it provides a tool to express 
receptors with fixed stoichiometry. The expression of heteromeric proteins in heterologous 
systems cannot be fully controlled and the subunit composition of the protein may vary for 
many reasons (e.g., temperature, subunit availability) (Nelson et al., 2003; Lopez-
Hernandez era/., 2005; Moroni et al., 2006). The presence of more than one type of 
stoichiometry often leads to erroneous conclusions. A well-known example is that of the 
actions of the agonist sazetidine-A on a4P2 receptors. Sazetidine-A was recently reported 
to bind selectively and with high-affinity to a4P2 nAChRs (Xiao et al., 2006). The 
functional properties described for this compound were unusual. It was reported that 
sazetidine-A desensitized a4P2 receptors 'expressed heterologously in SHEP-I cells 
without activating them. However, studies of native a4P2 receptors showed that sazetidine-
A acted as a conventional agonist of this receptor type (Xiao et al., 2007; Cucchiaro et al., 
2008). These conflicting findings were solved by recent studies that used the drastic 1: 10 
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or 10: 1 a4/~2 ratios to express enriched populations of ( a4)2(~2)3 or ( a4)3(~2)2 nAChRs, 
respectively (Zwart et al., 2008). This study clearly showed that sazetidine-A has a very 
low efficacy at (a4)3(~2)2 nAChRs but behaves as a full agonist at (a4)2(~2)3 nAChRs. The 
mistake of Xiao et al. (2006) stemmed directly from the fact that SHEP-1 cells transfected 
with a4 and ~2 subunits express a mixed population of (a4)z(~2)3 and (a4)3(~2)2 nAChRs, 
which is highly enriched in (a4)3(~2)2 nAChRs, the receptor subtype at which sazetidine A 
displays poor efficacy. 
The reasons for the functional and pharmacological differences between the 
( a4)2(~2)3 and ( a4)3(~2)z nAChRs are not clear. The distinct functional pharmacology of 
(a4)2(~2)3 and (a4)3(~2)2 nAChRs might reflect variations in the environment around the 
two functional ACh binding sites, which are located interfaces between a4 and ~2 subunits 
(Corringer et al., 2000). On both stoichiometries, the agonist sites are both located at the 
a4( + )/~2(-) interfaces and are thought to contribute equally to agonist binding. However, 
this may not be so, because of the two binding sites only one is flanked by non-ACh 
binding ~2(+)/a4(-) interfaces on both stoichiometries whereas the other site is flanked by 
a ~2(+)/a4(-) interface and a ~2(+)/~2(-) in the (a4)2(~2)3 stoichiometry or a a4(+)/a4(-) 
interface in the ( a4)3(~2)z stoichiometry. The latter interfaces might confer stoichiometry-
specific properties to the receptors, as recently shown for Zn2+ modulation (Moroni et al., 
2008). Alternatively, residues located at the ~2( + )/~2(-), a4( + )/a4(-) Qr ~2( + )/a4(-) 
interfaces may form additional binding sites that when bound do not activate the protein 
but modify the properties of the 'classic' ACh binding pocket. Even though there is no 
evidence that ACh binds any of these interfaces, other allosteric modulators, such as 
. galanthamine (Hansen et al. 2007), have been shown to modulate the function of nicotinic 
receptors by binding non-ACh binding interfaces. These sites represent potential 
therapeutic targets and will likely prove useful in developing subtype-selective compounds 
for studying .receptor subtypes assembly and localisation. All these questions can now be 
addressed by using concatenated ( a4)2(~2)3 and ( a4)3(~2)2 nAChRs. The identification of 
the role of each subunit in the pentameric concatenated receptors will allow the 
investigations of the contribution of each binding site to agonist binding as well as 
investigation of the role of the non-agonist binding interfaces in the two alternate 
stoichiometries of the a4~2 nAChR. 
The functional differences between the (a4)z(~2)3 and (a4)3(~2)2 stoichiometries 
might lead, as a consequence, to a different involvement of the two receptors in a4~2-
linked diseases. This was shown to be true in ADNFLE, where the two stoichiometries are 
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differentially affected by a specific ADNFLE-linked mutation. The use of concatenated 
receptors in this study was essential to clarify the changes induced by the mutation in the 
two alternate forms and that might cause seizures. Given the focal nature of this disease, 
the finding that some ADNFLE-linked mutations alter the subunit composition of a4p2 
nAChRs can help to understand the distribution of the two stoichiometries in specific brain 
areas. Because the (a.4)3(p2)2 stoichiometry is more affected by ADNFLE mutations than 
the (a.4)z(p2)3 stoichiometry and because seizures .seem to originate in the thalamus, one 
might conclude that this region is richer in (a4)3(p2)z receptors than in (a.4)2(p2)3 receptors. 
The results obtained in these studies strongly demonstrate that concatenated 
(a.4)z(p2)3 and (a.4)3(p2)2 receptors not only can be employed for a finer and more detailed 
dissection of receptor properties and architecture and for the design of stoichiometry-
specific drugs but that they also provide the pharmacological tools for the identification of 
the a.4p2 subunit arrangement present in neurones. There is, however, one problem that 
needs to be solved for concatenated receptors to realise their full potential. In comparison 
to receptor; assembled from free subunits, concatenated receptors have poor levels of 
functional expression (Baur et al., 2006; this study). Undoubtedly, the size of the 
constructs must operate against efficacious transcription, protein synthesis, receptor 
assembly and trafficking to the cell surface. One possible way to minimize low 
transcription or translation is to improve the quality of the codons of the cDNAs. The 
tremendous development in recombinant protein expression that have occurred in the last 
IO years have highlighted that codon usage (frequency of codons in host cells), GC 
content, cis elements and repeated sequences determine how efficiently proteins are 
expressed in expression systems. Perhaps, optimisation of the sequences of a.4 and p2 
cDNAs should aid to increase the functional expression of the concatenated constructs 
described in this study. 
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APPENDIX 1 
Table A.1. Primers used for concatenation of IJ2<QS>f32<QS)«4<Qs)P2cQs)a4 and f32<Qs)«4(Q8)«4(Qs)P2(Q8)«4 receptors 
fl2<Qs)P2cQs)«4<Qs)P2cQs)«4 
Subunit Primer sequence 
1st step F Ase I Kozak P2F 
GGCGCGCC GCCACC ATGGCCCGGCGCTGCGGCC TM=64°C 
1st step R Linker . P2R 
TTGCTGCTGTTGCTGCTGTTGCTG ATTTAT CTTGGAGCTGGGGGCTGAGTGGTC TM=64°C 
1st subunit p2 
2nd step F Asel kozak P2F TTTAAA GGCGCGCC GCCACC ATGGCC TM=66 °C 
2nd step R Xbal Linker P2R TTTAAA TCTAGA TTGCTGCTGTTGCTGCTGTTGCTG ATTTAT CTTGGAG TM= 66 °C 
1st step F Xbal P2F TTTAAA TCTAGA ATGGCCCGGCGCTGCGG TM=59°C 
1st step R Linker P2R 
2nd subunit P2 
TTGCTGCTGTTGCTGCTGTTGCTG TTCGAA CTTGGAGCTGGGGGCTGAGT TM=58 °C 
Xbal P2F 2nd step F TTTAAA TCTAGA ATGGCCCGGCGCTGCGG TM=61°C 
2nd step R Agel Linker TTT AAA ACCGGT TTGCTGCTGTTGCTGCTGTTGCTG TT TM=60°C 
3rd subunit a4 1st step F Agel a4 F TTTAAA ACCGGT ATGGAGCTAGGGGGCCCCGG TM=60°C 
1st step R Xhol Linker a4R CTCGAG TTGCTGCTGTTGCTGCTGTTGCTG ATTTATGATCATGCCAGCCAGCCAGG TM=60°C 
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2nd step F Linker Agel TFCGAA CAGCAACAGCAGCAACAGCAGCAA ACCGGT TM=60°C 
2nd step R Xhol Linker a4R TTTAAA CTCGAG TTGCTGCTGTTGCTGCTGTTGCTG ATT TM=61°C 
1st step F Xhol f:l2F TTTAAA CTCGAG ATGGCCCGGCGCTGCGGCCC TM=59°C 
1st step R Linker . f:l2R TTGCTGCTGTTGCTGCTGTTGCTG ATTTAT CTTGGAGCTGGGGGCTGAGTGGTC TM=58°C 
4th subunit fl2 
2nd step F Xhol f:l2F TTTAAA CTCGAG ATGGCCCGGCGCTGCGGCCC TM=61°C 
2nd step R Not I Linker f:l2R TTTAAA GCGGCCGC TTTGCTGCTGTTGCTGCTGTTGCTG ATTTATCTTG TM= 60 °C 
1st step F Not I a4F GCGGCCGC ATGGAGCTAGGGGGCCCCGGAG TM=58 °C 
1st step R Eco RV a4R GATATC TTAGATCATGCCAGCCAGCCAGGGCG TM=58 °C 
5th subunit a4 
'. 2nd step F Not I a4F TTTAAA GCGGCCGC ATGGAGCTAGGGGGCCCC TM=58°C 
2nd step R Eco RV a4R TTTAAA GATATC TTAGATCATGCCAGCCAGCCAGGGC TM=58 °C 
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1 fl2<Qs)a4<Qs)«4<Qs)P2<Qs)«4 
Subunit Primer sequence 
1st step F Xbal a4F 
TTTAAA TCTAGAATGGAGCTAGGGGGCCCCGGAG TM=59°C 
1st step R Linker a4R TTGCTGCTGTTGCTGCTGTTGCTG TTCGAA GATCATGCCAGCCAGCCAGGGCG TM=58°C 
2nd subunit a4 
2nd step F Xbal a4F TTTAAA TCTAGA ATGGAGCTAGG GGGCCCCGGA TM=61°C 
2nd step R Agel Linker a4R TTTTCC ACCGGT TTGCTGCTGTTGCTGCTGTTGCTG TTCGAAGATCAT TM=60°C 
Primers used for the subunit concatenation of the pentameric constructs j32(QS)l32(Q8)a4(Qs)l32(Q8)a4 and j32(Qs)U4(Q8)U4(QS)l32(Qs)a4 described in 
Chapter 3. Linkers are underlined whereas restriction sites are shown in bold. Melting temperature (TM) of each primer is shown. 
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Table A.2. Primers for concatenation of IJ2(AGs)ll2cAGs)«4<AGs)ll2<AGS)«4 and ll2cAGs)«4<AGS)«4cAGS)ll2cAGs)«4 receptors 
' 
ll2cAGS)IJ2cAGS)«4cAGS)ll2cAGS)0.4 
Subunit Primer sequence 
1st step F Asel Kozak P2F GGCGCGCC GCCACC ATGGCCCGGCGCTGCGGCC TM=64°C 
1st step R Linker . . P2R 
TTGCTGCTGTTGCTGCTGTTGCTG ATTTAT CTTGGAGCTGGGGGCTGAGTGGTC TM=64°C 
1st subunit P2 
kozak P2F 2nd step F Asel 
TTTAAA GGCGCGCC GCCACC ATGGCC TM=66 °C 
2nd step R Xbal Linker . P2R 
TTTAAA TCTAGA TTGCTGCTGTTGCTGCTGTTGCTG ATTTAT CTTGGAG TM=66°C 
1st step F Linker P2F AGCGCTGGAAGTGCTGGTAGCACGGATACAGAGGAGCGGCTGGTGG TM=64°C 
1st step R Linker P2R 
2nd subunit 112 
GGCACTTCCAGCGCTACCAGC CTTGGAGCTGGGGGCTGAGTGGTCT TM=64 °C 
XbaI Linker P2F 2nd step F 
TTTAAA TCTAGA GCGGGCAGCGCTGGAAGTGCTGGTAGC ACGG TM=64°C 
2nd step R Agel Linker P2R 
TTTAAA ACCGGT ACTACCGGCACTTCCAGCGCTACCAGC CTTG TM=64°C 
3rd subunit a.4 1st step F Linker a4F AGCGCTGGAAGTGCTGGTAGC CGGGCCCACGCCGAGGAGCG TM=66°C 
1st step R Linker a.4R TCCAGCGCTGCCCGCACTACCGGC GATCATGCCAGCCAGCCAGGGCGG TM=66°C 
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2nd step F Agel Linker a4F 
TTTAAA ACCGGT GCGGGCAGCGCTGGAAGTGCTGGTAGC CGGG TM=66°C 
2nd step R Xhol Linker 
TTTAAA CTCGAG GCTACCAGCACTTCCAGCGCTGCCCGCACTACCGG TM=66°C 
1st step F Linker ~2F GCTGGAAGTGCTGGTAGCGCTGGAAGT ACGGATACAGAGGAGCGGCTGGTG TM=63 °C 
1st step R Linker . ~2R 
4th subunit 117 AGCACTTCCAGCGCTGCCCGC CTTGGAGCTGGGGGCTGAGTGGTC TM=64°C 
Xhol Linker 
2nd step F 
AAATTT CTCGAG GCCGGTAGTGCGGGCAGCGCTGGAAGTGCTGGTAGCGCTGGAAG TM=64°C 
2nd step R Not I Linker TTTAAA GCGGCCGC GCTACCAGCACTTCCAGCGCTGCCCGCC TM=64°C 
1st step F Linker a4F AGCGCTGGAAGTGCTGGTAGCCGGGCCCACGCCGAGGAGC TM=64°C 
1st step R Eco RV a4R GATATC TTAGATCATGCCAGCCAGCCAGGGCG TM=64°C 
5th subunit a4 
2nd step F Not I Linker a4F AAATTT GCGGCCGC TGCGGGCAGCGCTGGAAGTGCTGGTAGC CGG TM=64°C 
2nd step R Eco RV a4R· TTTAAA GATATC TTAGATCATGCCAGCCAGCCAGGG TM=64°C 
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P2(AGS)Cl4(AGS)Cl4(AGS)P2(AGS)Cl4 
Subunit Primer sequence 
1st step F Linker a4F 
AGCGCTGGAAGTGCTGGTAGC CGGGCCCACGCCGAGGAGC TM=64°C 
1st step R Linker a4R 
TCCAGCGCTGCCCGCACTACCGGC GATCATGCCAGCCAGCCAGGGCG TM=64°C 
200 subunit a4 
2nd step F XbaI Linker a4F 
AAATTT TCTAGA GCGGGCAGCGCTGGAAGTGCTGGTAGC CGG TM=64°C 
2nd step R Agel Linker 
AAATTT ACCGGT GCTACCAGCACTTCCAGCGCTGCCCGCACTACCG TM=64°C 
1st step F Linker a4F 
GCTGGAAGTGCTGGTAGCGCTGGAAGT CGGGCCCACGCCGAGGAG TM=64 °C 
1st step R Linker a4R 
TCCAGCGCTGCCCGCACTACCGGC GATCATGCCAGCCAGCCAGGGCG TM=64°C 
3rd subunit a.4 
2nd step F Agel Linker 
•. TTTAAA ACCGGT GCCGGTAGTGCGGGCAGCGCTGGAAGTGCTGGTAGCGCTGGAAGT TM=64°C 
2nd step R XhoI Linker 
TTTAAA CTCGAG GCTACCAGCACTTCCAGCGCTGCCCGCACTACCG TM=64°C 
Primers used for the subunit concatenation of the pentameric constructs ~2(AGS)~2(AGS)<l4(AGS)~2(AGS)<l4 and ~2(AGS)<l4(AGS)<l4(AGS)~2(AGS)<l4 described 
in Chapter 3. Linkers are underlined whereas restriction sites are shown in bold. Melting temperature (TM) of each primer is shown. 
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Table A.3. Primers for concatenati<?n of fl2cAGs>«4cAGS>fl2<AGS>«4cAGS)fJ2 and fl2(AGs)«4cAGs)P2<AGs)«4(AGs)«4 receptors 
fl2<AGs>fl2cAGs)«4cAGs>P2cAGs>«4 
Subunit Primer sequence 
1st step F Ase I Kozak f32 F 
GGCGCGCC GCCACC ATGGCCCGGCGCTGCGGCC TM=64 °C 
1st step R Linker . f32 R 
GGCACTTCCAGCGCTACCAGC CTTGGAGCTGGGGGCTGAGTGGTC TM=64°C 
1st subunit p2 
2nd step F Ase I kozak f32 F 
TTTAAA GGCGCGCC GCCACC ATGGCC TM=66°C 
2nd step R Xbal Linker . f32 R 
TTTAAA TCTAGA ACTACCGGCACTTCCAGCGCTACCAGC CTTGG TM=66°C 
1st step F Linker a4F 
AGCGCTGGAAGTGCTGGTAGC CGGGCCCACGCCGAGGAGC TM=64 °C 
1st step R Linker a4R 
'. TCCAGCGCTGCCCGCACTACCGGC GATCATGCCAGCCAGCCAGGGCG TM=64°C 
2nd subunit a4 
2nd step F Xbal Linker a4F 
AAATTT TCTAGA GCGGGCAGCGCTGGAAGTGCTGGTAGC CGG TM=64°C 
2nd step R Agel Linker 
AAATTT ACCGGT GCTACCAGCACTTCCAGCGCTGCCCGCACTACCG TM=64°C 
3rd subunit P2 1st step F Linker f32 F 
GCTGGAAGTGCTGGTAGCGCTGGAAGTACGGATACAGAGGAGCGGCTGGTG TM=63 °C 
1st step R Linker f32 R 
ACTTCCAGCGCTGCCCGC CTTGGAGCTGGGGGCTGAGTGGTC TM=64°C 
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2nd step F Agel Linker TFTAAA ACCGGT GCCGGTAGTGCGGGCAGCGCTGGAAGTGCTGGTAGCGCTGGAAGT TM=64°C 
2nd step R Xhol Linker 132 R TTTAAA CTCGAG GCTACCAGCACTTCCAGCGCTGCCCGCCTTGG TM=64°C 
1st step F Linker a4F AGCGCTGGAAGTGCTGGTAGC CGGGCCCACGCCGAGGAGC TM=64°C 
1st step R Linker a4R TCCAGCGCTGCCCGCACTACCGGC GATCATGCCAGCCAGCCAGGGCG TM=64°C 4th subunit a4 
2nd step F Xhol Linker a4F AAATTT CTCGAG GCGGGCAGCGCTGGAAGTGCTGGTAGC CGG TM=64 °C 
2nd step R Not I Linker AAATTT GCGGCCGC GCTACCAGCACTTCCAGCGCTGCCCGCACTACCG TM=64°C 
1st step F Linker 132 F CAGCGCTGGAAGTGCTGGTAGCGCTGGAAGTACGGATACAGAGGAGCGGCTGGTGG TM=64°C 
1st step R Eco RV 132 R 
5th subunit p2 
GCGGCCGC GATATC TTACTTGGAGCTGGGGGCTGAGTGGTC TM=64°C 
·. 2nd step F Not I Linker 132 F TTTAAA GCGGCCGC TGCCGGTAGTGCGGGCAGCGCTGGAAGTGCTGGTAGCGCT TM=64°C 
2nd step R Eco RV 132 R TTT AAA GCGGCCGC GATATCTTACTTGGAGCTG TM=64°C 
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f}2(AGS)«4(AGS)fJ2(AGS)«4(AGS)«4 
Subunit Primer sequence 
1st step F Linker a4F 
GCTGGAAGTGCTGGTAGCGCTGGAAGT CGGGCCCACGCCGAG GAGC TM=64 °C 
1st step R Eco RV a4R 
GATATC TTAGATCATGCCAGCCAGCCAGGGCG TM=64 °C 
5th subuu:it a4 
2nd step F Not I Linker 
TTTAAA GCGGCCGC TGCCGGTAGTGCGGGCAGCGCTGGAAGTGCTGGTAGCGCT TM=64°C 
2nd step R Eco RV a4R 
TTTAAA GATATC TTAGATCATGCCAGCCAGCCAGGG TM=64°C 
Primers used for the subunit concatenation of the pentameric constructs j32(AGS)U4(AGs)l32(AGs)a4(AGs)l32 and j32(AGS)U4(AGs)l32(AGs)a4(AGS)a4 described 
in Chapter 3. Linkers are underlined whereas restriction sites are shown in bold. Melting temperature {TM) of each primer is shown. 
188 
